INTERMOLECULAR INC (Form: 10-Q, Received: 05/08/2012 16:18:59)

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2012.

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-35348

Intermolecular, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		20-1616267
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

3011 N. First Street San Jose, California		95134
(Address of Principal Executive Offices)		(Zip Code)

(408) 582-5700

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer o

Non-accelerated filer x		Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Shares outstanding of the registrant’s common stock:

Class		Outstanding as of May 1, 2012
Common stock, $0.001 par value		42,470,181

Table of Contents

INTERMOLECULAR, INC.

FORM 10-Q FOR THE THREE MONTHS ENDED MARCH 31, 2012

TABLE OF C ONTENTS

		Page
	PART I — FINANCIAL INFORMATION

Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets	3

	Condensed Consolidated Statements of Operations	4

	Condensed Consolidated Statements of Cash Flows	5

	Notes to Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25

Item 4.	Controls and Procedures	26

	PART II — OTHER INFORMATION

Item 1.	Legal Proceedings	27

Item 1A.	Risk Factors	27

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	47

Item 6.	Exhibits	48

	Signatures	49

Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

INTERMOLECULAR, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

	March 31,			December 31,
	2012			2011
ASSETS
Current assets:
Cash and cash equivalents	$	80,847		$	81,002
Short-term investments	1,251			—
Accounts receivable, net of allowance for doubtful accounts of zero as of March 31, 2012 and December 31, 2011	4,722			10,227
Accounts receivable, due from related parties	1,344			935
Inventory, current portion	1,797			—
Prepaid expenses and other current assets	1,383			1,763
Total current assets	91,344			93,927
Inventory, net of current portion	2,433			2,532
Property and equipment, net	24,147			25,128
Intangible assets, net	5,996			6,067
Other assets	162			160
Total assets	$	124,082		$	127,814

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	906		$	1,079
Accrued liabilities	3,075			3,759
Accrued compensation and employee benefits	2,078			2,452
Deferred revenue, current portion	764			1,575
Related party deferred revenue, current portion	7,888			9,593
Note payable, current portion	928			804
Total current liabilities	15,639			19,262
Related party deferred revenue, net of current portion	161			716
Deferred rent, net of current portion	914			1,004
Note payable, net of current portion	26,276			26,514
Other long-term liabilities	135			145
Total liabilities	43,125			47,641
Commitments and contingencies (note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding	—			—
Common stock, par value $0.001 per share — 200,000,000 shares authorized as of March 31, 2012 and December 31, 2011, respectively; 42,470,181 and 42,218,906 shares issued and outstanding	42			42
Additional paid-in capital	181,650			180,680
Accumulated deficit	(100,735		)	(100,549		)
Total stockholders’ equity	80,957			80,173
Total liabilities and stockholders’ equity	$	124,082		$	127,814

See accompanying notes to condensed consolidated financial statements

Table of Contents

INTERMOLECULAR, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

	Three Months Ended March 31,
	2012			2011
Revenue:
Collaborative development program and services revenue	$	12,195		$	7,793
Product revenue	678			678
Licensing and royalty revenue	3,509			3,217
Total revenue	16,382			11,688
Cost of revenue:
Cost of collaborative development program and services revenue	6,879			5,112
Cost of product revenue	234			234
Cost of licensing and royalty revenue	75			170
Total cost of revenue	7,188			5,516
Gross profit	9,194			6,172
Operating expenses:
Research and development	5,068			4,519
Sales and marketing	1,240			905
General and administrative	2,818			1,799
Total operating expenses	9,126			7,223

Income (loss) from operations	68			(1,051		)
Other income (expense):
Interest (expense) income, net	(249		)	4
Other expense, net	(6		)	(178		)
Total other income (expense), net	(255		)	(174		)

Loss before provision for income taxes	(187		)	(1,225		)
Income tax (benefit) provision	(1		)	1
Net loss	(186		)	(1,226		)
Accretion on redeemable convertible preferred stock	—			(4,041		)
Net loss attributable to common stockholders	$	(186	)	$	(5,267	)
Net loss per share of common stock, basic and diluted	$	(0.00	)	$	(0.93	)
Weighted-average number of shares used in computing net loss per share of common stock, basic and diluted	42,241,345			5,633,192

Related Party Transactions

The Condensed Consolidated Statements of Operations shown above include the following related party transactions:

	Three Months Ended March 31,
	2012		2011

Revenue:
Collaborative development program and services revenue	$	2,997	$	2,807
Licensing and royalty revenue	1,793		2,422
Total revenue	$	4,790	$	5,229

Cost of Revenue:
Cost of collaborative development program and services revenue	$	3	$	217
Cost of product revenue	—		34
Cost of licensing and royalty revenue	—		170
Total cost of revenue	$	3	$	421

See accompanying notes to condensed consolidated financial statements

Table of Contents

INTERMOLECULAR, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2012			2011
Cash flows from operating activities:
Net loss	$	(186	)	$	(1,226	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	1,852			1,508
Stock-based compensation	827			406
Revaluation of preferred stock warrant liability	—			235
Changes in operating assets and liabilities:
Prepaid expenses and other assets	385			262
Inventory	(1,698		)	109
Accounts receivable	5,096			(435		)
Accounts payable	(412		)	(702		)
Accrued and other liabilities	(1,044		)	(396		)
Deferred revenue	(811		)	(1,464		)
Related party deferred revenue	(2,260		)	(2,666		)
Net cash provided by (used in) operating activities	1,749			(4,369		)
Cash flows from investing activities:
Purchase of short-term investments	(1,251		)	—
Purchase of property and equipment	(333		)	(3,321		)
Capitalized intangible assets	(327		)	(179		)
Net cash used in investing activities	(1,911		)	(3,500		)
Cash flows from financing activities:
Payment of long-term debt	(114		)	—
Proceeds from exercise of common stock options	121			15
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	—			14,927
Net cash provided by financing activities	7			14,942
Net (decrease) increase in cash and cash equivalents	(155		)	7,073
Cash and cash equivalents at beginning of period	81,002			23,064
Cash and cash equivalents at end of period	$	80,847		$	30,137

Supplemental disclosure of cash flow information:
Cash paid for interest	$	386		$	—
Cash paid for income taxes, net of refunds received	$	25		$	7

Noncash investing and financing activities
Accretion of redeemable convertible preferred stock	$	—		$	4,041

See accompanying notes to condensed consolidated financial statements

Table of Contents

INTERMOLECULAR, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements of Intermolecular, Inc. and subsidiaries (the Company) have been prepared without audit in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations. The information in this report should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as filed with the SEC on March 16, 2012.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for any other future interim period or full year. The condensed consolidated balance sheet as of December 31, 2011 is derived from the audited consolidated financial statements as of the year then ended.

Use of Estimates

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenue and expenses. Such estimates include the valuations of accounts receivable, inventories, intangible assets, debt, capital stock, warrants and assumptions used in the calculation of income taxes and stock-based compensation, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company’s cash, cash equivalents and short-term investments consist of demand deposits, money market accounts and certificates of deposit maintained with high quality financial institutions.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company’s cash equivalents are comprised of money market funds and are maintained with high quality financial institutions.

Short-Term Investments

The Company considers all highly liquid investments purchased with a maturity between three and twelve months to be short-term investments. The Company has short-term investments consisting of certificates of deposit maintained with high quality credit institutions. The carrying value of these investments approximates their fair value due to the short term of their maturities.

Table of Contents

Inventory

Inventories are stated at the lower of cost or market value, with cost determined on an average cost basis. Current inventories consist of work-in-process for products that are expected to be sold in the next twelve months. Noncurrent inventories consist only of raw materials. Inventories in excess of salable amounts and spare parts inventories that are considered obsolete are recorded as a cost in the period in which they occur. The Company did not experience any material inventory impairments during the three months ended March 31, 2012 and 2011.

Impairment of Long-Lived Assets

The Company evaluates its long-lived assets, which consist of property and equipment and intangible assets, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Impairment exists if the carrying amounts of such assets exceed the estimates of future net undiscounted cash flows expected to be generated by such assets. Should impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the estimated fair value of the asset. As of March 31, 2012 and December 31, 2011, the Company has not recorded a significant impairment on any of its long-lived assets.

Revenue Recognition

The Company derives its revenue from three principal sources: collaborative development programs and other services; product sales; and technology licensing and royalty fees.

Collaborative development programs and other services —The Company enters into collaborative development programs and other research and development service agreements with customers under which the Company conducts research and development activities jointly with the customer. The agreements specify minimum levels of research effort required to be performed by the Company. Payments received under the agreements are not refundable if the research effort is not successful. The Company retains rights to certain elements of technology developed in the course of its performance, which the customer has an option to license in the future under the terms defined in the agreement. Most arrangements with customers have fixed monthly fees and requirements to provide regular reporting of research and development activities performed and revenue is recognized in a manner consistent with the fixed monthly fee. Payments received prior to performance are deferred and recognized as revenue when earned over future performance periods.

The Company considers arrangements that include specifically identified, dedicated equipment to contain a lease provision, as these arrangements convey the right to the customer to use specific equipment and provide the ability to the customer to direct the use of the equipment as well as control more than a minor amount of the output of the equipment. To date the Company has determined these arrangements to contain operating leases, with a lease term that corresponds to the term of the CDP arrangement. The amount of revenue allocated for the lease element is based on its relative fair value, but the impact of the allocation does not change the amount of revenue recognized for the total arrangement as the lease term is consistent with the CDP term.

Future minimum operating lease payments associated with CDP arrangements that contain operating leases were $15.2 million and $11.3 million as of March 31, 2012 and December 31, 2011, respectively.

Product maintenance and support services —Included in collaborative development programs and other services revenue, these services entitle customers to receive product updates and enhancements or technical support and maintenance, depending on the offering. The related revenue is recognized ratably over the period the services are delivered.

Product revenue —The Company recognizes revenue from the sale of products once delivery has occurred (title and risk of loss have passed to the customer), and customer acceptance, if required, has been achieved. The Company has determined that the software included with its equipment products is more than incidental to the product as a whole.

Licensing and royalty revenue —The Company recognizes revenue for licenses to intellectual property when earned pursuant to the terms of the agreements. Time-based license revenue is recognized ratably over the license term. Licensing and royalty revenue that becomes triggered by specific customer actions, such as exercise of a license option or by sales volume, is recognized when it occurs based on royalty reports or other information received from the licensee. Minimum and prepaid royalties and license fees are recognized ratably over the related periods.

Table of Contents

Multiple-element arrangements —Certain of the Company’s customer arrangements involve the delivery or performance of multiple products, services or licenses. Product sale arrangements include product maintenance and support. Collaborative development programs and other research and development services include licenses of technology and may also include sales of products.

In 2009, the Financial Accounting Standards Board (FASB) issued ASU 2009-13 Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements—a consensus of the FASB Emerging Issues Task Force (ASU 2009-13) and ASU 2009-14 Software (Topic 985): Certain Revenue Arrangements That Include Software Elements—a consensus of the FASB Emerging Issues Task Force (ASU 2009-14). ASU 2009-13 and 14 are amendments to the accounting standards for revenue recognition to remove tangible products containing software components and nonsoftware components that function together to deliver the product’s essential functionality from the scope of industry-specific software revenue recognition guidance, and also:

· provide updated guidance on whether multiple deliverables exist, how the deliverables in an arrangement should be separated, and how the consideration should be allocated;

· require an entity to allocate revenue in an arrangement using estimated selling prices (ESP) of deliverables if the Company does not have vendor-specific objective evidence of selling price (VSOE) or third-party evidence of selling price (TPE); and

· eliminate the use of the residual method and require an entity to allocate revenue using the relative selling price method.

For all transactions entered into after December 31, 2010, the Company recognizes revenue using estimated selling prices of the delivered goods and services based on a hierarchy of methods contained in ASU 2009-13. The Company uses VSOE for determination of estimated selling price of elements in each arrangement if available, and since third-party evidence is not available for those elements where vendor-specific objective evidence of selling price cannot be determined, the Company evaluates factors to determine its ESP for all other elements. In multiple-element arrangements where hardware and software are sold as part of the solution, revenue is allocated to the hardware and software as a group using the relative selling prices of each of the deliverables in the arrangement based upon the aforementioned selling price hierarchy.

Deferred Revenue

Deferred revenue represents amounts collected from customers for which the related revenue has not been recognized, because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount that is expected to be recognized as revenue within one year from the balance sheet date.

Table of Contents

Concentration of Revenue and Accounts Receivable

Significant customers are those that represent more than 10% of the Company’s total revenue or accounts receivable. For each significant customer, including related parties, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:

	Revenue				Accounts Receivable
	Three Months Ended March 31,				As of March 31,		As of December 31,
	2012		2011		2012		2011

Customer A	21	%	33	%	14	%	*
Customer B	*		11	%	*		*
Customer C	*		*		—		—
Customer D (1)	14	%	20	%	*		*
Customer E	*		11	%	*		*
Customer F	*		*		*		*
Customer G	33	%	*		52	%	78	%

* less than 10%

(1) In February 2012, Customer D filed for protection under the Corporate Reorganization Act (Act) in Japan. As part of any restructuring under this Act, Customer D may either voluntarily or involuntarily reduce or eliminate payments owed to the Company or shipments of products that include the Company’s technology, which would lead to a reduction in revenue from Customer D.

Share-Based Compensation

The Company applies the fair value recognition and measurement provisions of ASC 718 Compensation — Stock Compensation. Stock-based compensation is recorded at fair value as of the grant date and recognized as an expense over the employee’s requisite service period (generally the vesting period), which the Company has elected to amortize on a straight-line basis.

The Company accounts for stock options issued to nonemployees based on the fair value of the options determined using the Black-Scholes option-pricing model. The fair value of stock options granted to nonemployees is remeasured each reporting period as the stock options vest and the resulting change in value, if any, is recognized in the Company’s consolidated statements of operations during the period the related services are rendered.

Recent Accounting Pronouncements

In June 2011, the FASB issued ASU 2011-05, Comprehensive Income (Topic 220), Presentation of Comprehensive Income , which requires companies to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This update eliminates the option to present the components of other comprehensive income as part of the statement of equity. In December 2011, the FASB issued ASU 2011-12, Comprehensive Income (Topic 220), Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05 , to defer the effective date of the specific requirement to present items that are reclassified out of accumulated other comprehensive income to net income alongside their respective components of net income and other comprehensive income. We adopted the guidance in our first quarter of 2012 with no significant impact on our consolidated financial statements or related footnotes as comprehensive loss consists of the same components as net loss and therefore the Company does not separately disclose a statement of comprehensive loss.

Table of Contents

2. Fair Value of Financial Instruments

The following financial instruments are not measured at fair value on the Company’s Condensed Consolidated Balance Sheet at March 31, 2012, but require disclosure of their fair values: cash, accounts receivable and accounts payable. The estimated fair value of such instruments at March 31, 2012 approximates their carrying value as reported on the Condensed Consolidated Balance Sheet. The Company measures and reports its cash equivalents and short-term investments at fair value. The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):

	Fair Value Measurements Using
	Balance as of March 31, 2012		Quoted Prices in Active Markets For Identical Instruments (Level I)		Significant Other Observable Inputs (Level II)		Significant Unobservable Inputs (Level III)

Assets:
Money market funds	$	70,613	$	70,613	$	—	$	—
Certificates of deposit	1,251		1,251		—		—
Total assets measured at fair value	$	71,864	$	71,864	$	—	$	—

	Fair Value Measurements Using
	Balance as of December 31, 2011		Quoted Prices in Active Markets For Identical Instruments (Level I)		Significant Other Observable Inputs (Level II)		Significant Unobservable Inputs (Level III)

Assets:
Money market funds	$	75,660	$	75,660	$	—	$	—
Certificates of deposit	100		100		—		—
Total assets measured at fair value	$	75,760	$	75,760	$	—	$	—

3. Property and Equipment

Property and equipment consist of the following (in thousands):

	As of			As of
	March 31, 2012			December 31, 2011

Lab equipment and machinery	$	33,608		$	33,515
Leasehold improvements	2,100			2,086
Computer equipment and software	3,080			3,016
Furniture and fixtures	148			146
Construction in progress	5,643			5,088
Total property and equipment	44,579			43,851
Less accumulated depreciation	(20,432		)	(18,723		)
Property and equipment, net	$	24,147		$	25,128

As of March 31, 2012 and December 31, 2011 all tangible property and equipment were pledged as collateral against the note payable issued in connection with the closing of the asset purchase transaction with Symyx Technologies, Inc. (Symyx). Amortization of leasehold improvements is included in depreciation expense. Depreciation expense was $1.7 million and $1.5 million during the three months ended March 31, 2012 and 2011, respectively.

Table of Contents

The Company maintained dedicated equipment to support contractual customer capacity requirements as part of certain collaborative development programs that are classified as lab equipment and machinery that have a net book value of $7.5 million and $7.0 million as of March 31, 2012 and December 31, 2011, respectively.

4. Intangible Assets

Intangible assets consist of the following (in thousands):

	As of			As of
	March 31, 2012			December 31, 2011

Patents issued	$	3,614		$	3,562
Patents pending	2,586			2,566
Trademarks	38			38
Total intangible assets	6,238			6,166
Less patent amortization	(242		)	(99		)
Intangible assets, net	$	5,996		$	6,067

Amortization commences upon patent issuance. The useful life of the patents, once approved, will not exceed 20 years, and will depend on the nature of the patent. The average estimated amortization period of our current portfolio is approximately 17 years from the date of patent issuance. The average estimated remaining amortization period of patents acquired as part of the Symyx asset purchase transaction is approximately 6 years. Amortization expense during the three months ended March 31, 2012 and 2011 was $143,000 and $3,000, respectively.

5. Commitments and Contingencies

Leases

The Company entered into an operating lease agreement in May 2010 that expires in May 2015. Rent expense, which is being recognized on a straight-line basis over the lease term, was approximately $0.3 million and $0.5 million during the three months ended March 31, 2012 and 2011, respectively. Future commitments and obligations under this operating lease to be satisfied as they become due over the term are as follows (in thousands):

As of March 31:
Nine month period ending December 31, 2012	$	1,213
The years ending December 31,
2013	1,657
2014	1,707
2015	728

Total	$	5,305

During 2012, the Company made payments of $0.4 million related to this operating lease.

Symyx Asset Purchase and Note Payable

In connection with the consummation of the Symyx asset purchase transaction in November 2011, the Company issued Symyx a secured promissory note in a principal amount equal to $27.3 million with a term of 24 months and an interest rate equal to 4%. The note is payable in an amount equal to the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity, if applicable. The note is also pre-payable by the Company at any time without penalty or premium, and is secured by tangible personal property, excluding intellectual property. During the three months ended March 31, 2012 the Company paid Symyx $500,000, which included interest and principal in the amount of $386,000 and $114,000, respectively.

Table of Contents

6. Stockholders’ Equity

Stock-Based Compensation

The fair value of the employee stock options were estimated on the grant dates using a Black Scholes option pricing model with the following weighted average assumptions:

	Three Months Ended March 31,
	2012		2011

Expected term (in years)	6.0		6.0
Risk-free interest rate	1.2	%	2.6	%
Expected volatility	60	%	57	%
Expected dividend rate	0	%	0	%

Stock-based compensation expense, net of estimated forfeitures, was included in the following line items on the Condensed Consolidated Statements of Operations as follows (in thousands):

	Three Months Ended
	March 31,
	2012		2011

Cost of revenue	$	284	$	95
Research and development	209		67
Sales and marketing	125		131
General and administrative	209		113
Total stock-based compensation	$	827	$	406

The following table presents stock-based compensation expense, net of estimated forfeitures, by grant type (in thousands):

	Three Months Ended
	March 31,
	2012		2011
Stock options	$	793	$	406
Restricted stock awards and restricted stock units (“RSUs”)	34		—
Total stock-based compensation	$	827	$	406

The following table presents unrecognized compensation expense, net of estimated forfeitures, of the Company’s equity compensation plans as of March 31, 2012, which is expected to be recognized over the following weighted-average periods, (in thousands, except for weighted-average period):

	Unrecognized Compensation Expense		Weighted- Average Period (in years)
Stock options	$	7,962	3.2
RSUs	$	1,420	3.9

Table of Contents

The following table presents details on option grants made by the Company for the following periods:

	Three Months Ended			Three Months Ended
	March 31, 2012			March 31, 2011
	Granted	Weighted- Average Grant Date Fair Value		Granted	Weighted- Average Grant Date Fair Value
Stock options	893,179	$	4.69	618,250	$	3.42

The total intrinsic value of stock options exercised for the three months ended March 31, 2012 and March 31, 2011 was $1.0 million and $94,000, respectively.

The following table presents details on RSU grants made by the Company for the following period:

	RSU’s Outstanding
	Number of RSUs Outstanding	Weighted Average Grant-Date Fair Value		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)
Unvested as of December 31, 2011	—	$	—	—	$	—
Granted	274,070	6.47		3.9
Vested	—	—			—
Cancelled	—	—
Unvested as of March 31, 2012	274,070	$	6.47	3.9	$	1,702

Common Stock Warrants

As of March 31, 2012 and December 31, 2011 the Company had 912,368 outstanding warrants to purchase shares of common stock. Of these outstanding warrants, 86,250 and 78,750 were exercisable as of March 31, 2012 and December 31, 2011, respectively. During the three months ended March 31, 2012 and 2011, the Company recognized expenses related to these warrants in the amount of $7,000 and $12,000, respectively.

Common Stock

As of March 31, 2012 and December 31, 2011, the Company had reserved shares of common stock for issuance as follows:

	As of March 31,	As of December 31,
	2012	2011

Issuances under equity incentive plan	14,179,168	12,530,593
Issuances upon exercise of warrants	912,368	912,368
	15,091,536	13,442,961

Table of Contents

7. Net Loss per Share of Common Stock

The following table sets forth the computation of the Company’s basic and diluted net loss per share of common stock during the three months ended March 31, 2012 and 2011 (in thousands, except for share and per share amounts):

	Three Months Ended March 31,
	2012			2011

Net loss attributable to common stockholders	$	(186	)	$	(5,267	)

Shares used in computing net loss per share of common stock, basic and diluted	42,241,345			5,633,192

Net loss per share of common stock, basic and diluted	$	(0.00	)	$	(0.93	)

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:

	Three Months Ended March 31,
	2012	2011

Redeemable convertible preferred stock	—	28,027,099
Stock options to purchase common stock	8,786,124	7,742,377
RSUs	274,070	—
Common stock subject to repurchase	7,500	—
Common and preferred stock warrants	912,368	1,812,360

8. Income Taxes

Income tax benefit for the three months ended March 31, 2012 was $1,000 or 0.67% on a pre-tax loss of $187,000. The difference between the Company’s effective tax rate and the federal statutory rate of 35% is primarily attributable to the differential in foreign taxes, non-deductible stock compensation expense, other currently non-deductible items and movement in its valuation allowance.

The Company maintained a valuation allowance as of March 31, 2012 against all of its deferred tax assets. The Company intends to maintain a full valuation allowance until sufficient positive evidence exists to support its reduction.

9. Related Party Transactions

In March 2012, the Company amended the collaborative development program (CDP) agreement that it had entered into in March 2010 with a related party. Under the agreements, the two companies will work together to conduct research and development and other activities. Depending on the output of the research and development, the primary rightholder will be the Company or the other party. However, if the other party is not the primary rightholder, it will be able to license the developed technology from the Company. The other party’s vice chairman of the board of directors is a director of the Company and is also a managing member of a significant shareholder of the Company. As of March 31, 2012, this shareholder is a beneficial owner of approximately 12.7% of the Company’s common stock. During the three months ended March 31, 2012 and 2011, the Company recorded revenue in the amount of $1.3 million and $1.3 million, respectively, from these agreements.

Table of Contents

In November 2006, the Company entered into an Alliance Agreement with a related party that is a beneficial owner of approximately 9.1% of the Company’s common stock as of March 31, 2012. The other party and the Company each have an independent board member that serves on both companies board of directors. Under the agreement, the two companies will work together to conduct research and development and other activities with respect to materials and high productivity combinatorial technology for use in semiconductor applications. Depending on the output of the research and development, the primary rightholder could be either company. However, the party that is not the primary rightholder will be assigned the right to use the output property. Under the agreement, the other party will pay the Company fees for services and both parties may provide royalties to the other for licensed technology sold to third parties. Since November 2006, the agreement has been amended numerous times with the last amendment signed in October 2011. During the three months ended March 31, 2012 and 2011, the Company recorded revenue in the amount of $3.5 million and $3.9 million, respectively, in equipment sales, license fees and service fees and expensed $3,000 and $0, respectively, in related party cost of revenue and had accounts receivable in the amount of $0.9 million and $0.5 million as of March 31, 2012 and December 31, 2011, respectively, related to these agreements. The Company has a deferred revenue balance in the amount of $8.0 million and $10.2 million related to these agreements as of March 31, 2012 and December 31, 2011, respectively.

10. Information about Geographic Areas

Revenue

Revenue by geography is based on the billing address of the customer. The following table sets forth revenue by geographic area (in thousands):

	Three Months Ended March 31,
	2012		2011
	Revenues		Revenues

United States	$	12,048	$	7,253
Japan	3,565		3,700
Taiwan	735		735
Europe and Middle East	34		—
Total	$	16,382	$	11,688

Long-Lived Assets

Substantially all of the Company’s long-lived assets are located in the U.S. An insignificant amount of long-lived assets reside in the Company’s foreign subsidiaries and branches in Hong Kong, Japan and Taiwan.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the accompanying consolidated condensed financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. Our MD&A is organized as follows:

·	Overview . Discussion of our business and overall analysis of financial and other highlights affecting the company in order to provide context for the remainder of MD&A.
·	Strategy . Our overall strategy.
·	Basis of Presentation . A summary of the primary elements of our financial results.
·	Critical Accounting Estimates . Accounting estimates that we believe are most important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.
·	Results of Operations . An analysis of our financial results comparing the three months ended March 31, 2012 to the three months ended March 31, 2011.
·	Liquidity and Capital Resources . An analysis of changes in our balance sheets and cash flows, and discussion of our financial condition and potential sources of liquidity.

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2012 (the “2011 Annual Report”). This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our 2011 Annual Report. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Overview

We have pioneered a proprietary approach to accelerate research and development, innovation and time-to-market for the semiconductor and clean energy industries. Using our approach, we develop technology and intellectual property (IP) focused on advanced materials, processes, integration and device architectures in collaboration with our customers. This technology enables our customers to bring optimized, high-volume manufacturing ready integrated devices to market faster and with less risk than traditional approaches to research and development (R&D). We provide our customers with proprietary technology through various fee arrangements and grant them rights to associated IP, primarily through royalty-bearing licenses. Our proprietary approach is broadly applicable to high-volume integrated device markets, which include semiconductors, flat glass coatings and glass based devices, solar cells, light emitting diodes (LEDs), flat-panel displays, advanced batteries and other energy-efficient technologies.

We were founded in 2004 and are headquartered in San Jose, California. Our total revenue increased to $16.4 million for the three months ended March 31, 2012 from $11.7 million for the three months ended March 31, 2011. Our net loss decreased to $0.2 million

Table of Contents

for three months ended March 31, 2012 from a net loss of $1.2 million for the three months ended March 31, 2011. Since inception, we have incurred net losses leading to an accumulated deficit of $100.7 million as of March 31, 2012. During February 2012, one of our significant customers, Elpida, filed for protection under the Corporate Reorganization Act (Act) in Japan, and our revenue from Elpida may decline as a result. For example, as part of any restructuring under this Act, our collaborative development program (CDP) services revenue may be reduced or even eliminated, and Elpida may either voluntarily or involuntarily reduce or eliminate payments owed to us or shipments of products that include our licensed technology. As of March 31, 2012 we had $15.6 million in backlog from Elpida, of which $6.6 million is to be recognized as revenue during the remainder of 2012 with the balance to be recognized as revenue in periods beyond 2012. Of the $6.6 million in backlog to be recognized as revenue during 2012 that is attributable to Elpida, we received payment in the amount of $2.2 million in April 2012 for CDP services and license fees for the three month period ending June 30, 2012.

Strategy

Our mission is to drive our customers’ success by transforming R&D and accelerating innovation in markets that derive competitive advantage from the interaction of materials science, processes, integration and device architecture. We currently target large, high-volume semiconductor and high-growth emerging clean energy markets, including DRAM, flash memory, complex logic, flat glass, solar cells, LEDs and energy efficient-technologies. Within these broad markets, we target customers that have track records of technological innovation, deploy significant resources and are pursuing technical advancements that are critical to their success and strategy, including ATMI, Elpida, GLOBALFOUNDRIES, Guardian Industries, SanDisk, Taiwan Semiconductor Manufacturing Company (TSMC) and Toshiba. ATMI and Elpida have commenced shipping products incorporating technology developed through our CDPs and pay us licensing and royalty fees. To date, we have received the majority of our revenue from customers in DRAM, flash memory, complex logic and energy-efficient applications in flat glass coatings and glass based devices, and have not yet received a material amount of revenue from customers in solar cells, LEDs and other energy-efficient technologies.

Basis of Presentation

How We Generate Revenue

Our customer engagement process generates revenue in three ways: CDP and services revenue; product revenue; and licensing and royalty revenue. CDPs are our primary engagement model with customers and are structured to result in licensing and royalty revenue. When we initially engage with a customer, we generate revenue from micro-CDPs, CDPs and licensing of our HPC platform. When technology developed through CDPs is incorporated in our customers’ commercialized products, we generate licensing and royalty revenue. In certain cases, we sell HPC processing tools to our customers who pay a recurring license fee to operate those tools with our combinatorial processing capabilities.

·	CDP and services revenue . CDP revenue includes payments for full time equivalent (FTE) employees, milestone payments, subscription payments for dedicated and shared workflow tools used in the CDP and reimbursed payments for consumables and outside services from third parties. Individual CDPs typically range from one to three years. Services revenue outside of CDPs is substantially comprised of support and maintenance fees and extended warranty agreements.

·	Product revenue . Product revenue consists of sales of our workflow hardware and embedded software. In support of our business strategy, we selectively sell our proprietary tools to increase opportunities for CDPs and licensing fees and royalties. Historically, we have not sold a significant number of our workflow products and we do not anticipate selling a significant number in the future. As our other revenue streams increase we expect our product revenue to decrease as a percentage of our overall revenue. Product sales that originated prior to January 1, 2011 are generally recognized on a straight-line basis over the maintenance period once delivery has occurred (title and risk of loss have passed to the customer), and customer acceptance, if required, has been achieved.

Table of Contents

Licensing and royalty revenue . Licensing and royalty revenue consists of licensing fees and royalties for granting our customers rights to our proprietary technology and IP. Specifically, this includes licensing the HPC capabilities of our workflows, licensing our informatics and analysis software and licensing fees and royalties on products commercialized by our customers that incorporate technology developed through our CDPs. In the last three years, licensing and royalty revenue has been the fastest growing element of our revenue. Over the long term, we expect licensing and royalty revenue to be an increasing and significant component of our revenue.

Cost of Revenue

Our cost of revenue is variable and depends on the product mix and type of revenue earned in each period relating to our customer programs. As customers commercialize products that incorporate technology developed through our CDPs, we expect our cost of revenue to decrease as a percentage of total revenue as licensing and royalty revenue become an increasing component of our revenue. As a result of the Symyx asset purchase transaction the amortization of acquired patents is being recorded in cost of revenue.

·	Cost of CDP and services revenue . Our cost of CDP and services revenue is primarily comprised of salaries and other personnel-related expenses (including stock-based compensation) for our collaborative research and development scientists, engineers and development fab process operations employees. Additionally, our cost of revenue includes costs of wafers, targets, materials, program-related supplies and depreciation of equipment used in CDPs.

·	Cost of product revenue . Our cost of product revenue primarily includes our cost of products sold. Our cost of product revenue will fluctuate based on the type of product and configuration sold. Historically, we have not sold a significant number of our workflow products and we do not anticipate selling a significant number in the future. Our cost of product revenue is recognized in a similar manner as the corresponding product revenue and is generally recognized on a straight-line basis over the maintenance period for product sales that originated prior to January 1, 2011. The variability in cost of product revenue as a percentage of revenue is related to the quantity and configuration of products sold during the period and the corresponding maintenance period that product revenue and cost of product revenue is being recognized.

·	Cost of licensing and royalty revenue . Our cost of licensing and royalty revenue prior to January 1, 2012 included license fees paid to Symyx. As part of the completion of the Symyx asset purchase transaction in November 2011, in connection with our initial public offering, we no longer have an obligation to pay licensing fees to Symyx for any period on or after January 1, 2012. In 2012, our cost of licensing and royalty revenue is primarily comprised of the amortization of acquired patents and a licensing obligation payable to the Lawrence Berkeley Laboratories.

Research and Development

Our R&D expenses consist of costs incurred for development and continuous improvement of our HPC platform, expansion of software capabilities and application research and development that are not associated with customer programs. R&D costs include personnel-related expenses (including stock-based compensation expenses), for our technical staff as well as consultant costs, parts and prototypes, wafers, chemicals, supply costs, facilities costs, utilities costs related to laboratories and offices occupied by technical staff, depreciation on equipment used by technical staff, and outside services, such as machining and third-party R&D costs. Overhead costs that are not allocated to a customer program are recognized as expenses within R&D. We expect our R&D expenses will continue to increase for the foreseeable future as we continue to devote substantial internal resources to develop and improve our HPC platform and extend the applicability of our platform to a broader set of applications within the industries we serve.

Table of Contents

Sales and Marketing

Our sales and marketing expenses consist primarily of personnel-related costs (including stock-based compensation) for our sales and marketing employees, as well as payments of commissions to our sales employees, facility costs and professional expenses. Professional expenses consist of external website and marketing communication consulting costs and market research. We expect that our sales and marketing expenses will continue to increase for the foreseeable future as we increase the number of our sales and marketing employees to support the growth in our business and as we incur external marketing communication costs.

General and Administrative

General and administrative expenses consist primarily of personnel-related costs (including stock-based compensation) as well as professional services and facilities costs related to our executive, finance, legal, human resources, management information systems and information technology functions. Professional services consist of outside accounting, information technology, consulting and legal costs. We also incur significant additional accounting and legal costs related to compliance with rules and regulations enacted by the Securities and Exchange Commission, including the additional costs of achieving and maintaining compliance with Section 404 of the Sarbanes-Oxley Act, as well as additional insurance, investor relations and other costs associated with being a public company. In addition to these expenses, we expect that our general and administrative expenses will continue to increase for the foreseeable future.

Interest (Expense) Income, net

Interest (expense) income, net represents interest earned on our cash, cash equivalents and short-term investments. We expect interest income will vary each reporting period depending on our average investment balances during the period and market interest rates. Interest expense primarily consists of interest accrued or paid on our note payable to Symyx Technologies, Inc. (Symyx) in connection with the Symyx asset purchase agreement that closed in November 2011.

Critical Accounting Estimates

Our consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States and include our accounts and the accounts of our wholly-owned subsidiaries. The preparation of our consolidated financial statements requires our management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosures for contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the applicable periods. Management bases its estimates, assumptions and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances. Different assumptions and judgments would change the estimates used in the preparation of our consolidated financial statements which, in turn, could change the results from those reported. Our management evaluates its estimates, assumptions and judgments on an ongoing basis.

There have been no material changes in the matters for which we make critical accounting estimates in the preparation of our condensed consolidated financial statements during the three months ended March 31, 2012 as compared to those disclosed in our 2011 Annual Report. For further information on our critical and other significant accounting policies, see our 2011 Annual Report.

Recent Accounting Pronouncements

See Note 1 of the Notes to Condensed Consolidated Financial Statements included in this Form 10-Q for recent accounting pronouncements that could have an effect on us.

Table of Contents

Results of Operations

Comparison of the Three Months Ended March 31, 2012 and 2011

	Three Months Ended March 31,
	2012			2011			$ Change			% Change
				(In thousands)

Revenue:
CDP and services revenue	$	12,195		$	7,793		$	4,402		56	%
Product revenue	678			678			—			0	%
Licensing and royalty revenue	3,509			3,217			292			9	%
Total revenue	16,382			11,688			4,694			40	%
Cost of revenue	7,188			5,516			1,672			30	%
Gross profit	9,194			6,172			3,022			49	%
Operating expenses:
Research and development	5,068			4,519			549			12	%
Sales and marketing	1,240			905			335			37	%
General and administrative	2,818			1,799			1,019			57	%
Total operating expenses	9,126			7,223			1,903			26	%

Income (loss) from operations	68			(1,051		)	1,119
Other income (expense):
Interest (expense) income, net	(249		)	4			(253		)
Other expense, net	(6		)	(178		)	172
Total other income (expense), net	(255		)	(174		)	(81		)
Loss before provision for income taxes	(187		)	(1,225		)	1,038
Income tax (benefit) provision	(1		)	1			(2		)
Net loss	$	(186	)	$	(1,226	)	$	1,040

Revenue

Our revenue increased by $4.7 million, or 40%, to $16.4 million during the three months ended March 31, 2012 from $11.7 million during the three months ended March 31, 2011 due to increases in both CDP and services revenue and licensing and royalty revenue.

CDP and services revenue increased by $4.4 million, or 56%, to $12.2 million during the three months ended March 31, 2012 from $7.8 million during the three months ended March 31, 2011. This increase was primarily attributable to $4.7 million in revenue derived from the expansion of existing customer engagements, including a non-recurring increase in the amount of $0.8 million related to the expiration of a customer’s purchase option during the quarter, combined with $0.3 million in revenue derived from new customer engagements, offset by a $0.6 million decrease in revenue from the scheduled completion of CDPs. Of the growth from the expansion of existing customer engagements, $4.5 million in revenue was derived from two CDPs.

Product revenue remained consistent during the three months ended March 31, 2012 and 2011 at $0.7 million. There were no new product sales that were initiated during the three months ended March 31, 2012.

Licensing and royalty revenue increased by $0.3 million, or 9%, to $3.5 million during the three months ended March 31, 2012 from $3.2 million during the three months ended March 31, 2011. This increase was primarily attributable to an increase in minimum license fees for the sales of products subject to licensing fees and royalties as guaranteed by customer contracts, including a non-recurring increase in the amount of $0.2 million related to the expiration of a customer’s purchase option during the quarter, offset by a scheduled reduction in minimum license fee revenues.

Table of Contents

The following table presents revenue by geographic region (based on invoiced locations) during the three months ended March 31, 2012 and 2011 in dollars (in thousands) and as a percentage of revenue for the periods presented:

	Three Months Ended March 31,
	2012				2011
	Revenues		% of Revenues		Revenues		% of Revenues

United States	$	12,048	74	%	$	7,253	62	%
Japan	3,565		22	%	3,700		32	%
Taiwan	735		4	%	735		6	%
Europe and Middle East	34		0	%	—		0	%
Total	$	16,382	100	%	$	11,688	100	%

Cost of Revenue

Cost of revenue increased by $1.7 million, or 30%, to $7.2 million during the three months ended March 31, 2012 from $5.5 million during the three months ended March 31, 2011. This change is directly attributable to increased CDP and services revenue recognized from new and ongoing customer engagements, which resulted in a $1.8 million increase in direct labor, materials and other costs associated with these programs. This increase was partially offset by a decrease in cost of licensing and royalty revenue from the elimination of royalty payments to Symyx in connection with the Symyx asset purchase agreement that closed in November 2011 that eliminated our obligation to pay Symyx a 5% royalty on all HPC-derived revenue. The elimination of the royalty obligation was partially offset by the amortization of Symyx-acquired IP and licensing obligations payable to the Lawrence Berkeley Laboratories that collectively approximated $0.2 million during the three months ended March 31, 2012.

Cost of revenue as a percentage of revenue decreased from 47% during the three months ended March 31, 2011 to 44% during the three months ended March 31, 2012. To the extent we are successful in growing our revenue and increasing licensing and royalty revenue as a percentage of revenue we expect our cost of revenue as a percentage of total revenue to decline.

Research and Development

Research and Development (R&D) expenses increased by $0.5 million, or 12%, to $5.1 million during the three months ended March 31, 2012 from $4.5 million during the three months ended March 31, 2011. The change is primarily attributable to $1.0 million in higher personnel costs as a result of increased headcount and higher stock-based compensation expense and $0.1 million in consulting and professional service fees. These costs are partially offset by a $0.4 million decrease in facility and occupancy-related costs due to the elimination of costs from our prior facility, which closed in October 2011, and a $0.2 million decrease in depreciation expense due to increased utilization of lab equipment for customer programs whose costs are recognized in cost of revenue.

Sales and Marketing

Sales and marketing expenses increased by $0.3 million, or 37%, to $1.2 million during the three months ended March 31, 2012 from $0.9 million during the three months ended March 31, 2011. The change is primarily due to higher personnel costs related to increased wages and commissions expense.

Table of Contents

General and Administrative

General and administrative expenses increased by $1.0 million, or 57%, to $2.8 million during the three months ended March 31, 2012 from $1.8 million during the three months ended March 31, 2011. The increase is primarily attributable to $0.5 million in higher professional fees associated with legal and accounting services associated with being a public company, and $0.5 million in higher personnel costs as a result of increased headcount.

Income (Loss) from Operations

Our operating loss decreased by $1.1 million, to an operating income of $0.1 million during the three months ended March 31, 2012 from an operating loss of $1.0 million during the three months ended March 31, 2011. To the extent we are successful in growing our revenue and increasing licensing and royalty revenue as a percentage of our total revenue, and if our expenses increase at a slower rate than our revenue, we expect that our income from operations will increase in the future. Our operating expenses increased by $1.9 million to $9.1 million during the three months ended March 31, 2012 from $7.2 million during the three months ended March 31, 2011. We expect our operating expenses to continue to increase as we expand and invest in our business, making investments in both personnel and capital resources leading to increased depreciation expense.

Interest (Expense) Income, net

Interest (expense) income, net decreased by $0.3 million to an expense of $0.3 million during the three months ended March 31, 2012 from income of $4,000 during the three months ended March 31, 2011. The decrease is primarily attributable to interest expense associated with our note payable to Symyx.

Other Expense, net

Other expense, net increased by $0.2 million to an expense of $6,000 during the three months ended March 31, 2012 from an expense of $0.2 million during the three months ended March 31, 2011. This change was due to the conversion and subsequent exercise of our outstanding preferred stock warrant liability in connection with our initial public offering in November 2011 and accordingly is no longer outstanding or subject to remeasurement during the three months ended March 31, 2012.

Provision for Income Taxes

Provision for income taxes as of March 31, 2012 and 2011 consisted of income taxes on our foreign entities and were not significant during either period.

Net Loss

Our net loss decreased by $1.0 million, to a net loss of $0.2 million during the three months ended March 31, 2012 from a net loss of $1.2 million during the three months ended March 31, 2011. The difference between operating income and net loss during the three months ended March 31, 2012 was primarily related to interest expense associated with our note payable to Symyx.

Liquidity and Capital Resources

Since inception, we have substantially financed our operations through private and public sale of equity securities and, to a lesser extent, cash flow from operations. As of March 31, 2012, we had $82.1 million of cash, cash equivalents and short-term investments, $75.7 million of net working capital, and debt outstanding of $27.2 million.

Table of Contents

To date, we have incurred significant losses. During the three months ended March 31, 2012 and 2011, we incurred net losses of $0.2 million and $1.2 million, respectively. As of March 31, 2012, our accumulated deficit was $100.7 million.

We believe that we have the financial resources needed to meet business requirements for the next 12 months. Our future capital requirements will depend on many factors, including our rate of revenue growth, our expansion of our sales and marketing activities and overhead expenses, the timing and extent of our spending to support our R&D efforts and our ability to expand CDPs in the semiconductor industry, whether we are successful in obtaining payments from customers, the financial stability of our customers, whether we can enter into additional collaborations in our target industries, the progress and scope of collaborative R&D projects performed by us and our customers, the effect of any acquisitions of other businesses or technologies that we may make in the future, the filing, prosecution and enforcement of patent claims, how much we need to develop or enhance our solutions or HPC platform and any necessary responses to competitive pressures. To the extent that existing cash and cash equivalents and cash from operations are insufficient to fund our operations, we may need to raise additional funds through public or private equity or debt financing. We may also seek to invest in or acquire complementary businesses, applications or technologies, any of which could also require us to seek additional equity or debt financing. Additional funds may not be available on terms favorable to us or at all. We maintain almost all of our cash in the United States and therefore are not subject to restrictions or tax obligations as we access the cash.

During February 2012, one of our significant customers, Elpida, filed for protection under the Corporate Reorganization Act in Japan. Our revenue from Elpida may decline as a result. For example, as part of any restructuring under this Act, our CDP services may be reduced or even eliminated, and Elpida may either voluntarily or involuntarily reduce or eliminate payments owed to us or shipments of products that include our licensed technology. The use of our technology in their current product shipments generates a license fee for us, and may include a royalty when additional developed technology is incorporated in future Elpida products. Any adjustment in the amount of CDP services fees, license fees or royalties that Elpida would owe us pursuant to our agreement with them could be reduced or eliminated as a result of changes in their shipments and product development. If any of these were to occur our revenue would decline, and our financial condition and results of operations would be materially and adversely affected. During the three months ended March 31, 2012 we recognized $2.2 million in revenue from Elpida and as of March 31, 2012 had outstanding accounts receivable in the amount of $0.2 million and backlog in the amount of $15.6 million, of which $6.6 million is to be recognized during 2012 with the balance to be recognized in periods beyond 2012. Of the $6.6 million in backlog to be recognized as revenue during 2012 that is attributable to Elpida, we received payment in the amount of $2.2 million in April 2012 for CDP services and license fees for the three month period ending June 30, 2012.

Cash Flows

The following summary of our cash flows for the periods indicated has been derived from our condensed consolidated financial statements included elsewhere in this filing (in thousands):

	Three Months Ended March 31,
	2012			2011

Net cash provided by (used in) operating activities	$	1,749		$	(4,369	)
Net cash used in investing activities	$	(1,911	)	$	(3,500	)
Net cash provided by financing activities	$	7		$	14,942

Table of Contents

Cash Flows from Operating Activities

We experienced positive cash flows from operating activities during the three months ended March 31, 2012, and experienced negative cash flows from operating activities during the three months ended March 31, 2011.

Net cash provided by operating activities during the three months ended March 31, 2012 of $1.7 million reflects a net loss of $0.2 million and non-cash charges of $1.9 million for depreciation and amortization and $0.8 million in stock-based compensation. The net decrease in our operating assets and liabilities of $0.7 million was primarily the result of a $1.7 million increase in inventory, a $1.5 million decrease in accounts payable and accrued liabilities and a $3.1 million decline in deferred revenue related to the earn out of customer prepayments. This decline was partially offset by increased cash collections resulting in a net decrease in accounts receivable of $5.1 million and utilization of prepaid and other assets of $0.4 million.

As of March 31, 2012 we had $8.8 million in deferred revenue for which we have already received payment, of which $8.1 million will be recognized in revenue during 2012 and $0.7 million will be recognized as revenue during 2013.

Cash Flows from Investing Activities

Our investing activities consist primarily of purchases and sales of short-term investments, capital expenditures to purchase property and equipment and our investments in intangible assets relating to our patents and trademarks. In the future, we expect we will continue to make significant capital expenditures to support our expanding operations and incur costs to protect our investment in our developed technology and IP.

During the three months ended March 31, 2012, cash used in investing activities was $1.9 million as a result of the purchase of $1.3 million in certificates of deposit classified as short-term investments, $0.3 million in capital expenditures and $0.3 million in capitalized patent and trademark costs. The decline in capital expenditures compared to the prior year is primarily attributable to the completion of our clean room facility build-out as we completed our move to our new office location during 2011.

Cash Flows from Financing Activities

To date, we have financed our operations primarily with proceeds from the sale of our redeemable convertible preferred stock and proceeds received from our initial public offering.

During the three months ended March 31, 2012, cash provided by financing activities was related to the issuance of common stock as a result of employee option exercises in the amount of $121,000, offset by a principal payment related to our note payable to Symyx in the amount of $114,000.

Table of Contents

Contractual Obligations and Commitments

The following summarizes our contractual obligations as of March 31, 2012 (in thousands):

	Payments Due by Period
	Total		Less Than One Year		1 - 3 Years		3 - 5 Years		More Than 5 Years

Operating lease obligations	$	5,305	$	1,213	$	4,092	$	—	$	—
Note payable	27,203		689		26,514		—		—
Contractual interest payments on note payable	1,747		811		936		—		—
Purchase obligations(1)	1,988		1,988		—		—		—
Total	$	36,243	$	4,701	$	31,542	$	—	$	—

(1) Purchase obligations consist of firm, non-cancelable agreements to purchase property and equipment and inventory related items.

Operating lease agreements represent our obligations to make payments under our non-cancelable lease agreement for our facility in San Jose, California. During the three months ended March 31, 2012, we made regular lease payments of $0.4 million under this operating lease agreement.

In connection with the consummation of the Symyx asset purchase transaction, which occurred in connection with the consummation of our initial public offering, we issued a promissory note payable to Symyx. The note has a remaining principal amount equal to $27.2 million and a remaining term of approximately 20 months and an interest rate of 4% and is payable in amounts equal to the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity on November 23, 2013, if applicable.

Off-Balance Sheet Arrangements

As of March 31, 2012, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and foreign currency exchange rates. We do not hold or issue financial instruments for trading purposes.

Interest Rate Sensitivity

Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our outstanding debt obligations. Our cash, cash equivalents and short-term investment accounts as of March 31, 2012 total $82.1 million, consisting of $80.8 million in cash and money market funds with maturities of less than three months from the date of purchase and $1.3 million in certificates of deposit with maturities of less than twelve months from the date of purchase. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our consolidated financial condition or our results of operation.

Table of Contents

In connection with the consummation of the Symyx asset purchase transaction, which occurred in connection with the completion of our initial public offering, we issued a promissory note payable to Symyx. The note has a principal amount equal to $27.3 million and a term of 24 months and a fixed interest rate of 4% and is payable in amounts equal to the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity, if applicable. As of March 31, 2012, $27.2 million in principal remained outstanding on the note payable to Symyx. The interest rate on our debt is fixed; however, in the event we enter into other long-term debt arrangements, we could be subject to fluctuations in interest rates which could have a material impact on our future financial condition and results of operation.

Foreign Currency Exchange Risk

As we expand internationally, our consolidated results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. Our revenue is denominated in U.S. dollars. Our expenses are generally denominated in the currencies in which our operations are located, which is primarily in the United States, with an insignificant portion of expenses incurred in our wholly-owned subsidiaries in Hong Kong and Japan and our wholly-owned branch in Taiwan in their local currencies. The effect of a hypothetical 10% change in foreign currency exchanges rates applicable to our business would not have a material impact on our consolidated financial statements. To date, we have not entered into any material foreign currency hedging contracts although we may do so in the future.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2012. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of March 31, 2012, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost effective control system, misstatements due to error or fraud may occur and not be detected.

Table of Contents

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in other legal proceedings and claims arising in the ordinary course of our business. We are not currently a party to any legal proceedings the outcome of which, if determined adversely to us, we believe would individually or in the aggregate have a material adverse effect on our business, operating results, financial condition or cash flows.

ITEM 1A. RISK FACTORS

We describe our business risk factors below. This description includes any material changes to and supersedes the description of the risk factors disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission on March 16, 2012 (the “2011 Annual Report”). You should carefully consider the risks described below together with the other information set forth in this Quarterly Report on Form 10-Q, which could materially affect our business, financial condition or future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

We have marked with an asterisk (*) those risks described below that reflect substantive changes from the risks described under “Risk Factors” included in our 2011 Annual Report.

Risks Related to Our Financial Condition and Business

We have a limited operating history, which makes it difficult for investors to evaluate our current business and future prospects.

We were incorporated in June 2004 and do not have a long history of operating results on which you can base your evaluation of our business. We are still proving our business model, and we have not yet demonstrated our ability to generate significant revenue, particularly licensing and royalty revenue. As a result, it may be difficult for analysts and investors to evaluate our future prospects. If we do not generate significant licensing and royalty revenue, we may never be profitable. Furthermore, because of our limited operating history and because the semiconductor and clean-energy industries are rapidly evolving, we have limited experience in analyzing and understanding the trends that may emerge and affect our business. If we are unable to obtain significant licensing and royalty revenue from products that incorporate technology developed through our collaborative development programs (CDPs), we will have expended a significant amount of time and resources without obtaining the benefits we anticipated, and our financial condition and results of operations would be materially and adversely affected.

Our operating results may fluctuate from quarter to quarter, which may make it difficult to predict our future performance and may result in volatility in the market price of our common stock if we fail to meet the expectations of public market analysts and investors in these periods.

Our revenue, expenses and operating results have fluctuated, and may in the future fluctuate significantly from quarter to quarter due to a number of factors, many of which are outside our control. Factors that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Quarterly Report on Form 10-Q:

· our dependence on a limited number of customers;

· our ability to manage our growth, including an increasing number of employees, customers and CDPs;

Table of Contents

· the length of our sales and development cycles, and our ability to generate material revenue after we have devoted significant resources to developing a project;

· our ability to evolve existing products, anticipate trends in technology development and introduce new developments in a timely manner in the rapidly changing semiconductor and clean-energy industries;

· our customers’ ability to manufacture, market and sell products that incorporate technology developed through the CDPs;

· the financial stability of any of our customers;

· fluctuations in the number and price of products sold by our customers that incorporate technology developed through the CDPs, and the shortening life cycles of those products, in each case impacting our licensing and royalty revenue;

· our ability to scale our development efforts, our ability to secure new CDPs with new or existing customers and the timing of those CDPs;

· the degree to which existing CDPs are completed, extended or expanded;

· one-time, non-cash charges to revenue associated with the vesting of contingent warrants issued to two of our customers that are currently outstanding;

· our ability to maintain existing commercial terms or enter into new licensing arrangements with our customers once they begin to sell their end products;

· our ability to make the substantial research and development (R&D) investments required to stay competitive in our business;

· our ability to develop our high productivity combinatorial (HPC) platform and expertise to support our future growth plans in adjacent vertical markets such as clean-energy markets;

· any potential involvement in intellectual property litigation;

· any potential payments to our customers resulting from our intellectual property indemnification policies and obligations;

· our reliance on our customers to deliver timely and accurate information to accurately report our financial results from licensing and royalty revenue;

· our potential need for additional capital to finance our business;

· any delay in shipments caused by shortages of components incorporated in our customers’ products, design errors or other manufacturing problems associated with our customers’ products;

· the highly cyclical nature of and price volatility in the semiconductor industry;

· the emerging and uncertain nature of the clean-energy industry;

· potential warranty claims, product recalls and product liability for our HPC tools and for our customers’ products that incorporate technology developed through our CDPs;

· global or regional economic, political and social conditions; and

· business interruptions such as earthquakes and other natural disasters.

Due to these factors and other risks discussed in this section, you should not rely on quarter-to-quarter comparisons to predict our future performance. Our revenue mix may also vary from quarter to quarter as we enter into new CDPs and related customer arrangements, existing CDPs are completed, extended or expanded and licensing and royalty arrangements take effect. Unfavorable

Table of Contents

changes in any of these factors may adversely affect our business and operating results. Additionally, our common stock could be subject to significant price volatility should our actual or projected revenue or earnings fail to meet the expectations of the investment community. Furthermore, stocks of high technology companies are subject to extreme price and volume fluctuations that are often unrelated or disproportionate to the operating performance of those companies.

We have incurred operating losses since our inception and may not be able to achieve or maintain profitability.*

We have generated net losses each year since our inception, including $0.2 million for the three months ended March 31, 2012 and $30.0 million, $1.8 million and $5.3 million for the years ended December 31, 2011, 2010 and 2009, respectively. Our accumulated deficit as of March 31, 2012 was $100.7 million. We will need to significantly increase revenue to achieve profitability and we may not achieve or subsequently maintain profitability if our revenue increases more slowly than we expect or not at all.

Our ability to achieve our objectives and achieve or maintain the profitability of our business will depend, in large part, on potential customers accepting our HPC platform and methodology as effective tools in the development of new products; and on our success in helping our customers develop products that are successful in the marketplace. Historically, semiconductor companies have conducted R&D activities internally using traditional research methods. In order for us to achieve our business objectives, we must convince these companies that our technology and capabilities justify collaborating with us on their basic R&D programs. We must also convince potential customers in the clean-energy industry that our HPC platform and approach are useful tools in an emerging industry. We cannot assure you we will achieve the levels of customer acceptance necessary for us to maintain and grow a profitable business. In addition, our profitability and success are dependent, in part, upon the receipt of royalties on the sale of products by our key customers, and we have no ability to control the timing of such products’ introduction or their success or failure in the marketplace. Our ability to achieve profitability also depends upon many other factors, including many that are beyond our control. These factors include, without limitation:

· changes in the demand for our products and services;

· the introduction of competitive technologies;

· our ability to engage with new customers that would use our technology and expertise to further develop and commercialize their products;

· our ability to enter into CDPs with customers who are or become market leaders;

· the competitiveness and financial strength of our existing and potential customers;

· changes in the R&D budgets of our customers and potential customers;

· our ability to develop our technology for and secure customers in the clean-energy industry; and

· our participation in the development of products that our customers choose to commercialize that generate a substantial stream of licensing and royalty revenue for us.

In addition, we expect to continue to incur significant expenses or revenue adjustments in connection with, among other things:

· increased R&D spending, including expansion of our R&D teams and workflow platforms;

· expansion of our sales and marketing efforts;

· additional non-cash charges relating to amortization of intangibles and deferred stock compensation; and

· one-time, non-cash charges to revenue associated with the vesting of contingent warrants issued to two of our customers that are currently outstanding.

Table of Contents

We cannot assure you we will achieve the levels of customer acceptance necessary for us to maintain and grow a profitable business, or that any of these other factors will be satisfactory. Also, we cannot assure you that customers, even those that accept our HPC platform as a valid tool for R&D, will be satisfied with the technology developed through our CDPs or will be able to successfully commercialize end products incorporating the developed technology. Failure to achieve the necessary customer acceptance or extend or add current or new customer relationships, as well as difficulty with any of these other factors would adversely affect our revenue and profitability and our financial condition and results of operations would be materially and adversely affected.

We depend on a limited number of customers, which have historically been in the semiconductor industry, and a loss of any of them would adversely affect our business and operating results.*

Our customer base is highly concentrated. Revenue has historically come from a few customers, and we expect that revenue from a small number of customers will continue to account for a high percentage of our revenue for the foreseeable future. Due to the concentrated nature of manufacturers in the DRAM, flash memory and complex logic markets, our revenue is and may continue to be concentrated among and reliant upon key high-volume customers. For example, our three largest customers during the three months ended March 31, 2012, all of which are in the semiconductor industry, accounted for 68% of our revenue, and our two largest customers for the years ended December 31, 2011 and 2010, both of which are in the semiconductor industry, accounted for 47% and 72% of our revenue, respectively. Our largest customer accounted for 29% and 52% of our revenue in each of these periods, respectively. The loss of any of these customers or a decrease in the manufacturing or sales volumes of their products, or their failure to pay amounts due to us or renew or extend their existing relationships with us, and the related impact on our future anticipated licensing and royalty revenue, would materially and adversely affect our business, financial condition or results of operations, and we may not be able to replace the business from these customers. In particular, Elpida, recently filed for protection under the Corporate Reorganization Act in Japan, and our revenue from Elpida may decline as a result. For example, as part of any restructuring under this Act, our CDP services revenue may be reduced or even eliminated, and Elpida may either voluntarily or involuntarily reduce or eliminate payments owed to us or shipments of products that include our licensed technology. The use of our technology in their current product shipments generates a license fee for us, and may include a royalty when additional developed technology is incorporated in future Elpida products. Any adjustment in the amount of CDP services fees, license fees or royalties that Elpida would owe us pursuant to our agreement with them could be reduced or eliminated as a result of the restructuring or changes in their shipments and product development. If any of these were to occur our revenue would decline, and our financial condition and results of operations would be materially and adversely affected. During the three months ended March 31, 2012, we recognized $2.2 million in revenue from Elpida, and as of March 31, 2012 had outstanding accounts receivable in the amount of $0.2 million and backlog in the amount of $15.6 million, of which $6.6 million is to be recognized during 2012 with the balance to be recognized in periods beyond 2012. In addition, this type of loss could cause significant fluctuations in our results of operations because our expenses are fixed in the short term and our sales and development cycle to obtain new customers is long.

Our rapid growth has presented significant challenges to our management and administrative systems and resources, and we may experience difficulties managing our growth, which could adversely affect our business and operating results.*

We will need to continue to grow in all operational areas and to successfully integrate and support our existing and new employees, which may make it difficult to implement our business strategy in the time frame we anticipate, if at all. Our business has grown rapidly, and we expect this growth to continue as we expand our R&D capacity for current and additional CDPs. For example, we had 216 full-time employees as of March 31, 2012 and 107 employees at the end of 2008. The rapid expansion of our business and addition of new personnel has placed a strain on our management, operational systems and facilities and may continue to do so. To effectively manage our operations and growth as well as our obligations as a public company, we must continue to expend funds to enhance our operational, legal, financial and management controls, reporting systems and procedures and to attract and retain

Table of Contents

sufficient numbers of talented employees. If we are unable to effectively manage the addition of new employees, it may lead to employee claims against us based on, among other things, wage and hour violations, discrimination, harassment or wrongful termination which may divert our financial and management resources. If we are unable to expand our R&D capacity and implement improvements to our control systems efficiently and quickly, or if we encounter deficiencies in existing systems and controls, then we will not be able to successfully grow our business as planned. Our future operating results will also depend on our management’s ability to:

· implement and improve our sales, marketing and customer support programs and our R&D efforts;

· enhance our operational and financial control systems;

· expand, train and manage our employee base;

· integrate any acquired businesses; and

· effectively address new issues related to our growth as they arise.

We may not manage our expansion successfully, which could adversely affect our business, financial condition or results of operations.

Our business prospects and future growth depend on royalties, which may be difficult to structure and enforce.

We believe that our royalty-bearing licenses with our customers lay the framework for ongoing royalty revenue from our customers’ products that incorporate technology developed through our CDPs with these customers, and that this revenue stream will increase as revenue from products developed using our platform increases. We are dependent upon our ability to structure, negotiate and enforce agreements for the determination and payment of royalties. Unless we adequately demonstrate the value of our platform to our potential customers we may face resistance to structuring royalty arrangements in the future that are acceptable to us, or our customers may not agree to enter into royalty-bearing licenses with us at all. If we are unable to maintain the royalty-bearing license aspect of our business model, our operating results would suffer and we may not achieve profitability.

Our sales cycles are long, and we commit significant resources to a project before we have any commitment that a potential customer may agree to use our platform or service. One or more failures to enter into a CDP after we have devoted significant resources to a project could adversely affect our business and operating results.*

Our sales efforts require us to educate our potential customers about the benefits of our solutions, which often requires significant time and expense, including a significant amount of our senior management’s time and effort. Our sales cycles to date have typically ranged from 9 to 24 months and may be even longer in the future. Furthermore, we need to target those individuals within a customer’s organization who have overall responsibility for the profitability of their products. These individuals tend to be senior management or executive officers. We may face difficulty identifying and establishing contact with these individuals. In addition, our customers’ technology and product pipeline are highly confidential and they may choose to withhold certain information from us during the sales cycle to protect their own proprietary technology. Our ability to implement our HPC platform and methodology is heavily dependent upon the information provided to us by our customers. If our customers reveal the complexities of their specifications after we enter into a CDP with them, that complexity may cause delays unanticipated at the time we entered into the program. During our sales cycles, we incur significant expenses and, in many cases, may begin to build new systems, configure, modify, expand or customize existing systems, develop software and design workflows to meet our customers’ requirements prior to obtaining contractual commitments, without any assurance of resulting revenue. Where a potential customer engagement requires a new dedicated HPC platform, we may invest in new capacity ahead of a customer commitment. Our cycles to build, configure, modify, expand or customize the HPC platform to date have ranged from three to nine months and may be even longer in the future. Investment of time and expense in a particular customer engagement that does not ultimately result in material revenue will adversely affect our revenue and results of operations. Other factors impacting sales and the length of our sales and development cycles include, but are not limited to, the following:

Table of Contents

· the complexity and cost of our HPC platform and difficulties we may encounter in meeting individual customer specifications and commitments;

· our ability to build new systems, configure, modify, expand or customize existing systems, develop software and design workflows to meet our customers’ requirements;

· the limited number of customers that are appropriate sales targets for our platform and that are willing to enter into licensing agreements with us;

· our customers’ budgetary constraints and internal review procedures that must be completed to begin collaboration with us; and

· the cultural transition required for a customer’s internal R&D team to embrace us as a collaborative partner.

The semiconductor industry is rapidly changing and an inability to evolve existing products in a timely manner, anticipate trends in technology development and introduce new technologies could adversely affect our business and operating results.

We must continually devote significant engineering resources to keep up with the rapidly evolving technologies, materials and equipment used in semiconductor design and manufacturing processes. These innovations are inherently complex and require long development cycles. The semiconductor industry is subject to a number of evolving trends, including:

· the growing varieties of semiconductor architecture, applications and processes;

· differing market growth rates and capital requirements for different applications, such as flash memory, DRAM, logic and foundry, and the resulting effect on customers’ spending patterns and on our ability to compete in these market segments;

· the importance of growing market positions in larger market segments;

· the increasing consolidation of semiconductor manufacturing towards foundries and large scale manufacturers and subsequent concentration of research and innovation in manufacturing process development; and

· the cost, technical complexity and timing of a proposed industry transition from 300mm to 450mm wafers.

These and other changes could have a material impact on our business. Not only do we need the technical expertise to implement the changes necessary to keep our technologies current, but we also rely heavily on the judgment of our management and advisors to anticipate future market trends. Our customers expect us to stay ahead of the technology curve in their sectors and expect that the technology developed through our CDPs will help them develop new products that keep pace with or push the limits of technological innovation. If we are not able to accurately predict industry changes, or if we are unable to apply our HPC platform to our customers’ needs on a timely basis, our existing solutions will be rendered obsolete and we may lose customers. If we do not keep pace with technology, our existing and potential customers may choose to develop their own solutions internally as an alternative to ours, and we could lose market share to competitors, which could adversely affect our operating results.

Table of Contents

The clean - energy industry is in a very early stage of development, and we may not earn significant revenue from our initiatives in this industry for an extended period, if ever.*

The clean energy industry is comprised of several sectors including energy-efficient glass, solar cells, LEDs, advanced batteries and other energy-efficient technologies . Most sectors of the clean-energy industry are in the very early stages of development. Many of the associated technologies have not yet achieved commercial viability in comparison to available alternatives, and may never achieve market adoption. Many of the associated technologies will require substantial investments of capital to achieve scale, which may not be available on attractive terms, if at all. Companies within the clean-energy industry may also be hesitant to enter into CDPs with us given our recent entry into the clean-energy industry. Certain technologies may depend on government subsidies to be commercially viable, and those subsidies may not be available from federal and state governments facing increasing financial constraints. If sectors of the clean-energy industry take an extended period to achieve market acceptance and to garner significant revenue, we may not earn material revenue from our initiatives in this area until such time, if ever. Furthermore, it may be difficult for us to predict which clean-energy companies and which technologies may become market leaders, and we may invest time and resources in collaborations with companies who are ultimately unsuccessful in the clean-energy industry, which could adversely affect our operating results.

If a project to which we have devoted technology and significant resources fails to produce any measurable success or value to our customers in the form of differentiated technology and intellectual property, we may not earn licensing and royalty revenue sufficient to recover the upfront costs and cash invested in the CDP, which could adversely affect our results of operations.

In some cases, the revenue we receive from our customers during the development stage is not sufficient for us to fully recover our costs and cash invested in HPC platforms dedicated to customer engagement, and our business model relies on licensing and royalty revenue based on the sales by our customers in the end-markets of products incorporating the technology developed through our CDPs. Our CDPs involve complex R&D, and our ability to develop the differentiated technology and intellectual property sought by our customers is inherently uncertain and difficult to predict. In addition, there are a limited number of CDPs to which we can commit our resources at any given time. If a project to which we have devoted technology and significant resources fails to produce any measurable success or value to our customers in the form of differentiated technology and intellectual property that they may use in their products, we may not receive meaningful amounts of, or any, licensing and royalty revenue. In this case, we may not recover the upfront costs and cash invested in the CDP, which could adversely affect our results of operations. In addition, even if we successfully develop differentiated technology and intellectual property through a CDP that our customer is able to commercialize, there may be a significant delay before we receive any licensing or royalty revenue due to the complexities inherent in production and manufacturing in our target markets.

A decline in sales in the end markets for products incorporating technology developed through our CDPs could adversely affect our business and results of operations.

Our success is tied to our customers’ ability to successfully commercialize the products that incorporate technology developed through our CDPs. The markets for our customers’ products are intensely competitive and are characterized by rapid technological change. These changes result in frequent product introductions, short product life cycles and increased product capabilities. Competition is based on a variety of factors including price, performance, product quality, software availability, marketing and distribution capability, customer support, name recognition and financial strength. Products incorporating the technology developed through our CDPs may not achieve market success or may become obsolete. We cannot assure you that our customers will dedicate the resources necessary to promote and commercialize products developed through our CDPs, successfully execute their business strategies for such products, be able to manufacture such products in quantities sufficient to meet demand or cost-effectively manufacture products at high volume. Our customers are not contractually obligated to manufacture, distribute or sell any products incorporating our CDP-developed technology. Our customers may develop internally or in collaboration with others technology that they might utilize instead of technology developed through our CDPs. Any of these factors, as well as more general market or industry issues, could result in a decline in sales of the products incorporating our technology, which would result in a decrease in any

Table of Contents

associated licensing and royalty revenue or the failure of any licensing and royalty revenue to materialize at all, and could adversely affect our business and results of operations. Any failure of a customer to achieve market success for products developed through our CDPs could also negatively affect such customer’s willingness to work with us on other collaborations and could more generally harm our reputation and business prospects.

If we are unable to scale our development services and secure new CDPs, our growth prospects would be limited and our business and operating results could be adversely affected.

Our customers require a significant amount of individualized attention as well as dedicated lab space for CDPs. We have limited space and internal capacity, both in terms of personnel as well as capital equipment resources, to meet these types of demands for our customers. In addition, because of the significant confidentiality concerns associated with the projects and products we work on and the restrictions on resource and information sharing we have implemented in response, we are not able to fully capitalize upon economies of scale. If the demand for our services and products exceeds our capacity to meet such demand, we may be required to turn down potential opportunities, which would cause us to lose potential revenue, and our potential customers may take their business to a competitor or decide to develop or expand internal R&D capabilities. If we are unable to scale our development services to meet demand, our growth may be hindered and our business and operating results could be adversely affected.

We may not be successful in maintaining and managing CDPs, which would adversely affect our ability to develop successful products and our financial condition and operating results.

CDPs are complex and time-consuming to implement and they may require substantial resources to maintain. We may not be successful in all of our collaboration efforts and may fail to achieve the technological innovations sought by our customers in a reasonable amount of time or at all. When we collaborate with a customer, we rely to some degree on the efforts and resources of that customer. Our customers may not devote sufficient resources to collaborations or may otherwise fail in the aspects of the collaboration for which they are responsible. Disagreements over the implementation and management of the program may occur, which could lead to material delays and/or a failure to achieve the successful development of technology through the CDP. If we fail to achieve successful collaborations, or if our customers are dissatisfied with the results of or the way we design and manage a CDP, our operating results and financial condition would be materially and adversely affected.

Our strategy includes conducting proprietary R&D efforts in collaboration with and on behalf of multiple customers. Failure to adequately protect against potential conflicts of interest and breaches of confidentiality would harm our reputation and our relationships with our customers, and our business prospects and operating results would be adversely affected. Moreover, some potential customers may hesitate to grant us access to their proprietary information, which could impair our ability to provide value for such customers.

Our strategy includes conducting proprietary R&D efforts in collaboration with and on behalf of customers who in some cases may have overlapping interests and technologies. We seek to structure our collaborative agreements and business practices to minimize any potential conflicts and the possibility of any breaches of confidentiality. We may need access to some of our customers’ proprietary information, and they may be reluctant to share it with us because of the risk of a potential conflict between us and/or our customers and other potential customers and the risk of a breach of confidentiality. Our failure to do so could result in our inability to attract new customers or retain existing customers, or lead to our having incomplete information with respect to existing customers that could impair our ability to fully address the customers’ needs and demonstrate the value of our technology to the customers. Even if we make significant efforts to isolate each development activity, we may fail to meet the contractual confidentiality commitments as to one or more customers. Moreover, even if we meet these commitments, conflicts between a customer and us, or between or among customers, could nevertheless arise. In either event, we may become involved in a dispute with our customers regarding the solutions developed during the collaboration or the rights to these solutions, including possible litigation. Disputes of this nature could harm the relationship between us and our customers, and could adversely affect our ability to enter into new CDPs and cause our revenue and operating results to decline.

Table of Contents

Our financial obligation to Symyx Technologies, Inc. could adversely affect our financial health and our ability to raise additional capital to fund our operations and limit our ability to react to changes in the economy or our industry.

In connection with an agreement for the purchase of intellectual property and the termination of our royalty obligations under an existing license agreement, we issued a promissory note in the principal amount of $27.3 million to Symyx Technologies, Inc. (Symyx), a wholly-owned subsidiary of Accelrys, Inc., upon the consummation of our initial public offering. The promissory note has a term of 24 months, an interest rate equal to 4% and is payable in an amount equal to the lesser of the principal amount and the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity if applicable. The promissory note is secured by all of our tangible personal property, but excluding intellectual property. During the three months ended March 31, 2012, the Company paid Symyx $500,000, which included interest in the amount of $386,000 and principal in the amount of $114,000.

Our obligations under the promissory note require us to dedicate a substantial portion of our cash flow from operations to payments on interest and principal of the promissory note at or prior to maturity, thus reducing the availability of our cash flow to fund working capital, capital expenditures, research and development efforts, execution of our business strategy and other general corporate purposes. Such limitations increase our vulnerability to adverse general economic and industry conditions and limit our flexibility in planning for, or reacting to, changes in the economy, our industry and new opportunities that may arise. In addition, our obligations under the promissory note and the security interests granted in favor of Symyx may make it more difficult for us to borrow funds in the future to fund working capital, capital expenditures and other purposes, which could materially and adversely affect our business, financial conditions and results of operations.

We may be unable to make the substantial R&D investments required to remain competitive in our business.

The semiconductor and clean-energy industries require substantial investment in R&D to develop and bring to market new and enhanced technologies and products. To remain competitive, we anticipate that we will need to maintain or increase our levels of R&D expenditures to keep pace with the development efforts of our customers. We expect R&D expenses to increase in absolute dollars for the foreseeable future, due to the increasing complexity and number of platforms and solutions we plan to develop both for our customers and internally, the expansion of our customer base and any associated increase in upfront R&D costs. In addition, the ultimate success of products incorporating our technology will depend in part on significant continued investment in R&D by our customers. We do not know whether we or our customers will have sufficient resources to maintain or increase the level of investment in R&D required to remain competitive. In addition, we cannot assure you that the technologies, products and applications on which we and our customers have focused our R&D expenditures will become commercially successful. If we are required to invest significantly greater resources than anticipated in our R&D efforts without a corresponding increase in revenue, our operating results could be materially and adversely affected.

If we are unable to develop our platform and expertise to support our future growth plans, our business and operating results could be adversely affected.*

We intend to further develop and broaden our HPC platform, including our software and informatics capabilities, to address a wider range of markets and customers for multiple applications within semiconductors, flat glass, solar cells, light emitting diodes (LEDs), flat-panel displays, advanced batteries and other energy-efficient technologies. However, we have limited expertise and experience in certain of these fields, and if we are unable to build new systems, or configure, modify, expand or customize existing systems for these applications and develop our expertise to support these fields our business growth might be limited, and our business and operating results could be adversely affected.

Table of Contents

If we lose one or more of our key personnel without obtaining adequate replacements in a timely manner or if we are unable to retain and recruit skilled personnel, our operations could become disrupted and the growth of our business could be delayed or restricted.

Our success depends, in large part, on the continued contributions of our senior management team, in particular, the services of Mr. David Lazovsky, our President and Chief Executive Officer, and Dr. Tony Chiang, our Chief Technology Officer. If we lose the services of Mr. Lazovsky or Dr. Chiang, it could slow the execution of our business plan, hinder our development processes and impair our sales efforts, and searching for a replacement could divert our other senior management’s time and increase our operating expenses. In addition, our customers could become concerned about our future operations, which could harm our reputation.

None of our senior management is bound by written employment contracts to remain with us for a specified period. The loss of any of our senior management could harm our ability to implement our business strategy and respond to the rapidly changing market conditions in which we operate. Upon hiring or promotion, new senior management personnel must spend a significant amount of time learning our technology, business model and management systems and their new roles, in addition to performing their regular duties. Accordingly, until new senior personnel become familiar with our technology, business model and systems or with their new roles, we may experience some disruption to our ongoing operations. Moreover, the loss of a member of our senior management or our professional staff would require the remaining management to divert attention to seeking a replacement.

Our future success and competitiveness depends on our ability to retain and motivate our unique team of highly skilled scientists and engineers, who have expertise across various disciplines, fields and technologies, including engineering, materials science, process development and integration, equipment, device process technologies and device integration. In addition, as we grow, we will have to continue to retain, attract and motivate qualified and talented personnel, including our scientists and engineers, management, sales and marketing and legal and finance personnel. Because our CDPs are customer-specific and project-specific and last for a significant period of time, the loss of key scientists or engineers or other personnel could have an adverse effect on a particular development program and on our ability to deliver results to a customer in a timely manner or at all. We do not know whether we will be able to retain all of these employees as we continue to pursue our business strategy. Competition for personnel is intense in the semiconductor and clean-energy industries.

We may encounter difficulties in hiring qualified scientists and engineers because there is a limited pool of scientists and engineers with the specialized expertise required to understand and implement our platform in conjunction with our customers. Further, we may have difficulty in obtaining visas permitting entry for some of our employees who are foreign nationals into the United States, and delays in obtaining visas permitting entry into other key countries for several of our key personnel, which could disrupt our ability to strategically locate our personnel. The loss of the services of key employees or our inability to retain, attract and motivate qualified scientists and engineers could have a material adverse effect on our business, financial condition and results of operations.

We may be unable to effectively protect our intellectual property, which would negatively affect our ability to compete.*

We depend on our proprietary HPC platform for our success and ability to compete. If others are able to reproduce our technology, our business will suffer significantly unless we can prevent them from competing with us. As of March 31, 2012, we owned 423 U.S. patents and patent applications (some of which also have foreign counterparts), which we believe protect our rights in our HPC platform and our rights in the technology developed through the CDPs. While we continue to file patent applications to seek protection for the further evolution of our HPC platform, patent laws provide only limited protection. We cannot assure you that all maintenance fees have been paid or that all filings have been made with the appropriate regulatory or governmental authorities with respect to any IP registered or applied for outside of the U.S. that we purchase. Also, patent protection in foreign countries may be limited or unavailable where we need this type of protection. A more detailed description of how we protect our IP is set forth in Part I, Item 1: “Business — Intellectual Property” included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2012.

The patent positions of technology companies, including ours, are often uncertain and involve complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We apply for patents

Table of Contents

covering our HPC platform and further advancements of our HPC platform as we deem appropriate. However, we may not obtain patents on all inventions for which we seek patents, and any patents we obtain may be challenged (both before and after any such patents issue) and may be narrowed in scope or extinguished as a result of these challenges. Additional uncertainty may result from the recent and potential future passage of patent reform legislation by the United States Congress, legal precedent as handed down by the United States Federal Circuit and Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. For these reasons, among others, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing similar or superior products. In that case, our revenue and operating results could decline.

Our strategy includes obtaining patent protection for technology developed in collaboration with our customers. A portion of our revenue from our customers derives from the licenses granted to our customers under these patents. If we are unable to obtain this type of protection, we would not be able to enforce exclusive rights to the technologies in question, and our revenue and operating results could decline.

We have developed in the past, and may develop in the future, patented technology with U.S. federal government funding. When new technologies are developed with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise “march-in” rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government-funded technology may be subject to restrictions on transfer to foreign entities, and some U.S. government-funded data may be subject to public disclosure under the Freedom of Information Act.

Many of our customers and competitors have significant operations outside the United States. Foreign laws may not afford us sufficient protections for our intellectual property, however, and we may not always seek patent protection outside the United States. We believe that our success depends, in part, upon our ability to obtain international protection for our IP. However, the laws of some foreign countries may not be as comprehensive as those of the United States and may not be sufficient to protect our proprietary rights abroad. Accordingly, our international competitors could obtain foreign patent protection for, and market overseas, products and technologies for which we are seeking patent protection in the United States.

Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.

We rely in part on trade secret protection to protect our confidential and proprietary information and processes. However, trade secrets are difficult to protect. We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective. We require new employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, employees, collaborators or consultants may still disclose or misuse our confidential information, and we may not be able to meaningfully protect our trade secrets. In addition, others may independently develop substantially equivalent information or techniques or otherwise lawfully gain access to our trade secrets, and thereafter communicate this information to others without maintaining its confidentiality. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

Table of Contents

Significant litigation over intellectual property in the industry may cause us to become involved in costly and lengthy litigation, which could subject us to liability, require us to stop licensing our developed technology or force us to develop new technology.

Whether or not patents are granted to us, litigation may be necessary to enforce our IP rights, to defend against a claim of infringement of IP rights of others or to determine the validity and scope of the proprietary rights of others. Because infringement is a fact-intensive inquiry, and because patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing (or, in some cases, are not published until they issue as patents), we cannot be certain that we do not now, and will not in the future, infringe a third party’s patent rights. We may also become party to claims by our customers to IP rights developed by us in connection with a CDP. If our customers become involved in disputes with third parties over allegations that our customers’ practice of our IP rights infringes the IP rights of such third parties, it may also become necessary for us to become involved in such disputes.

Any claim, even if without merit, could be time consuming to defend, result in costly litigation, or require us to enter into licensing agreements, resulting in unexpected operating costs. Moreover, our opponents in any litigation may have significantly more resources with which to defend against or assert claims in the litigation. A successful claim of infringement against us in connection with the use of our technologies could force us to stop using our technologies that incorporate the infringed IP; pay substantial monetary damages or royalties; grant cross-licenses to third parties relating to our own IP; obtain a license from the owner of the infringed IP, which may not be available to us on acceptable terms or at all; or re-engineer our platform or products to avoid further IP infringement, which may be technically impossible or commercially infeasible. The occurrence of any of these eventualities could adversely affect our business. Even if we are successful in defending such a claim, litigation could also divert our resources, including our managerial and engineering resources. Any infringement claim or other litigation against or by us could have a material negative effect on our business.

Our intellectual property indemnification policies and obligations may adversely impact our business and operating results.

Any assertion by a third party asserting ownership or other rights to technology developed through our CDPs could result in our customers becoming the target of litigation and we may be bound to indemnify our customers under the terms of our license agreements. These obligations could result in substantial expenses to us, which could have a material adverse effect on our business, financial condition and results of operations. In addition to the time and expense required for us to satisfy our support and indemnification obligations to our customers, any litigation could severely disrupt or shut down the business of our customers, which in turn could damage our relations with them and have a material adverse effect on our reputation, business, financial condition and results of operations.

We will need to rely on our customers to deliver timely and accurate information to accurately report our financial results from licensing and royalty revenue in the time frame and manner required by law.

We will need to receive timely, accurate and complete information from our customers to accurately report our financial results on a timely basis. Licensing and royalty revenue we may receive in the future may be based on the revenue from the sale of our customers’ products that incorporate technology developed through our CDPs, and we will need to rely on our customers to provide us with complete and accurate information regarding revenue and payments owed to us on a timely basis. If the information that we receive is not accurate, we may not receive the full amount of revenue that we are entitled to under these arrangements on a timely basis, which could result in adjustments to our financial results in a future period. Although we typically have audit rights with these parties, performing this type of audit could be harmful to our collaborative relationships, expensive and time-consuming and may not be sufficient to reveal any discrepancies in a timeframe consistent with our reporting requirements.

Table of Contents

We may need additional capital in the future to finance our business.

Our future capital requirements may be substantial, particularly as we continue to develop our business and expand our collaborative development efforts. Although we believe that, based on our current level of operations and anticipated growth, our existing cash, cash equivalents and marketable securities, combined with the net proceeds from our initial public offering, will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months, we may need additional capital if our current plans and assumptions change. Our need for additional capital will depend on many factors, including our rate of revenue growth, our expansion of our sales and marketing activities and overhead expenses, the timing and extent of our spending to support our R&D efforts and our ability to expand CDPs in the semiconductor industry, whether we are successful in obtaining payments from customers, the financial stability of our customers, whether we can enter into additional collaborations in our target industries, the progress and scope of collaborative R&D projects performed by us and our customers, the effect of any acquisitions of other businesses or technologies that we may make in the future, the filing, prosecution and enforcement of patent claims, how much we need to develop or enhance our solutions or HPC platform and any necessary responses to competitive pressures.

If our capital resources are insufficient to meet our capital requirements, and our revenue is insufficient to support any of these activities, then we will have to raise additional funds. If future financings involve the issuance of equity securities, our then-existing stockholders would suffer dilution. If we raise future debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise sufficient funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and continue to incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate R&D programs, curtail or cease operations, obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may not be able to successfully execute our business plan or continue our business.

Failure of suppliers to timely deliver sufficient quantities of the components, materials or software used in our collaborations, may result in delays or other disruptions in executing our CDPs, which could adversely affect our business and operating results.

We have historically relied on a small number of contract manufacturing companies for the manufacture and assembly of a majority of our HPC tools. While we are not dependent on any single contract manufacturing company, key parts of our tools are currently available only from a limited number of sources. In addition, components of our capital equipment are available from only a few suppliers. If supplies from these vendors are delayed or interrupted for any reason, we may not be able to get equipment or components for our tools or our own research efforts in a timely fashion or in sufficient quantities or under acceptable terms, if at all. Even though alternative sources of supply would be available, it could be time-consuming and expensive for us to qualify new vendors and work with them to integrate our designs into the tools they manufacture for us. In addition, we depend upon our vendors to provide components of appropriate quality and reliability. Consequently, if supplies from these vendors were delayed or interrupted for any reason, it could materially and adversely affect our business.

Our business strategy requires us to evaluate, integrate and develop elements of our customers’ value chains, including development and manufacturing processes. Our ability to evaluate these effectively may sometimes depend on the cooperation from our customers’ materials suppliers and equipment manufacturers as well as access to their data and tools. If these third parties do not cooperate with us or provide us access to the necessary materials, tools or equipment we may not be able to deliver effective solutions to our customers, which would adversely affect our business and results of operations.

We have to evaluate multiple elements of our customers’ value chains to help them test and develop end products that meet their specifications, including the materials, tools and equipment used by them during the manufacturing process. Our ability to evaluate a customer’s value chain effectively may sometimes depend on cooperation from such customer’s materials suppliers and equipment manufacturers and on access to their data and tools. Our evaluation of the materials and equipment in the value chain must be

Table of Contents

unbiased to maintain credibility with our customers, and our evaluation sometimes results in recommendations that our customers change materials, tools or equipment. Our recommendations may negatively impact our relationships with materials and tool providers and equipment manufacturers. Tensions in our relationships with these providers and manufacturers may cause these parties to limit or deny our access to their newest materials and equipment, which would in turn limit our ability to complete our development activities with our customers or control the quality of the combinatorial methods applied to their development efforts, which would adversely affect our business and operations.

If we cannot compete successfully in our industry, our results of operations and financial condition would be adversely affected.*

Competition in our market may intensify in the future, which could slow our ability to grow or execute our strategy and could lead to increased pricing pressure, negatively impacting our revenue. Our current and potential customers may choose to develop their own combinatorial development methods internally, particularly if we are slow in deploying our solutions or improving them to meet market needs. We currently face indirect competition from the internal R&D groups of our current and potential customers, particularly those of our customers who work with us to develop knowledge of combinatorial methods and who may then use our methods independently. Several of them also design, develop, manufacture and market semiconductor products based on their own or other architectures and develop their own intellectual property internally. They often compete with each other and with us in various applications. Our customers are generally much larger and have significantly greater resources than us. We also face indirect competition from university collaborations, consortia and alliance partnerships. In addition, there may be other providers of high-throughput solutions for the design of and R&D relating to integrated devices of which we are not aware and there may be new entrants to the industry in the future, particularly if acceptance of these solutions grows. In addition, we believe that the demand for solutions that address the need for better integration between the design and manufacturing processes may encourage direct competitors to enter into our market. Other potential competitors include fabrication facilities that may decide to offer solutions competitive with ours as part of their value proposition to their customers. If these potential competitors change the pricing environment or are able to attract industry partners or customers faster than we can, we may not be able to grow and execute our strategy as quickly or at all.

The semiconductor industry is highly cyclical, subject to price volatility, difficult to predict and subject to significant downturns.

Currently, the substantial majority of our revenue is dependent upon the overall condition of the semiconductor industry, especially in light of the licensing component of our revenue. The semiconductor industry is highly cyclical and subject to rapid technological change and has been subject to significant economic downturns at various times, such as the recent economic downturn, characterized by diminished product demand, accelerated erosion of average selling prices and production overcapacity. The semiconductor industry also periodically experiences increased demand and production capacity constraints. In addition, the semiconductor industry has historically experienced price volatility. As a result, we may experience significant fluctuations in operating results due to general semiconductor industry conditions and overall economic conditions.

The semiconductor industry has experienced significant challenges as a result of tightening of credit markets, turmoil in the financial markets, and weakened global economy. There may also be sudden changes in our customers’ manufacturing capacity requirements and spending, which depend in part on capacity utilization, demand for our customers’ IC products by consumers, inventory levels relative to demand, and access to affordable capital. For example, pressures in the DRAM sector have caused financial difficulties for our customer, Elpida. In addition, the semiconductor industry has experienced significant consolidation in the past and may continue to see high levels of consolidation in the future. If any of our customers are acquired, the acquiror may not continue to engage in a CDP with us. Alternatively, our customers may opt to acquire companies or technologies that decrease their need for our services or otherwise divert their R&D resources. As a result of these and other potential changes, the timing and length of any cycles can be difficult to predict. Further, uncertainty about future global economic conditions and any effect on the semiconductor industry could make it challenging for us to forecast our operating results, make business decisions and identify the risks that may affect our business, financial condition and results of operations. If we are not able to timely and appropriately adapt to changes resulting from the difficult macroeconomic environment, our business, financial condition and results of operations may be significantly negatively affected.

Table of Contents

A substantial portion of our revenue is derived from business arrangements with related parties, and such arrangements could create conflicts of interest that could adversely affect our business and results of operations.*

Some of our customers and other business partners hold a significant stake in our capital stock. Related party transactions disclosed in our financial statements accounted for $4.8 million or 29.2% of our revenue during the three months ended March 31, 2012 and $21.0 million and $26.0 million, or 39.0% and 61.0%, of our revenue for the years ended December 31, 2011 and 2010, respectively. ATMI, which beneficially owned approximately 9.1% of our capital stock as of March 31, 2012, accounted for $3.5 million, or 21.1% of our revenue during the three months ended March 31, 2012 and $15.8 million and $22.1 million, or 29% and 51.8%, of our revenue for years ended December 31, 2011 and 2010, respectively. For more information about these transactions, see Note 9 to our condensed consolidated financial statements in this Quarterly Report on Form 10-Q. We have also entered into CDPs with GLOBALFOUNDRIES, whose majority stockholder, Advanced Technology Investment Company, LLC, beneficially owned approximately 3.8% of our capital stock as of March 31, 2012, and SanDisk Corporation and Toshiba Corporation, which collectively hold warrants exercisable for an aggregate of 822,368 shares of our common stock.

We believe that the transactions and agreements that we have entered into with related parties are on terms that are at least as favorable as could reasonably have been obtained at such time from third parties. However, these relationships could create, or appear to create, potential conflicts of interest when our board of directors is faced with decisions that could have different implications for us and our related parties or their affiliates. In addition, conflicts of interest may arise between us and our related parties and their affiliates. The appearance of conflicts, even if such conflicts do not materialize, might adversely affect the public’s perception of us, as well as our relationship with other companies and our ability to enter into new relationships in the future, including new CDPs with competitors of such related parties, which could have a material adverse effect on our ability to do business.

We are subject to warranty claims, product recalls and product liability.

We may, from time to time, be subject to warranty or product liability claims for our HPC tools that may in the future lead to expenses as we compensate affected customers for costs incurred related to product quality issues. Although we maintain product liability insurance, such insurance is subject to significant deductibles and there is no guarantee that such insurance will be available or adequate to protect against all such claims. Alternatively, we may elect to self-insure with respect to certain matters. We may incur costs and expenses in the event of any recall of a HPC tool sold to our customers. We may incur replacement costs, contract damage claims from our customers and reputational harm. Costs or payments made in connection with warranty and product liability claims and product recalls could materially affect our financial condition and results of operations.

Compliance with environmental, health and safety laws and regulations could increase costs or cause us to incur substantial liabilities.

We are subject to various foreign, federal, state and local environmental laws and regulations governing, among other matters, emissions and discharges of hazardous materials into the air and water, the use, generation, storage, handling, transportation and disposal of, and exposure to, hazardous materials and wastes, remediation of contamination and employee health and safety. In addition, under certain of these environmental laws, liability can be joint and several and without regard to comparative fault. Our operations involve the use of hazardous materials and produce hazardous waste, and we could become liable for any injury or contamination that could arise due to such use or disposal of these materials. Failure to comply with environmental laws and regulations could result in the imposition of substantial civil and criminal fines and sanctions, could require operational changes or limits or the installation of costly equipment or otherwise lead to third party claims. Future environmental laws and regulations, stricter enforcement of existing laws and regulations, or the discovery of previously unknown contamination or violations of such laws and regulations could require us to incur costs or become the basis for new or increased liabilities, which could impair our operations and adversely affect our business and results of operations.

Table of Contents

Acquisitions may harm our business and operating results, cause us to incur debt or assume contingent liabilities or dilute our shareholders.

We have made and may in the future make strategic investments or acquisitions where there is an opportunity to expand the potential applications and reach of our HPC platform. Exploring and implementing any investments or acquisitions may place strain upon our ability to manage our future growth and may divert management attention from our core development and licensing business. There are also other risks associated with this strategy. We cannot assure you that we will be able to make investments or acquire businesses on satisfactory terms, that any business acquired by us or in which we invest will be integrated successfully into our operations or be able to operate profitably, or that we will be able to realize any expected synergies or benefits from such investments or acquisitions. Our relative inexperience in effecting such transactions heightens these risks. In addition, to finance any acquisitions or investments, we may utilize our existing funds, or might need to raise additional funds through public or private equity or debt financings. Prolonged tightening of the financial markets may impact our ability to obtain financing to fund future acquisitions and we could be forced to obtain financing on less than favorable terms. Additionally, equity financings may result in dilution to our stockholders. We cannot predict the number, timing or size of investments or acquisitions, or the effect that any such transactions might have on our operating results.

Global or regional economic, political and social conditions could adversely affect our business and operating results.

We operate in multiple jurisdictions throughout the world and are subject to foreign business, political and economic risks. In particular, we are subject to risks arising from adverse changes in global economic conditions. Global economic uncertainties in the key markets of many of our customers may cause our customers to delay or reduce technology purchases and investments. The impact of this on us is difficult to predict, but if businesses defer licensing our technology, require fewer CDPs or development tools, or if consumers defer purchases of new products that incorporate technology developed through our CDPs, our revenue could decline. A decline in revenue would have an adverse effect on our results of operations and our financial condition.

In addition, some of our largest customers are located outside of the United States, primarily in Asia, which further exposes us to foreign risks. Also, a substantial portion of the consumer products market that serves as the end-market for the products we help our customers to develop is located in Asia. As a result, our operations are subject to substantial influence by political and economic conditions as well as natural disasters in Asia such as the 2011 earthquake and tsunami in Japan. Reduced end user demand as well as disruptions to the supply chain for our customers resulting from these or other events could lead to a reduction in our revenue and an adverse impact on our financial condition.

We are also subject to general geopolitical risks in connection with international operations, such as political, social and economic instability, terrorism, interference with information or communication of networks or systems, potential hostilities, changes in diplomatic and trade relationships, and disease outbreaks, and any disruptive effect these events would have on our business operations. Although to date we have not experienced any material adverse effect on our operations as a result of these types of regulatory, geopolitical, and other factors, we cannot assure investors that these factors will not have a material adverse effect on our business, financial condition, and operating results or require us to modify our current business practices. Inconsistencies among, and unexpected changes in, a wide variety of foreign laws and regulatory environments with which we are not familiar, including, among other issues, with respect to employees, protection of our intellectual property, and a wide variety of operational regulations and trade and export controls under domestic, foreign, and international law may also have unexpected, adverse impacts on our operations and financial condition.

Table of Contents

In the future, exchange rate fluctuations could affect our revenue, which could adversely affect our business and operating results.*

Our licensing and royalty revenue is derived from sales of our customers’ products that incorporate technology developed through our CDPs. To the extent that sales for these customer products are denominated in a foreign currency, an increase in the value of the U.S. dollar relative to such foreign currencies could adversely affect our licensing and royalty revenue irrespective of the volume of such products sold, which could adversely affect our business and operating results.

In addition, we derive a significant portion of our revenue from customers in foreign countries. We expect that a significant portion of our total future revenue will continue to be derived from companies based in foreign countries. If the U.S. dollar increases in value relative to the currencies in any of these countries, the cost of our CDPs, which have historically been billed in U.S. dollars, will be more expensive to existing and potential customers in those countries, which could adversely affect our ability to generate new or expand existing CDPs.

Business interruptions could delay us in the process of developing our products and could disrupt our sales.

Our headquarters are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We are also vulnerable to other types of natural disasters and other events that could disrupt our operations, such as terrorist acts and other events beyond our control. We do not carry insurance for earthquakes and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our cash flows and success as an overall business.

Our ability to use our net operating loss carryforwards to offset future taxable income, and our ability to use our tax credit carryforwards, may be subject to certain limitations.

In general, a corporation that undergoes an “ownership change” under Section 382 of the Internal Revenue Code is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards (NOLs) to offset future taxable income and its ability to utilize tax credit carryforwards. As of December 31, 2011, we reported U.S. federal NOLs of approximately $26.7 million. In general, an “ownership change” occurs if the aggregate stock ownership of certain stockholders (generally, 5% shareholders, applying certain aggregation and look-through rules) increases by more than 50 percentage points over such stockholders’ lowest percentage ownership during the testing period (generally, three years). We have not determined whether an ownership change has occurred in the past. If we have experienced an ownership change in the past, our ability to utilize NOLs and tax credit carryforwards could be limited. Furthermore, future changes in our stock ownership, such as certain stock issuances and transfers between stockholders, some of which changes are outside of our control, could result in ownership changes under Section 382 of the Internal Revenue Code. For these reasons, we may not be able to utilize a material portion of our NOLs and tax credit carryforwards, even if we attain profitability.

Risks Related to Ownership of Our Common Stock

Our stock price may be volatile, which may cause the value of our common stock to decline and subject us to securities class action litigation.

The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early stage companies have historically been particularly volatile. These fluctuations could be in response to, among other things, the factors described in this “Risk Factors” section or elsewhere in this Quarterly Report on Form 10-Q, or other factors, some of which are beyond our control, such as:

· fluctuations in our financial results or outlook or those of our customers or of companies perceived to be similar to us;

· changes in estimates of our financial results or recommendations by securities analysts;

· changes in market valuations of similar companies;

Table of Contents

· changes in our capital structure, such as future issuances of securities or the incurrence of debt;

· announcements by us or our competitors of significant contracts, acquisitions or strategic alliances;

· litigation involving us, our general industry or both;

· additions or departures of key personnel;

· regulatory developments in the U.S., countries in Asia, and/or other foreign countries;

· investors’ general perception of us; and

· changes in general economic, industry and market conditions.

Furthermore, the stock markets have experienced price and volume fluctuations that have affected, and continue to affect, the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market fluctuations, as well as general economic, political and market conditions, such as recessions, interest rate changes and international currency fluctuations, may negatively affect the market price of our common stock.

In the past, many companies that have experienced volatility in the market price of their stock have become subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

We have incurred and will continue to incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could harm our results of operations.

As a public company, we have incurred and will continue to incur significant accounting, legal and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We have incurred and will continue to incur costs associated with corporate governance requirements, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act, as well as rules implemented by the Securities Exchange Commission, or SEC, and the exchange on which we list our common stock. The expenses incurred by public companies for reporting and corporate governance purposes have increased dramatically in recent years. We expect these rules and regulations to substantially increase our financial and legal compliance costs. In addition, these rules and regulations are subject to change from time to time, and we may incur additional financial and legal compliance costs as we seek to understand and comply with changes in these rules and regulations. We also expect these rules and regulations to make it more difficult and expensive for us to maintain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage previously available. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers.

If we experience material weaknesses or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.

As a public company, we will be required, under Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting for the fiscal year ending December 31, 2012. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting, as well as an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. A material weakness is a control deficiency or combination of control deficiencies that results in more than a remote likelihood that a material misstatement of annual or interim financial statements will not be prevented or detected.

Table of Contents

We are in the early stages of the costly and challenging process of hiring personnel and compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. We cannot assure you that there will not be material weaknesses and significant deficiencies in our internal controls in the future. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm were to issue an adverse opinion on the effectiveness of our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, which would cause the price of our common stock to decline.

We have not completed a testing cycle under Section 404 of the Sarbanes-Oxley Act and cannot assure you that we will be able to implement and maintain an effective internal control over financial reporting in the future. Any failure to maintain such controls could severely inhibit our ability to accurately report our financial condition or results of operations.

The concentration of our capital stock ownership by our executive officers, directors and 5% stockholders will limit your ability to influence corporate matters.*

Our executive officers, directors, current five percent or greater stockholders and entities affiliated with them together beneficially owned approximately 70.0% of our common stock outstanding as of March 31, 2012. Entities affiliated with Redpoint Ventures, entities affiliated with CMEA Ventures and entities affiliated with U.S. Venture Partners beneficially owned approximately 17.9%, 17.8% and 12.7% of our common stock outstanding as of March 31, 2012. This significant concentration of share ownership may adversely affect the trading price for our common stock because investors often perceive disadvantages in owning stock in companies with concentrated stock ownership. Also, these stockholders, acting together, will be able to influence our management and affairs and matters requiring stockholder approval, including the election of directors and the approval of significant corporate transactions, such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may have the effect of delaying or preventing a change of control, including a merger, consolidation or other business combination involving us, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control, even if that change of control would benefit our other stockholders.

A significant portion of our total outstanding shares may be sold into the public market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.*

If our existing stockholders sell, or if the market believes our existing stockholders will sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. As of March 31, 2012, we had 42,470,181 shares of common stock outstanding. Of these shares, 32,820,181 shares are currently restricted from transfer as a result of contractual lock-up and/or market standoff agreements entered into in connection with our initial public offering. The lock-up restrictions are scheduled to terminate on May 15, 2012, subject to extension in certain cases for up to 34 additional days under certain circumstances where we announce or pre-announce earnings or a material event occurs within approximately 17 days prior to, or approximately 16 days after, the termination of the lock-up period. In addition, the underwriters of our initial public offering may, in their sole discretion and at any time without notice, release all or any portion of the securities subject to the lock-up restrictions. Once released, these shares will generally become eligible for sale, subject in some cases to the volume limitations and other restrictions of Rule 144 and Rule 701 promulgated under the Securities Act of 1933, as amended, or the Securities Act, and upon the lapse of our right of repurchase with respect to any unvested shares.

In addition, as of March 31, 2012, the holders of 26,492,877 shares of our common stock are entitled to certain rights with respect to the registration of such shares under the Securities Act, subject to the lock-up restrictions described above. If we register such shares of common stock following the expiration of the lock-up restrictions, these stockholders could sell those shares in the public market without being subject to the volume and other restrictions of Rule 144 and Rule 701.

Table of Contents

We also registered approximately 14.5 million shares of our common stock subject to outstanding stock options and reserved for issuance under our equity plans. These shares can be freely sold in the public market upon issuance, subject to vesting restrictions and the lock-up restrictions described above.

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. If any of the analysts who may cover us change their recommendation regarding our stock adversely, or provide more favorable relative recommendations about our competitors, our stock price would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:

· staggered board of directors;

· authorizing the board to issue, without stockholder approval, preferred stock with rights senior to those of our common stock;

· authorizing the board to amend our bylaws and to fill board vacancies until the next annual meeting of the stockholders;

· prohibiting stockholder action by written consent;

· limiting the liability of, and providing indemnification to, our directors and officers;

· eliminating the ability of our stockholders to call special meetings; and

· requiring advance notification of stockholder nominations and proposals.

Section 203 of the Delaware General Corporation Law prohibits, subject to some exceptions, “business combinations” between a Delaware corporation and an “interested stockholder,” which is generally defined as a stockholder who becomes a beneficial owner of 15% or more of a Delaware corporation’s voting stock, for a three-year period following the date that the stockholder became an interested stockholder.

These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws could discourage potential takeover attempts, reduce the price that investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions.

Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(a) Sales of Unregistered Securities

None.

(b) Use of Proceeds from Public Offering of Common Stock

On November 17, 2011, the Securities and Exchange Commission (SEC) declared effective our registration statement on Form S-1 (File No. 333-175877), as amended, filed in connection with the initial public offering of our common stock. Pursuant to the registration statement, we registered the offer and sale of 9,650,000 shares of our common stock with an aggregate offering price of $96.5 million. We issued and sold 5,681,796 shares of our common stock at a public offering price of $10.00 per share for an aggregate offering price of approximately $56.8 million, before deducting underwriters’ discounts and commissions and offering expenses. Symyx Technologies, Inc. (Symyx), a wholly-owned subsidiary of Accelrys, Inc., sold 3,968,204 shares of our common stock at a public offering price of $10.00 per share for an aggregate offering price of approximately $39.7 million, before deducting underwriters’ discounts and commissions and estimated offering expenses. The offering did not terminate until after the sale of all of the shares covered by the registration statement. The managing underwriters of the offering were Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Barclays Capital Inc., Pacific Crest Securities LLC and Needham & Company, LLC. After deducting underwriting discounts, commissions and offering expenses paid or payable by us of approximately $7.6 million, our net proceeds from the offering were approximately $49.2 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee directors as compensation for board or board committee service.

There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on November 18, 2011 pursuant to Rule 424(b). In connection with an agreement for the purchase of intellectual property and the termination of our royalty obligations under an existing license agreement, we issued a promissory note in the principal amount of $27.3 million to Symyx upon the consummation of our initial public offering. The promissory note has a term of 24 months, an interest rate equal to 4% and is payable in an amount equal to the lesser of the principal amount and the greater of $500,000 per quarter or the amount of accrued interest, with a balloon payment at maturity if applicable. The promissory note is secured by all of our tangible personal property, but excluding intellectual property. We also agreed to reimburse Symyx for 50% of their underwriting discounts and commissions from the sale of their shares in our initial public offering, which amount was equal to $1.4 million. A portion of the net proceeds of our initial public offering will be used to make payments of scheduled interest and payment of principal on the promissory at any time at or prior to maturity. From November 17, 2011, the date on which the SEC declared effective the registration statement on Form S-1 for our initial public offering, through December 31, 2011, we used a portion of the net proceeds of our initial public offering to pay Symyx $1.4 million in satisfaction of our agreement to reimburse Symyx for 50% of their underwriter discounts and commissions. Between December 31, 2011 and March 31, 2012, the Company paid Symyx $500,000, which included interest in the amount of $386,000 and principal in the amount of $114,000. We have invested the remainder of funds received in short and intermediate-term, interest-bearing obligations, investment-grade instruments, or guaranteed obligations of the U.S. government.

Table of Contents

ITEM 6. EXHIBITS

Exhibit		Incorporated by Reference			Filed
Number	Exhibit Description	Form	Date	Number	Herewith

10.1†	Amendment dated March 28, 2012 to the Collaborative Development Agreement by and among SanDisk Corporation, Toshiba Corporation and Intermolecular, Inc. dated March 15, 2010.				X

10.2†	Research Agreement by and among Guardian Industries Corp. and Intermolecular, Inc. dated as of February 8, 2010 (the “Sol-Gel Agreement”), incorporating Task Order #1 effective as of February 8, 2010, Task Order #1.1 effective as of July 22, 2010, Task Order #2 effective as of October 22, 2010 and Task Order #3 effective as of May 1, 2011, as amended on November 1, 2011. Research Agreement by and among Guardian Industries Corp. and Intermolecular, Inc. dated as of July 15, 2010 (the “Master Agreement”), incorporating Task Order #1 effective as of July 22, 2010 and Task Order #2 effective as of November 30, 2010. Amendment Number One to Sol-Gel Agreement and Master Agreement effective as of January 1, 2012.				X

31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X

31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X

32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X

32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X

101.INS*	XBRL Instance Document				X

101.SCH*	XBRL Taxonomy Extension Schema Document				X

101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document				X

101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document				X

101.LAB*	XBRL Taxonomy Extension Label Linkbase Document				X

101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document				X

†	Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.
*	Pursuant to Rule 406T of SEC Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	INTERMOLECULAR, INC.
	(Registrant)

Date: May 8, 2012	By:	/s/ Peter L. Eidelman
		Peter L. Eidelman
		Chief Financial Officer

Exhibit 10.1

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

First Addendum to

[*] Collaborative Development Program Agreement

This First Addendum (“First Addendum”) to the [*] Collaborative Development Program Agreement dated as of March 15, 2010 (the “Agreement”) dated as of March 28, 2012 and effective as of March 15, 2012 (“First Addendum Effective Date”) is entered into by and among TOSHIBA CORPORATION doing business at 1-1, Shibaura 1-chome, Minato-ku, Tokyo 105-8001, Japan (together with its Affiliates, “Toshiba”), SANDISK CORPORATION doing business at 601 McCarthy Boulevard, Milpitas, CA 95035 USA (together with its Affiliates, “SanDisk”), and INTERMOLECULAR, INC. doing business at 3011 North 1 st Street, San Jose, CA 95134 USA (together with its Affiliates, “Intermolecular”). Toshiba, SanDisk and Intermolecular shall be referred to herein individually as a party or collectively as the parties. Any capitalized terms not defined herein shall have the meanings given to them as set forth in the Agreement.

RECITALS

WHEREAS, the parties desire to amend and supplement the Agreement as further specified below;

NOW THEREFORE, in consideration of the mutual promises and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound, the parties hereto confirm, agree and ratify that the Agreement is amended and supplemented as follows:

1. Extension of Initial Term

1.1 The Initial Term of the Agreement is hereby extended by one additional year period from [*] through and including [*] (“First Extended Period”) in accordance with Section 11.1 of the Agreement. All references to the “Initial Term” as used in the Agreement shall now mean the period from [*] through and including [*]. During the First Extended Period, Intermolecular agrees to provide capabilities summarized in accordance with Exhibit A. The Development Plan for the First Extended Period (“First Extended Development Plan”) shall be mutually agreed upon as soon as practicable and no later than 30 days after the First Addendum Effective Date by all parties in accordance with the guidelines and target criteria provided in Exhibit B (“Proposal of Development Plan”).

2. Service Fees and Workflow Infrastructure Subscription Fees

2.1 Toshiba and SanDisk each will fund for the CDP under the First Extended Development Plan for the First Extended Period and each agrees to pay Intermolecular during the First Extended Period [*] US Dollars (US$[*]) for a cumulative total [*] US Dollars (US$[*]) in exchange for Intermolecular’s performance of the services described in the First Extended Development Plan and access to the Workflow Infrastructure during the First Extended Period in accordance with the provisions commencing in the third sentence of Section 5.1 of the Agreement. Subject to Section 5.7 of the Agreement, these amounts shall be paid by each of Toshiba and SanDisk in equal monthly payments of [*] US Dollars (US$[*]) over the First Extended Period starting upon

the First Addendum Effective Date. Notwithstanding any fees stated in Section 5.2 of the Agreement, Intermolecular shall provide Toshiba and SanDisk without charge to continued exclusive access to the Workflow Infrastructure (as modified in Exhibit A) as per such Section 5.2. Toshiba and SanDisk shall not incur any fees specified or implied under Section 5.3 of the Agreement.

2.2 During the First Extended Period, Toshiba and SanDisk may request use of (i) [*], or (ii) [*], or (iii) [*] (each individually “Additional Capability”). If so requested, Toshiba and SanDisk each agree to pay Intermolecular [*] US Dollars (US $[*]) for each monthly period for the use of each such Additional Capability within sixty (60) days from their respective receipt of the invoice to be issued by Intermolecular at the end of such month .

3. License Fees

3.1 In addition to any other license fees payable by Toshiba and SanDisk under Section 5.4 of the Agreement if applicable, Toshiba and SanDisk each agree to pay Intermolecular [*] US Dollars (US$[*]) for a cumulative total of [*] US Dollars (US$[*]) for the Intermolecular Background IP development license rights set forth in Section 4.1.1 in the CDP Field during the First Extended Period. Intermolecular acknowledges and agrees that Toshiba’s and SanDisk’s exercise of such license includes internal pre-production development activities at fabrication and R&D centers controlled by Toshiba and/or SanDisk. For the avoidance of doubt, Toshiba’s and SanDisk’s exercise of such license is limited to the Term through the last day of the First Extended Period (and not to any additional extended periods unless mutually agreed in writing). Intermolecular shall invoice each of Toshiba and SanDisk in the amount of [*] US Dollars (US$[*]) on April 15 th , 2012. Toshiba and SanDisk each will pay Intermolecular based on such invoices, within sixty days (60) from their respective receipt of such invoices.

4. Intellectual Property

4.1 Section 2.2.2 of the Agreement is updated and modified as follows: The IP Committee shall consist of two (2) or more named members (at least one technical employee, at least one patent attorney/agent/IP staff member, and other reasonably named party employees). The IP Committee shall meet monthly either in person or via telephone conference. Within ten (10) business days of the First Addendum Effective Date, the parties will agree upon a schedule for the monthly IP Committee meetings, and will memorialize the schedule in Exhibit D. In addition to the IP Committee goals set forth in Section 2.2.2, the IP Committee members will assess whether all past and potential Intermolecular patent filings fall within Category 2, 3, 4, 5, 6, 7 or 8, and will memorialize the assessment in Exhibit C. The second column of Exhibit C (“Agreed Category/Status”) specifies a numerical categorization (Category 2, 3, 4, 5, 6, 7 or 8) for cases in which the parties have agreed to the IP ownership category assignment as of March 15, 2012. The parties shall not revisit the IP ownership category assignment for such cases. All other patent filings related to the [*] shall be jointly owned by Intermolecular, SanDisk and Toshiba.

4.2 On a monthly basis, beginning the first month after the First Addendum Effective Date, Intermolecular shall prepare a report of all invention disclosures prepared by and/or received by Intermolecular during the previous thirty (30) days that pertain to [*] technology (“Intellectual Property Report”). Each Intellectual Property Report shall include for each invention disclosure included therein: (a) a copy of the invention disclosure, (b) prior art search results, and (c) the

inventor(s) comments regarding the prior art search results. Intermolecular shall provide a copy of the Intellectual Property Report to IP staff members identified by SanDisk and/or Toshiba on the first business day of each month during the First Extended Period.

4.3 Within twenty ( 20 ) business days of receiving an Intellectual Property Report, SanDisk and Toshiba will advise Intermolecular in writing of any objections to preparing and filing a patent application for any invention disclosure included in the Intellectual Property Report. If either SanDisk or Toshiba objects to any invention disclosure, Intermolecular agrees not to prepare and file a patent application for such invention disclosure. After expiration of the twenty ( 20 ) business day period, Intermolecular may prepare and file a patent application for any invention disclosure to which neither SanDisk or Toshiba have objected (the “Default Permission”). The Default Permission is to enable Intermolecular to obtain an earlier filing date, if required. Otherwise, at the very next scheduled IP Committee meeting after such Default Permission date, SanDisk and/or Toshiba may re-characterize the invention disclosure as trade secret or public domain, and/or re-characterize ownership of the invention on an objective basis in accordance with Section 3 (“IP Ownership”) of the Agreement. If following the First Addendum Effective Date SanDisk and/or Toshiba for the first time (a) re-characterizes an invention disclosure as trade secret or public domain for which a patent application has been prepared or is under preparation, SanDisk and Toshiba each agree to reimburse Intermolecular fifty (50) percent of Intermolecular’s outside counsel and Patent Office costs incurred in the drafting, preparation, filing and abandonment of such patent applications for a cumulative total of hundred (100) percent of such costs, or (b) re-characterizes ownership of the invention for which a patent application has been filed, SanDisk and Toshiba each agree to reimburse Intermolecular fifty (50) percent of Intermolecular’s outside counsel and Patent Office costs incurred in preparing and recording an assignment of ownership necessary to reflect the re-characterized ownership for a cumulative total of hundred (100) percent of such costs.

4.4 Intermolecular agrees not to file and/or prosecute in the U.S. Patent & Trademark Office, World Intellectual Property Office, European Patent Office, or any other governmental or regional patent office (collectively, “Patent Offices”) any of the invention disclosures/patent applications identified in Exhibit E (collectively, “Inactivated Invention Disclosures/Patent Applications”). If any Inactivated Invention Disclosures/Patent Applications has been filed in any Patent Office, Intermolecular shall immediately take all necessary steps to formally abandon such patent applications and prevent publication of such patent applications. In addition, within ten (10) business days of the First Addendum Effective Date, Intermolecular shall provide, for each Inactivated Invention Disclosures/Patent Applications, written confirmation that the invention disclosure/patent application has either: (a) not been prepared and/or filed in any Patent Office, or (b) if previously filed, filing details (e.g., application and/or serial number, filing date, title, list of named inventors) and evidence of formal abandonment of such patent application (e.g., Notice of Abandonment and/or copies of documents submitted to the Patent Office to formally abandon such patent application).

5. Miscellaneous

5.1 Section 7.1.3 of the Agreement is clarified that “CDP” in that section has been extended through the conclusion of the First Extended Period. All references to the Agreement in any other document shall be deemed to refer to the Agreement as modified by this First Addendum. Except as expressly modified by this First Addendum, all of the terms and conditions of the Agreement shall remain in full force and effect. In the event that the terms of this First

Addendum conflict with the terms of the Agreement, the terms of this First Addendum shall control.

IN WITNESS WHEREOF, the parties hereto have executed this First Addendum as of the date first written above.

Toshiba Corporation		SanDisk Corporation

By:	/s/ Yasuo Naruke	By:	/s/ Ben Tessone

Name:	Yasuo Naruke	Name:	Ben Tessone

Title:	Vice President	Title:	Vice President, WW Procurement


Intermolecular, Inc.

By:	/s/ David Lazovsky

Name:	David Lazovsky

Title:	President and CEO

Exhibit A

Total FTEs to be allocated to the CDP: [*] FTEs. Of the [*] FTEs, [*] FTEs are provided pursuant to payments made by SanDisk and Toshiba under this First Addendum. The additional [*] FTEs shall be provided separately by Intermolecular.

[*]

Exhibit B

[*]

Exhibit C

[*]

Exhibit D

IP Committee Meeting Schedule

Date	Time	Location
[*]	18:00 PST	Phone/California
[*]	18:00 PST	Phone/Japan
[*]	18:00 PST	Phone/California
[*]	18:00 PST	Phone/Japan
[*]	18:00 PST	Phone/California
[*]	18:00 PST	Phone/Japan
[*]	18:00 PST	Phone/California
[*]	18:00 PST	Phone/Japan
[*]	18:00 PST	Phone/California
[*]	18:00 PST	Phone/Japan
[*]	18:00 PST	Phone/California
[*]	18:00 PST	Phone/Japan

Exhibit E

Inactivated Invention Disclosures/Patent Applications

IM Docket No.		Title
[*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]

Exhibit 10.2

RESEARCH AGREEMENT

This Research Agreement (this “Agreement”) is effective as of February 8, 2010 (the “Effective Date”) between Guardian Industries Corp., a Delaware corporation located at 2300 Harmon Road, Auburn Hills, Michigan 48326 (hereinafter referred to as “Guardian”), and Intermolecular, Inc., a Delaware corporation located at 2865 Zanker Road, San Jose, California 95134 (hereinafter referred to as “Intermolecular”).

1. BACKGROUND . Guardian and Intermolecular intend to work together on a non-exclusive basis on research and development tasks relating to [*] coatings for float glass. The details of this research effort will be described in a Task Order which must be finalized and agreed-to within 30 days after this Agreement is signed. The Task Order, once signed by the parties, will be incorporated into this Agreement as Exhibit 1. If the parties fail to agree on the contents of the Task Order within 30 days of signing this Agreement, this Agreement shall be terminated immediately unless the parties mutually agree in writing to an extension of the 30 period. If the Agreement is terminated due to a failure to reach agreement on the Task Order, the rights and obligations in Sections 6-11, 14-16, 19, 20, and 29 will survive the termination of this Agreement.

2. PROJECT MANAGERS . Intermolecular and Guardian will each appoint a project manager who will oversee the work under this Agreement. The parties will use reasonable efforts to direct communications under this Agreement through the project managers. Either party may change its project manager at its discretion by providing notice to the other party.

3. PROGRESS REPORTS; MEETINGS . Intermolecular and Guardian will discuss the progress of work under this Agreement at least on a monthly basis unless more frequent reports are required in the Task Order. Intermolecular will also submit written progress reports at intervals defined in the Task Order, but at minimum on a monthly basis.

4. TERM AND TERMINATION . This Agreement will terminate at the completion of the work defined in the Task Order, which is expected to last for [*] months. At termination, Intermolecular will provide a final written progress report to Guardian outlining the work completed prior to termination and will include with such report any remaining deliverables that are due under the Task Order.

5. SAFETY PROCEDURES / REGULATIONS. During the performance of work under this agreement the parties’ employees, representatives, and agents will be required to follow all applicable safety procedures in the parties respective facilities they visit, provided that they are given notice of the safety procedures at such facility. Each party will also comply with all applicable laws and regulations relating to the work performed under this Agreement.

6. CONFIDENTIALITY. Intermolecular and Guardian acknowledge that the work under this Agreement will involve the exchange of certain confidential information. The information will be protected under the terms of the Mutual Non-Disclosure Agreement that has been entered into between the parties.

For example, Guardian may share with Intermolecular certain information about Guardian’s prior research into [*] coatings, technical requirements and specifications for such coatings, manufacturing capabilities relating to such coatings, and financial modeling relating to the sale of such coatings. This information, and any information based upon or derived from this information, will be considered Guardian Confidential Information. Similarly, Intermolecular may share with Guardian certain information about high-productivity combinatorial (“HPC”) technology that will be used under this Agreement. This information may include techniques, methodologies, processes, test vehicles, synthetic procedures, technology, systems, or combination thereof used for the simultaneous, parallel, or rapid serial: (i) design, (ii) synthesis, (iii) processing, (iv) process sequencing, (v) process integration, (vi) device integration, (vii) analysis, or (viii) characterization of more than two (2) compounds, compositions, mixtures, processes, or synthesis conditions. This information, and any information based upon or derived from this information, will be considered Intermolecular Confidential Information.

7. PREEXISTING TECHNOLOGY . Each party shall retain all right, title and interest in all materials, software, programming documentation, technical ideas, concepts, know-how, inventions, discoveries, improvements, works of authorship, techniques and all related intellectual property rights created, conceived or developed by or for that party prior to the Effective Date (the “Prior Technology”).

8. TECHNOLOGY DEVELOPED UNDER THE AGREEMENT . Intellectual property rights created as a result of the work under this Agreement (the “Project-Related Technology”) will be owned by the party whose employees are the inventors or creators of the intellectual property. Intellectual property jointly invented or created by the parties will be jointly owned by the parties. Commercialization by Guardian of intellectual property owned or co-owned by Intermolecular, including the commercialization of any new [*] coating developed (or co-developed) by Intermolecular under this Agreement, will require the payment of royalties as outlined below.

9. INDEPENDENTLY DEVELOPED TECHNOLOGY. Each party retains all right, title and interest in and to all materials, software, programming documentation, technical ideas, concepts, know-how, inventions, discoveries, improvements, works of authorship, techniques and all related intellectual property rights created, conceived or developed by or for that party outside of or independent from this Agreement (the “Independent Technology”). Intermolecular acknowledges that Guardian has conducted prior research into [*] coatings, and that such independent research may continue after this Agreement is terminated. Guardian’s research into [*] coatings, if any, will be considered Independent Technology unless it is substantially and fundamentally based on Project-Related Technology that is owned or co-owned by Intermolecular. Guardian’s commercialization of Independent Technology will not require the payment of royalties to Intermolecular.

10. LICENSES . Intermolecular hereby grants Guardian a worldwide royalty-bearing license under Intermolecular’s Project-Related Technology to: (i) use, make, have made, import, offer to sell, sell, lease and otherwise dispose of products incorporating Intermolecular’s Project-Related Technology. This license is exclusive with respect to coated glass used for [*] applications provided that Guardian continues to ship an agreed-upon minimum amount of licensed products. After all elements of the Task Order are completed and the parties have more information about the expected time for development and commercialization of the products subject to the exclusive license, the parties agree to negotiate in good faith to establish the minimum targeted volume and date on which the minimums will begin to apply. This license is non-exclusive for all other products not used for [*] applications but which incorporate Intermolecular’s Project-Related Technology.

11. ROYALTIES . Guardian acknowledges and agrees that it will pay Intermolecular a royalty as defined in Exhibit 2 of this Agreement for products covered by the exclusive license, and [*]% Net Sales per quarter (as defined in Exhibit 2) for products covered by the non-exclusive license. Guardian will provide quarterly reports to Intermolecular on the sales of licensed products and will pay the applicable royalties on a quarterly basis. Each party shall be responsible for all of its own costs of commercializing products or licensing intellectual property rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sub-licensees

12. RESEARCH COMPENSATION . As consideration for the work performed by Intermolecular under this Agreement, Guardian will pay Intermolecular [*] U.S. dollars (US$[*]) in equal monthly installments of US$[*]. Guardian will also provide or pay for consumables (such as [*], and [*]), outsourced metrology and characterization not supported internally by Intermolecular, and other mutually agreed out-of-pocket costs to support the Task Order. Guardian must provide express approval of such out of pocket costs prior to Intermolecular incurring such expenses; however, such approval shall not be unreasonably withheld if the work is necessary to complete the Task Order activity.

13. PAYMENT TERMS . All payments shall be due to Intermolecular 30 days after Guardian receives the related valid invoice(s) from Intermolecular, provided that any relevant milestones or research and development services tied to the payment have been satisfied. All payments hereunder shall be made in U.S.

dollars by Guardian or one of its U.S. affiliates. All payments due to Intermolecular under this Agreement shall be made by bank wire transfer as follows:

	U.S. Domestic Wire Transfer
To:		[*]

Routing & Transit #:		[*]

For credit of:		Intermolecular, Inc.
Credit account #:		[*]
By order of:		[Name of Sender]

or another U.S. bank account designated by Intermolecular.

14. LIMITATION OF LIABILITY. EXCEPT FOR A BREACH BY EITHER PARTY OF THEIR RESPECTIVE CONFIDENTIALITY OBLIGATIONS HEREUNDER OR A BREACH OF ANY LICENSE RESTRICTIONS, UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE TO THE OTHER UNDER ANY CONTRACT, STRICT LIABILITY, NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY LOST PROFITS, LOST BUSINESS OPPORTUNITY, INJURY TO BUSINESS REPUTATION OR EQUIPMENT DOWNTIME, OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT OR SPECIAL DAMAGES OF ANY KIND IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND IN NO EVENT WILL EITHER PARTY’S AGGREGATE LIABILITY TO THE OTHER EXCEED THE AMOUNTS PAID OR PAYABLE BY GUARDIAN TO INTERMOLECULAR UNDER THIS AGREEMENT.

15. WARRANTIES. Intermolecular warrants that: (i) it and its employees and agents have all necessary rights, authorizations, or licenses to provide the services set forth in any agreed upon Task Order; (ii) each of its employees or agents assigned to work on a Task Order hereunder shall have the proper skill, training and background so as to be able to perform in a competent and professional manner and that all work will be so performed in accordance with the standards set forth in the applicable Task Order; and (iii) Intermolecular has the authority to grant the licenses included in this Agreement.

16. DISCLAIMER . Intermolecular and Guardian specifically disclaim any representation, warranty or guarantee that the research and development under this Agreement will be successful, in whole or in part. It is understood that the failure of the parties to successfully develop and commercialize products in the course of a Task Order shall not constitute a breach of any representation or warranty or other obligation under this Agreement. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, GUARDIAN AND INTERMOLECULAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO ANY INFORMATION DISCLOSED HEREUNDER, OR ANY DELIVERABLES PROVIDED HEREUNDER, AND HEREBY EXPRESSLY DISCLAIM ANY WARRANTIES OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY DEVELOPED TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

17. INSURANCE. Before having its employees conduct any work at the site of the other party, each party shall procure and maintain for itself and its employees all insurance coverage as required by applicable federal or state law, including: (a) worker’s compensation benefits as required by state law, for any state in which work may be performed under the Agreement; (b) commercial general liability insurance including contractual liability and completed operations coverage, with limits not less than $[*] each occurrence covering property damage, bodily injury and personal injury liability; and (c) Automobile Liability

Insurance, with a minimum of $[*] Combined Single Limit Bodily Injury and Property Damage Liability coverage. Carriers must have a Standard & Poor’s rating of A or better.

18. FORCE MAJEURE. The Parties each shall be excused from the performance of its obligations, other than obligations of payment, hereunder in the event that such performance is prevented by force majeure, and such excuse shall continue as long as the condition constituting such force majeure prevails and for thirty (30) days after the termination of such condition. For the purpose of this Agreement, force majeure shall mean any circumstance beyond the control of the party concerned, including, without limitation, acts of God, expropriations, war, civil commotion, terrorist activities, destruction of production facilities or materials by fire, earthquake, flood or storm, labor disturbances (other than only of the workforce of the party concerned) and failure of public utilities. The party affected by a force majeure shall immediately give written notice to the other party of the nature and likely duration (if it can be assessed) of the force majeure. Performance of this Agreement shall be suspended for the duration of the force majeure. Should the force majeure last for a period of longer than three (3) months the parties shall meet and discuss appropriate remedial measures. The Party suffering a force majeure shall give notice of the cessation of the force majeure as soon as performance of the Agreement is no longer prevented.

19. GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, excluding its conflict of law principles. In exercising their rights under the license granted hereunder, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement. Without limiting the foregoing, each party agrees to comply with all applicable export and re-export control laws and regulations maintained by the United States government.

20. ARBITRATION. If any dispute arises under this Agreement, the Parties agree that a good-faith attempt to resolve the dispute shall be made by presenting the position of the Parties to authorized representatives of Intermolecular and Guardian, who have authority to settle the matter, at a meeting at a neutral site. If no such meeting can be arranged within two (2) weeks from the request for such meeting, or if the named persons are unable to reach agreement within one (1) week after such meeting, the Parties agree that the dispute shall be resolved by binding arbitration by a single arbitrator in Wilmington, Delaware. The arbitration will be conducted under the Commercial Rules of the American Arbitration Association, and the award shall be enforceable by any court of competent jurisdiction.

21. ENTIRE AGREEMENT. This Agreement supersedes any and all other agreements, either oral or written, between the Parties hereto with respect to this subject, and this Agreement together with any exhibits constitutes the entire agreement between the Parties with respect to this subject matter. No change or modification in the terms hereof, in a manner not expressly provided in this Agreement shall be binding unless reduced to writing and duly executed by the Parties in the same manner as the execution of this Agreement. Any attempt to so change or modify the terms of this Agreement shall be considered void and of no effect.

22. NOTICES. Unless otherwise agreed to by the Parties, the communications required or permitted to be given or made under this Agreement shall be made in writing, via personal delivery, registered mail, facsimile transmission, addressed to the appropriate party at the address indicated below. All communications made pursuant to this section shall be deemed made or given on the date of such personal delivery, mailing or transmission.

If to Guardian:		Director of Science and Technology
		Guardian Science and Technology
		14511 Romine Road
		Carleton, Michigan 48117

With a copy to:		General Counsel
		Guardian Industries Corp.
		2300 Harmon Road
		Auburn Hills, MI 48326

If to Intermolecular:		Craig Hunter
		Intermolecular, Inc.
		2865 Zanker Road
		San Jose, CA 95134
		Fax:

With a copy to:		Legal Department
		Intermolecular, Inc.
		2865 Zanker Road
		San Jose, CA 95134
		Fax: (408) 416-2301

The Parties may change the name and address to which notices should be sent under this section by providing prior written notice to the other party.

23. SEVERABILITY . If any term, provision, covenant or condition of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants or conditions shall remain in full force and effect and shall in no way be affected, impaired or invalidated.

24. RELATIONSHIP OF THE PARTIES . Nothing contained herein shall be construed to place the Parties in the relationship of partners, joint venturers or agency, and neither party shall have the power to obligate or bind the other party in any manner. Intermolecular is acting, in performance of this Agreement, as an independent contractor. Personnel supplied by Intermolecular hereunder are not Guardian’s employees or agents and Intermolecular assumes responsibility for their acts or omissions. Intermolecular shall be solely responsible for the payment of compensation of Intermolecular’s employees or agents assigned to perform services hereunder and such employees or agents shall be informed that they are not entitled to any Guardian employee benefits. Guardian shall not be responsible for paying worker’s compensation, disability benefits, and unemployment insurance or for withholding and paying employment taxes for any Intermolecular employee or agent, but such responsibility shall be solely that of Intermolecular.

25. OBLIGATIONS TO THIRD PARTIES . The Parties warrant and represent that they each have the ability to enter into this Agreement, that entering and performing under this Agreement will not violate any agreements they may have with any other third party, and that there exist no restrictions or obligations to any third parties which will restrict their performance of duties under the terms and conditions of this Agreement.

26. ASSIGNMENT . This Agreement and any rights granted hereunder shall inure to the benefit of and be binding upon each of the Parties and their respective successors and permitted assigns. Neither party shall assign or transfer this Agreement either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other party, and any attempt to do so will be null and void; provided, however, that either party may assign this Agreement without such consent, to a parent, subsidiary, or affiliate, or to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets).

27. SURVIVAL. All provisions of this Agreement relating to confidentiality, proprietary rights, indemnification, warranties and otherwise as set forth in Sections 6-16 shall survive any expiration or termination of this Agreement.

28. NON-WAIVER . The failure of either party at any time to require performance of any provision hereof by the other party shall not be deemed a waiver and thereafter shall not deprive that party of its full

right to require such performance in the particular instance or at any other time. Any waiver must be in writing executed by the waiving party.

29. PUBLICITY; DISCLOSURE OF AGREEMENT . Neither party shall publicize nor disclose any aspect of the development efforts contemplated in this Agreement or any other terms of this Agreement without the prior written consent of the other party, except to the extent required by law, to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, in connection with the enforcement of this Agreement or rights under this Agreement, or in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction.

By signing below, the parties agree to the terms of this Agreement.

Guardian
	Guardian Industries Corp.

	By:	/s/ Scott Thomsen
	Name:	Scott Thomsen
	Title:	GVP/CTO
	Date:	February 12, 2010

Intermolecular
	Intermolecular, Inc.

	By:	/s/ Tony Chiang
	Name:	Tony Chiang
	Title:	Chief Technology Officer
	Date:	February 16, 2010

Exhibit 2- Royalties

As described in Section 11, Guardian will pay Intermolecular a royalty based upon the total Net Sales per quarter of products covered by the exclusive and non-exclusive license.

Non-Exclusive Royalty:

The royalty for products covered by the non-exclusive license shall be [*] % of Net Sales. Net Sales is derived from the following formula:

[*].

[*]

Exclusive Royalty:

The royalty for products covered by the exclusive license shall be Net Sales multiplied by the greater of [*]% or the Calculated Royalty. The Calculated Royalty is derived from the following formula:

[*]

[*].

[*]:

[*]

[*].

[*] :

The [*], and [*] are intended to provide a reasonable approximation of their [*] without requiring the disclosure of [*]. Guardian has the right to [*] by giving written evidence to Intermolecular that [*]. However, Guardian otherwise has no obligation to [*] to Intermolecular. Intermolecular agrees to [*].

Although the [*] are established in [*], the parties understand that Guardian may manufacture the licensed products in [*]. For products manufactured in such [*] will be adjusted to account for a material change in the [*]. The [*] will be reviewed quarterly by the parties and [*] from the last date of adjustment (or from the Effective Date, if no adjustments have yet been made) [*] will be adjusted accordingly for products manufactured in that [*] after the date of adjustment. The [*] will be determined at approximately 5:00 p.m., US Eastern Standard Time the [*]. If the [*] does not appear on a [*], the [*] shall be determined by reference to another publicly available service for [*] as may be reasonably selected by Intermolecular.

Books and Records; Audit Rights:

Guardian agrees to keep accurate and complete records and books of accounting recording the sales volume and price of licensed products in sufficient detail to calculate the royalty due. Such records and books of accounting shall be made available for inspection during normal business hours by an independent Certified Public Accountant engaged by Intermolecular, upon 15 days prior written notice to Guardian, to the extent

necessary to verify the accuracy of the royalty reports under this Agreement. Intermolecular agrees that it shall be entitled to learn only the Net Sales (“NS”) and Net Sales Price Per Square Meter (“NSSM”), as those terms are defined above, during the relevant audit period and that all other information made available to the Certified Public Accountant shall remain confidential to Guardian. The number of such inspections shall be limited to one inspection during any four quarterly accounting periods, and a final inspection covering the final four quarterly accounting periods within one year after any termination of this Agreement. If the inspection establishes that Guardian has under-reported its royalty obligations by more than the greater of $[*] or [*] percent ([*]%) of the total amount of running royalty due for the period under audit as shown by the audit, Guardian will reimburse Intermolecular for the reasonable costs of the inspection.

-CONFIDENTIAL-

Task Order # 1

[*] Coating Development

Task Order # 1 is entered into as of Feb 8 th , 2010 under the terms of the Master Research and Development Agreement between Guardian Industries Corp. (hereinafter referred to as “Guardian”) and Intermolecular (here in after referred to as “IM”).

SCOPE

The primary focus of this Task Order is to [*], referred to as [*] that would [*] as outlined below, which include [*] and [*].

[*]

	*[]**	*[]**	*[]**
[*]
1	[*]	[*]	[*]
2	[*]	[*]	[*]
[*]
3	[*]	[*]	[*]
4	[*]	[*]	[*]
5	[*]	[*]	[*]
[*]
6	[*]	[*]	[*]
7	[*]	[*]	[*]
8	[*]	[*]	[*]
9	[*]	[*]	[*]
[*]
10	[*]	[*]	[*]
11	[*]	[*]	[*]
12	[*]	[*]	[*]
13	[*]	[*]	[*]
14	[*]	[*]	[*]
[*]
15	[*]
16	[*]
17	[*]

IM shall direct its efforts on the [*]. The project is divided into [*] that are to be completed sequentially. Each [*] is to be defined before the start of the work. [*] will be defined as a result of [*]. Similarly, [*] will be defined as a result of [*]. IM will [*] at the end of [*] and hold [*] to discuss project work and next steps.

[*]:

The primary goal of [*] is to [*] a [*] that would [*].

[*] :

A [*] was held on [*] at [*]. The [*] that Guardian and IM have agreed to [*] is based on the [*]. A [*] set of [*] was discussed and a [*] of [*] was [*] based on which IM will [*], which are shown below.

[*]:

[*]

	*[]**	*[]**	*[]**	*[]**
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]	[*]	[*]	[*]	[*]
[*]		[*]	[*]
	[*]

[*]:

[*] of these [*] include [*] of [*] including [*] and [*] containing [*] of IM’s choice. In addition [*] of [*] in conjunction with [*] would be [*]. [*] will be [*] on [*] of [*] and [*] in an [*]. [*] and [*] will be made using [*]. [*] that [*] of [*] will be [*] for [*] in [*] of this task order via [*] of [*] of [*] on [*] and [*] of [*] by [*] and [*]. [*] of [*] will be [*] for [*] and [*] in [*].

Since IM [*] a [*] or [*], IM, as part of the [*], is to [*] to [*] of [*] by [*]. For this purpose, Guardian [*] of [*] on [*]. In addition, IM will also [*] and [*], which will be [*], to [*] on [*]. This work is intended to [*] and [*] for [*]. IM will [*] for [*] on [*] and on [*],[*] and [*]. IM will [*] ([*])[*] and [*] to [*] over the course of [*] to [*] of [*], if any, on [*]. IM will also [*] a [*] for [*] of [*].

IM will submit to Guardian a document which provides [*] of [*] which include, [*] and [*]. These [*] are ultimately intended to [*] to the [*] of [*] to [*] of [*] of [*]. In addition to [*] the [*]:

[*]

[*].

[*]:

[*]

[*].

[*]:

The [*] and [*] of [*] will be [*] by the [*] of [*]. [*] will be [*] and [*] a [*] of [*] of [*]. The [*] and [*] of [*] will be [*] and [*] by [*] and [*] to [*] of [*].

[*]:

[*].

[*]:

The [*] and [*] of [*] will be [*] by the [*] of [*]. [*] will be [*] and [*]. The [*] and [*] of [*] will be [*] and [*] by [*] and [*] to [*] of [*]

[*] :

[*].

Task Order Management

The IM Task Order Manager will be [*]

The Guardian Task Order Managers will be [*].

[*]

[*]:

[*]

[*].

[*]:

[*].

[*]:

[*].

[*]:

[*].

[*]

[*].

[*]

Intellectual Property

Any Project-Related Intellectual Property developed in the course of work on Task Order 1 will be managed according to the terms of the Master Research and Development Agreement between Guardian and IM.

Subcontracting

No subcontracting is expected for this task order. Any need for subcontracting must be reviewed and approved by Guardian prior to conducting any subcontracts.

Payment Terms

The payment terms for this task order will be managed according to the terms of the Master Research and Development Agreement between Guardian and IM.

Intermolecular				Guardian Industries Corp.

By:	/s/ Tony Chiang			By:	/s/ Scott Thomsen

Print Name:			Tony Chiang	Print Name:			Scott Thomsen

Title:		Chief Technology Officer		Title:		Chief Technology Officer

Date:		February 18, 2010		Date:		February 16, 2010

-CONFIDENTIAL-

Task Order # 1.1

[*] Coating Development

Task Order # 1.1 is entered into as of July 22, 2010 under the terms of the Research Agreement dated February 8, 2010 (“Research Agreement”) between Guardian Industries Corp. (“Guardian”) and Intermolecular, Inc. (“IM”) and is [*] of the efforts described in Task Order #1 dated February 8, 2010. Terms that are capitalized but not specifically defined herein shall have the meanings set forth in the Research Agreement.

SCOPE

The primary focus of this Task Order # 1.1 is to [*].

[*]:

IM shall [*] to [*] there is a [*] in [*] on [*]. [*] has a [*] of [*] while [*]. [*] for [*] has not been [*] for. [*] the [*] on [*] is [*] to [*] on the [*] and [*] in the [*].[*] for [*] of [*] between [*] and [*] than [*]. The goal of the work for IM is to [*] the [*] and [*] to [*] a [*] with [*]. Guardian will provide [*] and [*] to IM in support of this Task Order # 1.1. [*] is [*]

[*]:

The [*] will be focused on determining [*] and [*] of [*] and [*].

[*]

Guardian will supply the [*] and [*], [*] and [*] for IM to [*] and [*].

At the end of [*],[*] will be [*] to [*] for [*] of [*] and [*] in [*]. The [*] to [*] and the [*] will be [*] and [*] to [*]. In addition, [*] of the [*] are to be supplied to Guardian [*] and [*].

[*] :

[*].

[*]

Task Order Management

The IM Task Order Manager will be [*].

The Guardian Task Order Managers will be [*].

[*]

[*]:

[*].

[*]:

[*].

Intellectual Property

Any Project-Related Intellectual Property developed in the course of work on Task Order #1.1 will be managed according to the terms of the Research Agreement between Guardian and IM. However, for [*] under this Task Order #1.1, [*] shall not be considered Program Technology (and therefore would not be royalty bearing). All other technologies (i.e. other than the technologies identified above), including but not limited to technologies resulting from the development or modification of a [*] shall be considered Program Technology and shall be royalty bearing under the terms of the Research Agreement provided such technology is invented or co-invented by IM.

[*]

[*]:

[*]

[*]:

[*] [*] [*] [*]

[*]:

[*] [*] [*] [*]

[*]:

[*] [*] [*]

Subcontracting

No subcontracting is expected for this task order. Any need for subcontracting must be reviewed and approved by Guardian prior to conducting any subcontracts.

Research Compensation

Guardian will pay IM [*] U.S. dollars ($[*]) for the first month of work from the effective date and each additional month that Guardian approves continued work on [*]. Other compensation will be managed according to Section 12 of the Research Agreement.

Payment Terms

The payment terms for this task order will be managed according to the terms of the Research Agreement between Guardian and IM.

Intermolecular, Inc.				Guardian Industries Corp.

By:	/s/ J. Craig Hunter			By:	/s/ Jean-Marc Lemmer

Print Name:			J. Craig Hunter	Print Name:			Jean-Marc Lemmer

Title:		VP & GM, Clean Energy Tech		Title:		Senior Director, Product R&D

Date:		July 27, 2010		Date:		July 27, 2010

-CONFIDENTIAL-

Task Order # 2

[*] Coating Development

Task Order # 2 is entered into as of October 22 nd , 2010 under the terms of the Research Agreement dated February 8, 2010 (“Research Agreement”) between Guardian Industries Corp. (hereinafter referred to as “Guardian”) and Intermolecular (here in after referred to as “IM”). Terms that are capitalized but not specifically defined herein shall have the meanings set forth in the Research Agreements.

GOAL

The goal of Task order 2 is to:

1. [*] the [*] of the [*] and [*] on the [*] and [*].

2. [*] a [*] that [*] the [*] at the [*] on [*] which is defined as a [*] on a [*].

SCOPE

The primary focus of this Task Order is to [*] an [*] that would [*], which include the [*] and [*].

[*]

	*[]**	*[]**	*[]**
[*]
1	[*]	[*]	[*]
2	[*]	[*]	[*]
3	[*]	[*]	[*]
4	[*]	[*]	[*]
[*]
5	[*]	[*]	[*]
6	[*]	[*]	[*]
7	[*]	[*]	[*]
[*]
8	[*]	[*]	[*]
9	[*]	[*]	[*]
10	[*]	[*]	[*]
11	[*]	[*]	[*]
[*]
12	[*]	[*]	[*]
13	[*]	[*]	[*]
14	[*]	[*]	[*]
15	[*]	[*]	[*]
16	[*]	[*]	[*]
[*]
17	[*]	[*]	[*]
18	[*]	[*]	[*]

[*]

	*[]**	*[]**	*[]**
[*]
1	[*]	[*]	[*]
2	[*]	[*]	[*]
3	[*]	[*]	[*]
4	[*]	[*]	[*]
5	[*]	[*]	[*]
6	[*]	[*]	[*]
[*]
7	[*]	[*]
8	[*]	[*]
9	[*]	[*]

The [*] to [*] with [*] is an [*] in [*] on [*] to [*]. It is a [*] that the [*] this [*]and [*] or [*] with the [*] of [*] to [*] the [*] at the [*] for [*].

IM shall direct its efforts on the [*] of [*] of [*] for [*]. The project is [*] that are to be [*]. The [*] are:

[*]

[*].

The [*] must be [*] at the [*] for [*] in [*] on the [*] for all [*].

The [*] for [*] of the [*] will follow [*] of [*] and the [*] at IM. Once the [*] and [*] will continue [*] with the [*] and [*] the [*]. The [*] for [*] are [*] in the [*]. Once the [*] the [*] will continue on [*] at [*] or [*] depending upon the [*] and [*]. [*] will be made based on [*] and [*] of [*] of [*] or [*] on a [*].

[*]:

The [*] with [*] will include [*] of [*] of [*] and [*]. The [*] will be selected for [*] with [*] and [*] with [*]. [*] will be [*] and [*] in the [*].

[*]:

[*]

· [*]

· [*].

· [*]

· [*]:

[*]

· [*]:

· [*]

· [*].

· [*]

[*]

[*].

[*]:

[*]

[*]

The [*] will include [*] of [*]. This approach is used by [*] and the [*]. [*] are [*] for [*] the [*] and [*].

[*]:

[*]

[*] :

[*]:

[*]

[*]:

[*]

· [*]

[*]

[*].

[*]

[*]:

The [*] is a [*] of the [*] with Task Order 1, [*]. [*] was [*] in [*] of [*] of the [*] of the [*]. [*] have been [*] for [*] at [*] in [*] of the [*]. The [*] and [*] have been established for the [*]:

[*].

[*]

IM will [*] for [*] per agreement with Guardian based on [*].

[*]:

[*]

[*]:

[*]

Task Order Management

The IM Task Order Manager will be [*]

The Guardian Task Order Managers will be [*].

[*]:

The [*] for the [*] are [*] in the [*]. It is anticipated the [*] will be [*] for [*] as [*] as [*] and as [*] as the [*]. This [*] is to be [*] on a [*] with the [*] that the [*] at the [*] of the [*]. The [*] that the [*] by [*] should be [*].

[*]:

[*]:

[*]

[*]:

[*].

Intellectual Property

Any Project-Related Intellectual Property developed in the course of work on Task Order 2 will be managed according to the terms of the Research Agreement between Guardian and IM However, for [*] with [*] under this Task Order 2, [*] from [*] to the [*] by [*] or [*] of the [*] or [*] or [*] the [*] in [*] shall not be considered Program Technology (and therefore would not be royalty bearing). All other technologies (i.e. other than the technologies identified above), including but not limited to technologies resulting from the development or modification of a [*] shall be considered Program Technology and shall be royalty beating under the terms of the Research Agreement provided such technology is invented or co-invented by IM.

[*]

[*]:

[*]

[*]:

*[]**	*[]**	*[]**	*[]**	*[]**

[*]:

*[]**	*[]**	*[]**	*[]**

[*]:

*[]**	*[]**	*[]**

Subcontracting

No subcontracting is expected for this task order. Any need for subcontracting must be reviewed and approved by Guardian prior to conducting any subcontracts.

Payment Terms

The payment terms for this task order will be managed according to the terms of the Research Agreement between Guardian and IM.

IM.				Guardian Industries Corp.

By:	/s/ J. Craig Hunter			By:	/s/ Scott Thomsen

Print Name:			J. Craig Hunter	Print Name:			Scott Thomsen

Title:		VP & GM, Clean Energy		Title:		Chief Technology Officer

Date:		December 10, 2010		Date:		December 15, 2010

APPENDIX

[*]

-CONFIDENTIAL-

Task Order # 3

[*] Coating Development

Task Order # 3 is entered into as of May 1 st , 2011 under the terms of the Research Agreement dated February 8, 2010 (“Research Agreement”) between Guardian Industries Corp. (hereinafter referred to as “Guardian”) and Intermolecular, Inc. (here in after referred to as “IM”). Terms that are capitalized but not specifically defined herein shall have the meanings set forth in the Research Agreements.

GOAL

The goal of Task Order 3 is to:

1. [*].

2. [*].

3. [*].

SCOPE

The primary focus of this Task Order is to [*] an [*] to as [*] that would [*] the [*][*] as [*], which include the [*],[*].

[*]

	*[]**	*[]**	*[]**
[*]
1	[*]	[*]	[*]
2	[*]	[*]	[*]
3	[*]	[*]	[*]
4	[*]	[*]	[*]
[*]
5	[*]	[*]	[*]
6	[*]	[*]	[*]
7	[*]	[*]	[*]
[*]
8	[*]	[*]	[*]
9	[*]	[*]	[*]
10	[*]	[*]	[*]
11	[*]	[*]	[*]
[*]
12	[*]	[*]	[*]
13	[*]	[*]	[*]
14	[*]	[*]	[*]
15	[*]	[*]	[*]
16	[*]	[*]	[*]
[*]
17	[*]	[*]	[*]
18	[*]	[*]	[*]

[*]

	*[]**	*[]**	*[]**
[*]
1	[*]	[*]	[*]
2	[*]	[*]	[*]
3	[*]	[*]	[*]
4	[*]	[*]	[*]
5	[*]	[*]	[*]
6	[*]	[*]	[*]
[*]
7	[*]	[*]
8	[*]	[*]
9	[*]	[*]

The [*] to [*] with [*] is an [*] in [*] on [*] to [*]. It is a requirement that the [*] on [*] and [*] or [*] the [*] of the [*] of [*] to [*] the [*] on [*] and [*] of [*] than [*] and [*] at the [*] for [*].

IM shall [*] on the [*] of [*] of [*] for [*]. The [*] is [*] into [*]. The [*] are:

[*]: [*].

The [*] must be [*] at the [*] for [*] in [*] on the [*] for [*].

The [*] for the [*] will [*] of [*] and the [*] at [*]. Once the [*] have been [*] and [*] have been [*] will [*] at [*] with the [*] of [*] and [*] the [*]. The [*] for [*] are [*] the [*]. Once the [*] at [*] the [*] will [*] on [*] at [*] upon the [*] and [*]. [*] will be [*] of [*] than [*] and [*] and [*] of [*] of [*] or [*] on a [*].

[*]

The [*] will [*] on [*] of [*] at [*] and [*]. The [*] that may [*] in the [*]. For [*] of this [*], the [*] will be [*] to [*] and the [*] to [*]. [*] on these [*] the [*] is [*] for these [*].

[*]

[*]:

[*]

[*] :

[*]

[*] :

[*]

[*] :

[*]

[*] :

[*]

· [*]

[*]

[*]

The [*] will include [*] of [*] and [*]. This [*] is [*] by [*] and the [*]. [*] of [*] are [*] for [*] the [*] and [*].

[*]

. [*]

[*]

[*]:

[*]

[*]:

[*]:

[*]

[*]:

The [*] will [*] on [*]. [*] to be made by [*], [*] and [*]. Other [*] may be [*] as [*] and [*].

[*]:

[*]:

[*].

Task Order Management

The IM Task Order Manager will be [*]

The Guardian Task Order Managers will be [*].

[*]:

The [*] for the [*] are listed in the [*]. The [*] of this [*] is [*] for [*] from [*] through [*]. The [*] the [*] until the [*] (see [*] in [*] in [*]). A [*] will be [*] by the [*] of [*] to [*] the [*] for [*].

[*]:

[*]

[*]:

[*]

[*].

Intellectual Property

Any Project-Related Intellectual Property developed in the course of work on Task Order 3 will be managed according to the terms of the Research Agreement between Guardian and IM. Any work under this Task Order 3, resulting from modifications made to the [*] shall not be considered Program Technology (and therefore would not be royalty bearing). All other technologies (i.e. other than the technologies identified above), including but not limited to technologies resulting from the [*] shall be considered Program Technology and shall be royalty bearing under the terms of the Research Agreement provided such technology is invented or co-invented by IM.

Prior Technology

Guardian Prior Technology includes the following:

[*]

[*] [*] [*] [*] [*] [*]

[*]:

[*] [*] [*] [*]

[*]

[*] [*] [*]

Subcontracting

No subcontracting is expected for this task order. Any need for subcontracting must be reviewed and approved by Guardian prior to conducting any subcontracts.

Research Compensation / Payment Terms

As consideration for work performed under this Task Order, Guardian will pay IM 6 monthly installments of US$[*] on a monthly basis as described above. Other expenses will be treated as described in the Research Agreement.

IM.				Guardian Industries Corp.

By:	/s/ J. C. Hunter			By:	/s/ Scott Thomsen

Print Name:			James C. Hunter	Print Name:			Scott Thomsen

Title:		VP & GM, Clean Energy		Title:		President

Date:		May 13, 2011		Date:		May 19, 2011

APPENDIX: A

[*]

Amendment to Task Order #3 ([*])

Guardian and Intermolecular

GUARDIAN INDUSTRIES CORP., a Delaware corporation located at 2300 Harmon Road, Auburn Hills, Michigan 48326 (hereinafter referred to as “Guardian”) and INTERMOLECULAR, INC., a Delaware corporation located at 3011 North First Street, San Jose, California 95134 (hereinafter referred to as “Intermolecular”), entered into a Task Order effective May 1, 2011 (“Task Order No. 3”) under the terms of a RESEARCH AGREEMENT effective Feb. 8, 2010 (“ [*] Agreement”) .

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to modify the terms of Task Order No. 3 (hereinafter “Amendment”) as set forth below.

1. AMENDMENT EFFECTIVE DATE

1. This Amendment shall have an effective date of Nov. 1, 2011 (“Amendment Effective Date”)

2. TIMELINES

1. The portion of Task Order No. 3 titled “Timelines” which currently reads — “ The duration of this work is scheduled for [*] months from [*] through [*] is modified as follows - The duration of this work is scheduled for [*] months from [*] through [*] .

3. RESEARCH COMPENSATION/PAYMENT TERMS

1. The portion of Task Order No. 3 titled “Research Compensation / Payment Terms” which currently reads “ As consideration for work performed under this Task Order, Guardian will pay IM 6 monthly installments of US$ [*] on a monthly basis as described above. ” is modified as follows - As consideration for work performed under this Task Order, Guardian will pay IM 8 monthly installments of US$ [*] on a monthly basis as described above.

All capitalized terms not defined herein shall have the meanings given them in the [*] Agreement or Task Order #3. This Amendment shall be deemed to be incorporated into Task Order #3 and made a part thereof. All references to Task Order #3in any other document shall be deemed to refer to Task Order #3, as modified by this Amendment. Except as modified by this Amendment, all of the terms and conditions of Task Order #3 and the [*] Agreement shall remain in full force and effect. In the event that the terms of this Amendment conflict with the terms of Task Order #3, the terms of this Amendment shall control.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Amendment Effective Date.

Guardian Industries Corp.		Intermolecular, Inc.

By:	/s/ Jean-Marc Lemmer	By:	/s/ J. Craig Hunter

Name:	LEMMER Jean-Marc	Name:	J. Craig Hunter

Title:	Senior Director, Product R&D	Title:	Senior VP and GM, Clean Energy Group

Date:	Dec. 7, 2011	Date:	Dec. 5, 2011

RESEARCH AGREEMENT

This RESEARCH AGREEMENT (this “ Agreement ”) is effective as of July 15, 2010 (the “ Effective Date ”) between GUARDIAN INDUSTRIES CORP ., a Delaware corporation located at 2300 Harmon Road, Auburn Hills, Michigan 48326 (hereinafter referred to as “ Guardian ”), and INTERMOLECULAR, INC ., a Delaware corporation located at 2865 Zanker Road, San Jose, California 95134 (hereinafter referred to as “ Intermolecular ”).

1. DEFINITIONS.

1.1. “ Affiliate ” shall mean any individual or entity directly or indirectly controlling, controlled by or under common control with, a party to this Agreement. For purposes of this Agreement, the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of an entity shall be deemed to constitute control.

1.2. “ Development Program ” shall mean the activities that are conducted by Guardian and Intermolecular on a collaborative basis under this Agreement in accordance with one or more Task Orders for the purposes of developing a Project Set.

1.3. “ FTE ” shall mean a full-time employee or contractor dedicated to the conduct of the Development Program or, in the case of less than full-time dedication, a full-time equivalent person-year, based on approximately one thousand eight hundred (1,800) hours per year, of work on or related to the Development Program.

1.4. “ Guardian Product ” shall mean a Guardian product incorporating any Program Technology.

1.5. “ HPC Technology ” shall mean all techniques, methodologies, processes, test vehicles, synthetic procedures, technology, systems, or combination thereof (collectively, “ Techniques ”) (a) subject to or covered by any Intellectual Property Right owned by Intermolecular or licensed to Intermolecular, (b) used by Intermolecular in performance of a Development Program or provided by Intermolecular to Guardian pursuant to a Development Program, and (c) used for the simultaneous parallel or rapid serial: (i) design, (ii) synthesis, (iii) processing, (iv) process sequencing, (v) process integration, (vi) device integration, (vii) analysis, or (viii) characterization of more than two (2) compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such. For the avoidance of doubt, HPC Technology does not include glass production techniques such as [*] technologies.

1.6. “ Intellectual Property Rights ” shall mean rights in and to all (a) U.S. and foreign patents and patent applications claiming any inventions or discoveries made, developed, conceived, or reduced to practice, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof, (b) copyrights, (c) unpatented information, trade secrets, data, or materials, (d) mask work rights, and (e) any other intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction, but not trademarks, service marks, trade names, trade dress, domain names and similar rights.

1.7. “ Project Set ” shall mean the specific Program Technology developed pursuant to a particular Task Order.

1.8. “ Program Technology ” shall mean any and all technology, materials, processes, documentation and any related Intellectual Property Rights developed as a result of activities performed pursuant to a Task Order under this Agreement, including each Project Set.

1.9. “ Third Party ” shall mean any person or entity other than Guardian and its Affiliates, Intermolecular and its Affiliates, and their permitted assigns.

2. DEVELOPMENT PROGRAM .

2.1. Development Program . Guardian and Intermolecular shall conduct each Development Program in a collaborative effort pursuant to a written task order (each, a “ Task Order ”). Each Task Order will describe the development activities to be conducted by each party with the goal of developing a Project Set for such Task Order. Any revision to a Task Order shall be carried out pursuant to Section 2.3 below and when agreed upon will be incorporated into this Agreement, superseding or supplementing the previous Task Order. Each party will commit appropriate resources in equipment, facilities and personnel reasonably necessary to complete its respective tasks in accordance with each Task Order, including the resources listed in such Task Order. Except as set forth in Section 7.2 or as stated in a Task Order, Intermolecular and Guardian will each bear their own respective costs associated with the Development Programs.

2.2. Development Program Support . Guardian and Intermolecular shall each provide at least that number of FTEs set forth in the applicable Task Order to conduct their respective obligations under such Task Order, such FTEs to be allocated over the course of the activities as set forth in the applicable Task Order. Neither party is required to perform development activities other than in accordance with the Task Orders or utilize a total number of FTEs in excess of the number of FTEs described in such Task Orders.

2.3. Task Order Changes . Modifications to a Task Order will only be binding if in writing and signed by both parties.

2.4. Development Records . Guardian and Intermolecular shall maintain records of each Development Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in the performance of the Development Program (including information sufficient to establish dates of conception and reduction to practice of inventions).

2.5. Project Managers . Intermolecular and Guardian will each appoint by written notice to the other party a principal point of contact to be its project manager (the “ Project Managers ”) who will coordinate and act as a liaison with the other party with respect to this Agreement and oversee the work under this Agreement. The parties will use reasonable efforts to direct communications under this Agreement through the project managers. Either party may from time to time change its project manager at its discretion by providing written notice to the other party.

2.6. Dispute Escalation Process . If either party believes that the other party has failed to perform its obligations under a Task Order, it will notify the other party of the perceived deficiency. Upon receipt of notice, the Project Managers will promptly discuss a corrective action plan in person or by telephone and will attempt in good faith to agree to a mutually acceptable corrective action plan. If the Project Managers cannot agree upon a corrective action plan within ten (10) days of the original notice date, the issue will be escalated to senior management at the respective parties. The respective

management representatives will immediately discuss the issue in person or by telephone and the parties will attempt in good faith to resolve the issue for a period of ten (10) days. If the issue is not resolved by mutual agreement within the second ten (10) day period, the parties may resort to remedies available in this Agreement or at law.

2.7. Progress Reports; Meetings . Intermolecular and Guardian will discuss the progress of work under this Agreement at least on a monthly basis unless more frequent reports are required in the applicable Task Order. Intermolecular will also submit written progress reports at intervals defined in the applicable Task Order, but at minimum on a monthly basis.

3. SAFETY PROCEDURES / REGULATIONS . Each party agrees to follow and to cause such party’s employees, representatives and agents to follow all applicable safety procedures of the other party when performing work under this Agreement at such other party’s facility, provided that such other party provides notice of the safety procedures at such facility. Each party will also comply with all applicable laws and regulations relating to the work performed under this Agreement.

4. CONFIDENTIALITY. Intermolecular and Guardian acknowledge that the work under this Agreement will involve the exchange of certain confidential information. The information will be protected under the terms of the Mutual Non-Disclosure Agreement that has been entered into between the parties.

5. OWNERSHIP AND LICENSES .

5.1. Ownership of Intellectual Property Rights .

5.1.1. Prior Technology . Each party shall retain all right, title and interest in all materials, software, programming documentation, technical ideas, concepts, know-how, inventions, discoveries, improvements, works of authorship, techniques and all related Intellectual Property Rights created, conceived or developed by or for that party prior to the Effective Date (the “ Prior Technology ”). Each Task Order will specify any Prior Technology either party intends to use in connection with the activities under the Task Order. For purposes of this Agreement, Prior Technology does not include HPC Technology.

5.1.2. Program Technology Ownership.

5.1.2.1. Program Technology . Intellectual Property Rights created as a result of the work under this Agreement will be owned by the party whose employees are the inventors or creators of such Intellectual Property Rights. Any Intellectual Property Rights jointly invented or created by the parties will be jointly owned by the parties subject to the terms of Section 6 below. Guardian agrees that it will not commercialize or license any jointly-owned Intellectual Property Rights except subject to the payment terms, field restrictions, and other terms and conditions applicable to the commercialization and sublicensing of Intermolecular-owned Intellectual Property Rights set forth in Section 5 below.

5.1.2.2. Cooperation. Each party agrees to execute all papers, including patent applications, invention assignments and copyright assignments, and otherwise agrees to assist the other party, as reasonably required and at such party’s reasonable expense, to perfect in the applicable party the rights, title and other interests in the Program Technology.

5.1.3. Independently Developed Technology . Each party shall retain all right, title and interest in and to all materials, software, programming documentation, technical ideas, concepts, know-how, inventions, discoveries, improvements, works of authorship, techniques and all related Intellectual Property Rights created, conceived or developed by or for that party outside of or independent from this Agreement (the “ Independent Technology ”). For purposes of this Agreement, Independent Technology does not include HPC Technology or HPC Derivatives.

5.1.4. HPC Technology . Without limiting the foregoing Sections 5.1.2 or 5.1.3, as between the parties, Intermolecular shall own all right, title, and interest in and to the HPC Technology and all improvements, derivatives and modifications thereof developed by either party or both parties during the course of the Agreement (“ HPC Derivatives ”). Guardian hereby assigns, and agrees to assign to Intermolecular in the future when any such HPC Derivatives are first fixed in a tangible medium or reduced to practice, as applicable, all of its right, title and interest in and to any HPC Derivatives.

5.2. LICENSES .

5.2.1. Program Technology . Subject to Sections 7 and 11 of this Agreement, Intermolecular hereby grants Guardian a worldwide, royalty-bearing, non-transferable (subject to Section 12.12) license under and to Intermolecular’s Intellectual Property Rights in the Program Technology to (a) engage in Development Programs with Intermolecular and (b) use, make, have made, import, offer to sell and sell Guardian Products within the field of use (the “ Field ”) defined in the applicable Task Order from which the Program Technology was generated.

5.2.2. Prior Technology . Subject to Sections 7 and 11 of this Agreement, each party hereby grants the other party a worldwide, non-exclusive, non-transferable, royalty-free license, without right of sublicense, to use such party’s Prior Technology (a) to the extent necessary for such party to carry out its obligations under the Development Program and (b) to the extent necessary to exercise any licenses granted under the Program Technology.

5.2.3. HPC Technology . Subject to Sections 7 and 11 of this Agreement, Intermolecular hereby grants Guardian a worldwide, royalty-free, non-exclusive, non-transferable (subject to Section 12.12) license, without right of sublicense, under and to Intermolecular’s Intellectual Property Rights in the HPC Technology and HPC Derivatives to engage in the Development Programs with Intermolecular.

5.2.4. Guardian’s Affiliate and Third Party Licensees . Subject to Sections 7 and 11of this Agreement, Guardian shall have the right, but not the obligation, to grant sublicenses of part or all the Program Technology (a) to Guardian’s Affiliates to use, make, have made, import, offer to sell and sell Guardian Products, and/or (b) Third Party Licensees to use, make, have made, import, offer to sell and sell products in the applicable Field.

5.2.5. Reservation of Rights . Except for the rights expressly granted by each party to the other under this Agreement, all other rights are reserved.

5.3. Exclusivity; Election .

5.3.1. Guardian must make an election by written notice to Intermolecular to take an exclusive license or a non-exclusive license to a particular Project Set within a time period defined within the applicable Task Order.

5.3.2. If Guardian elects in writing to receive an exclusive license to a Project Set and Guardian is in compliance with the royalty obligations for an exclusive license set forth in the applicable Task Order, the license granted to Guardian under Section 5.2.2 above, and the sublicense rights granted in Section 5.2.4, will be exclusive in the Field to such Project Set, except as to Intermolecular for purposes of Intermolecular undertaking the Development Program for Guardian. If applicable, the Task Order will define the minimum royalty payments required to maintain exclusivity and any initial grace period during which minimum royalties are not due.

5.3.3. If Guardian elects in writing to receive a non-exclusive license to a Project Set or after a defined period of exclusivity has expired, and provided Guardian is in compliance with the royalty obligations for a non-exclusive license set forth in the applicable Task Order, the license granted to Guardian under Section 5.2.2 above, and the sublicense rights granted in Section 5.2.4, will be non-exclusive in the Field to such Project Set. If applicable, the Task Order will define the revenue sharing Guardian will receive from any licenses granted by Intermolecular to third parties under the Program Technology. Intermolecular may not solicit third party licenses to a Project Set before the expiration of any defined period of exclusivity.

6. INTELLECTUAL PROPERTY PROTECTION

6.1. IP Committee. The parties will also establish a committee (the “ IP Committee ”) that will be responsible for reviewing invention disclosures, patent filing decisions and Intellectual Property Rights ownership decisions resulting from activities under the Development Programs, including determination of the Intellectual Property Rights, if any, in all Program Technology developed pursuant to the Development Programs. The IP Committee will meet on at least a calendar quarterly basis or as otherwise agreed to by the parties. The IP Committee shall consist of two (2) members from each party, one from its technical employee and the other one from its patent attorney, agent or IP staff member. All decisions of the IP Committee must be made by unanimous vote of the parties. If there is disagreement between the parties regarding the existence or ownership of Intellectual Property Rights, the parties will escalate the dispute as appropriate within their respective organizations as promptly as possible for resolution; provided, however, that neither party shall publicly disclose or otherwise publish any information, or otherwise jeopardize the opportunity to file a patent application, regarding an invention claimed by the other party hereunder resulting from or relating to Development Program activities during any period where the ownership of such claimed invention has not yet been determined. Each party agrees that it will not unreasonably delay or prolong resolution of any ownership, inventorship or other claim regarding the Program Technology or Intellectual Property Rights.

6.2. Patent Prosecution . Intermolecular shall have the first right to prepare, file, prosecute and maintain, at its own expense and in consultation with Guardian, patent applications and patents claiming Program Technology, and to conduct any interferences, re-examinations, reissues, oppositions or requests for patent term extension or governmental equivalents thereto. In the event that Intermolecular does not file, prosecute or maintain any such patent or patent application (including the failure to do so in only certain countries), or undertake such other activities described above, then Guardian shall have the right to assume such activities at its own expense but without affecting the ownership and license provisions set forth in Section 5.

6.3. Cooperation . Intermolecular and Guardian shall both use reasonable efforts to keep the other fully informed as to the status of patent matters with respect to Program Technology described in Section 6.1, including by providing the other the opportunity to review and comment on complete copies

of any documents a reasonable time in advance of applicable filing dates and prosecution deadlines, and upon request, providing to the other party copies of any substantive documents that a party receives from the United States Patent and Trademark Office and any foreign patent offices, promptly after receipt, including notice of all official actions, interferences, reissues, re-examinations, oppositions, or requests for patent term extensions. Intermolecular and Guardian shall each reasonably cooperate with and assist the other at its own expense in connection with such activities, at the other party’s request. The Project Managers will (a) facilitate communication between the parties regarding patents and patent applications with respect to Program Technology arising from the Development Program, (b) discuss and provide input on patent strategy with respect to Program Technology, and (c) review applications and other substantive papers with respect to Program Technology prior to filing with the patent office.

6.4. Enforcement .

6.4.1. Notice . Each party shall promptly notify the other of its knowledge of any actual or potential commercially material infringement of the Program Technology by a Third Party.

6.4.2. Program Technology . (a) Intermolecular shall have the right, but not the obligation, to take reasonable legal action to enforce Intellectual Property Rights relating to the Program Technology, against commercially material infringements that involve the manufacture, use, sale, offer for sale or import of the Program Technology. (b) With respect to material infringements that involve the manufacture, use, sale, offer for sale or import of those inventions in the Field, if Intermolecular does not take action sufficient to halt such infringement within six (6) months following receipt of notice of such infringement, then Guardian shall have the right, but not the obligation, to take action to stop such infringement at its sole expense. Neither party may enter into any settlement which admits or concedes that any aspect of the Program Technology is invalid or unenforceable, without the prior written consent of the other party, such consent not to be unreasonably conditioned, delayed or withheld.

6.4.3. Cooperation; Costs . Each party agrees to render such reasonable assistance in connection with enforcement activities described in this Section 6.4 as the enforcing party may request. Costs of maintaining any such action shall be paid by and belong to the party bringing the action; provided, however, that prior to Intermolecular undertaking any action pursuant to Section 6.4.2, Intermolecular and Guardian shall discuss in good faith arrangements to underwrite the costs of such action, pursuant to which Guardian shall have the option to participate in such action by agreeing to contribute up to the percentage revenue share amount payable to Guardian set forth in the applicable Task Order of the third party costs of such action in exchange for an equivalent share of any damages or settlement recovered from such action (after the deduction of the costs and fees of the action).

6.4.4. Recoveries . Any damages or settlement recovered from any action under this Section 6.3 (after the deduction of the costs and fees of the action) shall be allocated to the party undertaking the action, except that any damage award or settlement (after the deduction of the costs and fees of the action) received by Intermolecular in connection with actions in which Guardian has participated pursuant to Section 6.4.3 shall be shared by the parties in proportion to the percentage of legal costs borne by each party.

6.4.5. Third Party Claims of Infringement . If the manufacture, use or sale of any Program Technology pursuant to this Agreement results in any claim, suit or proceeding alleging patent infringement against Guardian or Intermolecular, the party named as the defendant in that claim, suit or

proceeding shall promptly notify the other party hereto in writing setting forth the facts of such claims in reasonable detail. The named defendant shall have the exclusive right and obligation to defend and control the defense of any such claim, at its own expense; provided, however, defendant shall not enter into any settlement which admits or concedes that any aspect of the Program Technology is invalid or unenforceable, without the prior written consent of the other party, such consent not to be unreasonably conditioned, delayed or withheld. The named defendant shall keep the other party hereto reasonably informed of all material developments in connection with any such claim, suit or proceeding. The other party shall, upon request, provide reasonable assistance and cooperation to the named defendant and may elect to participate in the defense of the claim, suit or proceeding, at its own expense using counsel of its own choice.

7. PAYMENTS .

7.1. Program Fees . As consideration for the work performed by Intermolecular under this Agreement, Guardian will pay Intermolecular the program fees (“Program Fees”) set forth in Exhibit A according to the schedule set forth therein. It is understood that although the parties have agreed upon a fixed fee to cover approximately two years of research under the Development Program, the parties have not defined up-front all of the Task Orders for the Development Program. The parties will work together in good faith to reach agreement on the Task Orders so that the research efforts are continuous during the Development Program. However, if Intermolecular has completed work on all pending Task Orders but the parties are unable to reach agreement on the following Task Order, Guardian may suspend the payment of Program Fees for a maximum period of thirty (30) days until the parties have reach agreement and Intermolecular has resumed work under one or more new Task Orders. In no event will the timeline for payment of the Program Fees exceed thirty (30) months from the Effective Date. Suspension of the Program Fees will not reduce the obligation of Guardian to pay the total amount of the Program Fees.

7.2. Expenses. Guardian will provide or pay for (a) consumables, such as substrates, mask sets, materials, and targets, (b) outsourced metrology and characterization not supported internally by Intermolecular, (c) reasonable travel and lodging expenses for Intermolecular personnel performing activities at Guardian’s facilities, and (d) subject to Guardian’s prior written approval not to be unreasonably withheld, any other out-of-pocket costs to support the Development Programs. Notwithstanding the foregoing, Intermolecular agrees to provide targets for Development Programs at no cost to Guardian at a cost of up to [*] Dollars ($[*]) per year. Any additional targets will be provided at Guardian’s reasonable expense with Guardian’s prior approval being required before such targets are ordered.

7.3. Royalties. For any royalties that are due to Intermolecular (as defined in the applicable Task Order), no later than [*] ([*]) days after the end of each Guardian fiscal quarter, Guardian will issue Intermolecular a written report containing the number of Guardian Products shipped by or on behalf of Guardian and all applicable Guardian Affiliates to any Third Parties during such quarter and the corresponding royalty amount to be paid to Intermolecular. Guardian will make all applicable royalty payments at the same time as issuing the report.

7.4. Third Party Royalty Payments. If Guardian exercises its right to sublicense the Program Technology to Third Party licensees as allowed under Section 5.2.4, Guardian shall pay Intermolecular a pass-through royalty equal to [*]percent ([*]%) of the royalties received by Guardian from the applicable sublicensed Program Technology or an amount equal to the applicable non-

exclusive royalty rate for the Program Technology based on applying the net sales calculations as set forth in this Agreement to the Third Party licensee. Upon Intermolecular’s request, Guardian will conduct audits of such Third Party licensee to determine the accuracy of the net sales figures provided to Guardian upon which Guardian calculates its payments to Intermolecular hereunder. Any other sublicensing arrangement and fee structure requires Intermolecular’s prior written consent on a case-by-case basis.

7.5. Payment Method; Late Payment. All payments hereunder shall be made in U.S. dollars by Guardian or one of its U.S. Affiliates. All payments due to Intermolecular under this Agreement shall be made by bank wire transfer as follows:

U.S. Domestic Wire Transfer
To:	[*]

Routing & Transit #:	[*]

For credit of:	Intermolecular, Inc.
Credit account #:	[*]
By order of:	[ Name of Sender ]

or another U.S. bank account designated by Intermolecular.

7.6. Taxes. Prices and payments due to Intermolecular are exclusive of all present and future taxes, duties, levies and other charges by any name (including any interest, penalties or additions thereto) imposed by any foreign, federal, state, local or other taxing authorities (including, without limitation, export, sales, use, excise and value-added taxes) on or with respect to the transactions or payments under this Agreement (excluding taxes imposed on Intermolecular’s net income by Intermolecular’s jurisdiction of organization or by reason of Intermolecular’s connection to such jurisdiction other than solely as a result of this Agreement) (collectively, “Taxes”).

7.7. Records; Inspection. Guardian shall keep complete, true and accurate books of account and records on its own behalf for the purpose of determining the royalty amounts payable under this Agreement. Such books and records shall be kept at Guardian for at least three (3) years following the end of the calendar quarter to which they pertain. Such records will be open for inspection during such three (3) year period by an independent auditor reasonably acceptable to Guardian, solely for the purpose of verifying royalty statements hereunder. Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice. Inspections conducted under this Section 7.7 shall be at the expense of Intermolecular, unless a variation or error producing an increase exceeding [*] percent ([*]%) of the royalties payable for any period covered by the inspection is established and confirmed in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by Guardian. Each party agrees to hold in confidence pursuant to Section 4 all information concerning royalty payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for that party to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law.

8. LIMITED WARRANTIES.

8.1. By Intermolecular . Intermolecular represents and warrants that: (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; and (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.

8.2. By Guardian. Guardian represents and warrants that: (a) it has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; and (b) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.

8.3. Disclaimer . Intermolecular and Guardian specifically disclaim any representation, warranty or guarantee that the research and development under this Agreement will be successful, in whole or in part. It is understood that the failure of the parties to successfully develop and commercialize products under any Development Plan, Task Order or the Development Program shall not constitute a breach of any representation or warranty or other obligation under this Agreement. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, GUARDIAN AND INTERMOLECULAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO ANY INFORMATION DISCLOSED HEREUNDER, OR ANY DELIVERABLES PROVIDED HEREUNDER, AND HEREBY EXPRESSLY DISCLAIM ANY WARRANTIES OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR VALIDITY OF ANY PROGRAM TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

9. INSURANCE. Before having its employees conduct any work at the site of the other party, each party shall procure and maintain for itself and its employees all insurance coverage as required by applicable federal or state law, including: (a) worker’s compensation benefits as required by state law, for any state in which work may be performed under the Agreement; (b) commercial general liability insurance including contractual liability and completed operations coverage, with limits not less than $[*] each occurrence covering property damage, bodily injury and personal injury liability; and (c) Automobile Liability Insurance, with a minimum of $[*] Combined Single Limit Bodily Injury and Property Damage Liability coverage. Carriers must have a Standard & Poor’s rating of A or better.

10. LIMITATION OF LIABILITY. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, AND EXCEPT FOR ANY BREACH OF ANY LICENSE GRANT OR CONFIDENTIALITY OBLIGATION UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY, ITS AFFILIATES OR TO ANY THIRD PARTY CLAIMING THROUGH OR UNDER THE OTHER PARTY HERETO, FOR ANY LOST PROFITS, LOSS OF DATA, EQUIPMENT DOWNTIME OR FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT OR INCIDENTAL DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY WAY OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR A BREACH OF A LICENSE GRANT OR A CONFIDENTIALITY OBLIGATION, IN NO EVENT SHALL EITHER PARTY’S CUMULATIVE LIABILITY TO THE OTHER UNDER THIS AGREEMENT EXCEED [*] ([*]). IN ADDITION, GUARDIAN ACKNOWLEDGES AND AGREES THAT AS BETWEEN THE PARTIES, INTERMOLECULAR SHALL NOT BE LIABLE FOR ANY PRODUCT LIABILITY CLAIMS RESULTING FROM THE MANUFACTURE, SALE OR USE OF ANY PRODUCTS THAT

GUARDIAN MAKES OR SELLS AS A RESULT OF THE ACTIVITIES CONTEMPLATED UNDER THIS AGREEMENT. The parties acknowledge and agree that the foregoing limitations of liability are an essential element of this agreement and that in their absence the terms of this agreement would be substantially different.

11. TERM AND TERMINATION .

11.1. Term . The term of this Agreement shall commence on the Effective Date, and, unless terminated earlier as provided in this Section 10.1, shall continue in full force and effect for a period two (2) years (the “ Term ”).

11.2. Termination for Breach . Either party may terminate this Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations, and such default has continued for sixty (60) days after written notice was provided to the breaching party by the non-breaching party. Termination will be effective at the end of the sixty (60) day period unless the breach has been cured before the expiration of the sixty (60) day period.

11.3. Effect of Termination .

11.3.1. Accrued Rights and Obligations . Termination of this Agreement for any reason shall not release either party from any liability or obligation that, at the time of termination, has already accrued to the other party or that is attributable to a period prior to termination, nor shall it preclude either party from pursuing any rights and remedies it may have at law or in equity with respect to any breach of this Agreement.

11.3.2. Termination of Licenses and Task Orders. In the event that Guardian materially breaches its obligations to pay for licenses granted pursuant to a specific Task Order, and does not cure such breach in accordance with Section 11.2 above, then in addition to any other remedy available to Intermolecular, Intermolecular may terminate the licenses granted to Guardian pursuant to such Task Order. In the event that Guardian materially breaches its obligations to pay Program Fees for a particular Task Order, and does not cure such breach in accordance with Section 11.2 above, then in addition to any other remedy available to Intermolecular, Intermolecular may terminate such Task Order and any other Task Orders then in effect, refuse to agree to perform additional Task Orders, and Guardian shall not have any license rights to any Program Technology developed as a result of any of the terminated Task Orders.

11.3.3. Survival . Sections 2.4, 4, 5.1, 5.2.5, 6, 7, 8, 10, 11.3 and 12 shall survive the expiration or termination of this Agreement for any reason.

12. MISCELLANEOUS

12.1. Force Majeure . Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment obligations then owing) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood, lockout, embargo, act of terrorism, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing party and such party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance.

12.2. Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, excluding its conflict of law principles.

12.3. Compliance with Laws . In exercising their rights under the license granted hereunder, each party shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement. Without limiting the foregoing, each party agrees to comply with all applicable export and re-export control laws and regulations, including the Export Administration Regulations (“ EAR ”) maintained by the United States government, and shall not, directly or indirectly, sell, export, re-export, transfer, divert, or otherwise dispose of any software, source code, or technology (including products derived from or based on such technology) received under this Agreement to any country (or national thereof) subject to antiterrorism controls or U.S. embargo, or to any other person, entity, or destination prohibited by the laws or regulations of the United States, without obtaining prior authorization from the competent government authorities as required by those laws and regulations.

12.4. Entire Agreement . This Agreement supersedes any and all other agreements, either oral or written, between the parties hereto with respect to this subject, and this Agreement together with any exhibits constitutes the entire agreement between the parties with respect to this subject matter. No change or modification in the terms hereof, in a manner not expressly provided in this Agreement shall be binding unless reduced to writing and duly executed by the parties in the same manner as the execution of this Agreement. Any attempt to so change or modify the terms of this Agreement shall be considered void and of no effect.

12.5. Patent Marking . Each party agrees to use reasonable efforts to mark and have their Affiliates and licensees mark all products sold or licensed pursuant to this Agreement to the extent such marking provides a legal benefit in the country or countries of manufacture and sale of such products.

12.6. Notices . Unless otherwise agreed to by the parties, the communications required or permitted to be given or made under this Agreement shall be made in writing, via personal delivery, registered mail, facsimile transmission, addressed to the appropriate party at the address indicated below. All communications made pursuant to this section shall be deemed made or given on the date of such personal delivery, mailing or transmission.

If to Guardian:		Director of Science and Technology
		Guardian Science and Technology
		14511 Romine Road
		Carleton, Michigan 48117

With a copy to:		General Counsel
		Guardian Industries Corp.
		2300 Harmon Road
		Auburn Hills, MI 48326

If to Intermolecular:		Craig Hunter
		Intermolecular, Inc.
		2865 Zanker Road
		San Jose, CA 95134

		Fax:

With a copy to:		Legal Department
		Intermolecular, Inc.
		2865 Zanker Road
		San Jose, CA 95134
		Fax: (408) 416-2301

The Parties may change the name and address to which notices should be sent under this section by providing prior written notice to the other party.

12.7. Severability . If any term, provision, covenant or condition of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants or conditions shall remain in full force and effect and shall in no way be affected, impaired or invalidated.

12.8. Headings; Construction . The captions to the several sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation. As used in this Agreement, the word “including” means “including without limitation.”

12.9. Facsimile Signatures. . This Agreement may be executed by the exchange of facsimile signatures of the parties, which will be deemed valid and binding as if they were originally made.

12.10. Relationship of the Parties . The relationship of the parties is that of independent contractors. Neither party shall be deemed to be an agent, partner, joint venturer or legal representative of the other for any purpose as a result of this Agreement or the transactions contemplated thereby. Personnel supplied by either party are not the other party’s employees or agents and such supplying party assumes responsibility for their acts or omissions. The supplying party shall be solely responsible for the payment of compensation of such party’s employees or agents assigned to perform services hereunder and such employees or agents shall be informed that they are not entitled to any employee benefits of the other party. Neither party shall be responsible for paying worker’s compensation, disability benefits, and unemployment insurance or for withholding and paying employment taxes for any employee or agent of the other party.

12.11. Assignment . This Agreement and any rights granted hereunder shall inure to the benefit of and be binding upon each of the Parties and their respective successors and permitted assigns. Neither party shall assign or transfer this Agreement either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other party, and any attempt to do so will be null and void; provided, however, that either party may assign this Agreement without such consent, to a parent, subsidiary, or affiliate, or to a successor in interest to its business (whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets).

12.12. Non-Waiver . The failure of either party at any time to require performance of any provision hereof by the other party shall not be deemed a waiver and thereafter shall not deprive that party of its full right to require such performance in the particular instance or at any other time. Any waiver must be in writing executed by the waiving party.

12.13. Representation by Legal Counsel . Each party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.

12.14. Publicity; Disclosure of Agreement . Neither party shall publicize nor disclose any aspect of the development efforts contemplated in this Agreement or any other terms of this Agreement without the prior written consent of the other party, except to the extent required by law, to such party’s attorneys, accountants, advisors, investors and financing sources and their advisors and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, in connection with the enforcement of this Agreement or rights under this Agreement, or in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction.

[ Signature Page Follows ]

By signing below, the parties agree to the terms of this Agreement.

Guardian
	Guardian Industries Corp.

	By:	/s/ Scott Thomsen
	Name:	Scott Thomsen
	Title:	CTO/GVP
	Date:	June 29, 2010

Intermolecular
	Intermolecular, Inc.


	By:	/s/ J. Craig Hunter
	Name:	J. Craig Hunter
	Title:	VP & GM, Clean Energy Tech
	Date:	June 28, 2010

Exhibit A

Program Fees

1. Program Fees . The total amount of Program Fees due hereunder shall be $[*].

2. Payment Schedule .

2.1. $[*] invoiced [*] days after the Effective Date.

2.2. $[*] invoiced at one-month intervals following [*] days after the Effective Date until the total amount of Program Fees has been paid.

The monthly payments in this Payment Schedule shall reflect the minimum Program Fees for services performed in the prior month. No payment will be treated as a deposit for future services and will be fully earned upon invoice date.

	Guardian Industries Corp.
	14511 Romine Road
	Carleton, MI 48117
	T: 734 654 1111

Task Order # 1

[*].

This Task Order # 1 (“Task Order #1”) is entered into as of 22 July 2010 (the “Task Order Effective Date”) under the terms of the Research Agreement dated July 15, 2010 (the “Agreement”) between Guardian Industries Corp. (hereinafter referred to as “Guardian”) and Intermolecular Inc. (hereinafter referred to as “Intermolecular”). Terms that are capitalized but not specifically defined herein shall have the meanings set forth in the Agreement.

Scope of the Collaboration .

The scope of work for this Task Order #1 covers three main project sets: [*]. [*] and [*] are [*] and [*] is [*].

Specific Goals for the Collaboration .

For the [*] project, the following goals are identified:

[*].

For the [*] project:

[*].

For the [*] project:

[*].

[*]

[*].

The [*] and [*] to [*] the [*] of [*] in the [*] produced by Guardian. [*] in the [*] in order to [*] in the [*]. While the [*] the [*], the [*] used to [*] the [*] are [*], and so [*] the [*] from the [*] and thus the [*] is [*].

For the [*] can be [*] in [*]; however the [*] is [*] of [*]. Other [*] or the [*] and [*], or [*] and [*]. Understanding of the [*] is [*] to this [*] and [*] at the [*].

[*] is known to be [*] in [*] that are [*]. The scope of this work would be to [*] an [*], and to provide along the way, [*] of the [*].[*] to [*] are:

[*].

a. [*].

[*]

a. [*]

b. [*]

c. [*]

d. [*]

e. [*]

[*]

a. [*].

b. [*].

For the project scope, the effort should be divided as follows:

[*]

To [*] the [*] of these [*] or [*] for the project will be required.

[*]:

[*] the [*] is via the [*]:

[*].

a. [*]

b. [*]

i. [*]

c. [*]

[*]

a. [*]

[*]

a. [*]

b. [*]

[*]

[*]:

[*]

a. [*]

b. [*]

[*]

a. [*]

[*].

For [*] this [*] must be [*] to [*]. [*] the [*] should be [*] in with the [*] as a [*] and as an [*]. If [*] as [*] and [*] is desired.

[*].

In addition to the [*] for [*], the [*] can be [*] as [*] and also within [*].

[*], the [*] is that of [*] as [*] used in [*]. The [*] of the [*] is to [*] the [*] in each [*]; however the [*] of [*] is as [*].

For the [*] as [*] are:

[*]

In addition to the [*], it is [*] to [*] a [*] to [*] the [*] of the [*] with [*] in a [*].

The [*] for this work is:

[*]

It is [*] that [*] the [*] on their [*], and [*] this to [*] for [*] and [*]. However, this process [*] as [*] may have [*] than [*].

[*] of the [*] will use the [*] as [*] for the [*] and [*] however also include [*] for [*] to the [*].

[*] for [*]:

[*] will be [*] as a [*] of the [*]:

[*]

[*] should be [*] by [*] and [*] for [*] and [*]. [*] for [*] is [*] at a [*].[*] and [*] should be [*].

[*] is a [*] should be [*] using [*] and [*] on [*] using the [*].

[*] should be [*] — [*], however [*] and [*] should be [*]. This [*] as part of the [*].

[*] should be [*] as [*] per [*] of [*].[*] in a [*].[*] for [*] is [*] and [*].

At this time, [*] is [*] for [*], and [*] control not [*], so these [*] can be [*].

[*]:

[*] of the [*] shall determine the [*] of [*] for the above [*] in an [*].

[*]

[*]:

[*]

[*]:

[*]

[*].

[*]

Due to [*], the [*] will focus on the [*] of [*] as [*] from [*] — [*] and [*]. By [*] the [*] of the [*], a [*] will be [*] as [*], and then in [*].

Following the [*] by [*] and [*] with the identified [*] will be [*] and [*]. With [*] of this, [*] will [*] for [*] according to the [*] below.

Once the [*] of each [*] has been [*], the [*] will be [*]. It may be [*] that [*] are [*] in [*] in [*]. It may be [*] that [*] may [*] the [*]. This should be [*] for [*].

[*]

Initial focus for the [*] will be to [*] and [*] the [*] of [*] for [*]. The work will [*] and [*] the [*] in [*].

[*].

[*]

[*].

[*] are [*] as a [*] for [*], and this [*] of [*] should be [*] a [*] of the [*] from the [*].[*] that [*] of a [*] to be [*] to [*] the [*] — a [*] is [*] as [*], and a [*] that is [*]. The [*] that of the [*]; however will [*] a [*] of [*] and [*] during the [*].

To [*] the [*] there are [*] and [*] that are [*] to [*] the [*] is [*] to [*] though [*].[*] the [*] or [*] during [*].

[*] of the [*] is [*], and may be [*] the [*].[*] of [*] and [*] can be used to [*].

[*]:

[*] [*]

As [*],[*] that [*].[*] by [*] at [*] for [*].[*] is [*] for [*].

[*]

[*] of each [*] are to be [*] at [*], [*] and [*].

For this work, the [*] be [*] for [*] in as [*] and [*]:

[*].

[*]

The [*] are to [*] at [*] for [*] ([*]) or [*] ([*]).

[*]

For this [*] an [*] of [*]:

[*]

The [*] of the [*] will be to [*] any [*] in [*] of the [*]. [*] the [*] will be [*] that a [*] ([*]) does [*] an [*] than a [*]. The [*] is [*] in [*] of [*] and [*] ([*] and [*] the [*] and [*]).

[*]

[*]:

[*]: [*]

[*]

[*] :

[*]

Project Management

The project managers from Intermolecular and Guardian will discuss the progress of work under this Task Order #1 on a [*] basis, with [*] being treated as a separate project.

For the purpose of this Task Order #1, Intermolecular’s project managers will be [*] . Guardian’s project managers will be [*] .

Intellectual Property

Any project related IP developed in the course of work shall be managed according to the terms of the Research Agreement between Guardian and Intermolecular.

Subcontracting No subcontracting is expected for this task order. Any need for subcontracting must be reviewed and approved by Guardian prior to conducting any subcontracts.

Prior Technology

Guardian has extensive and specific prior technology that should be understood at the start of this program. Prior technology includes the following:

[*]

Project Sets .

For the purposes of this Task Order #1,

[*] ,

[*] and

[*] .

[*] .

Project Term

Unless otherwise agreed upon by the parties in writing or terminated under the Agreement, the development obligations under this Task Order #1 for a Project Set will expire if Guardian does not specify further tasks for that particular Project Set under this Task Order #1 for a period of [*] consecutive days. Completion of a Project Set will be the date of expiration of the Project Set.

Payment Terms

The payment terms for this task order will be managed according to the terms of the Research Agreement between Guardian and Intermolecular.

Exclusivity .

(a) Unless Guardian notifies Intermolecular within [*] ( [*] ) days following the Task Order Effective Date of its election to take a non-exclusive license to a particular Project Set, Guardian will be deemed to have elected to receive an exclusive license to such Project Set and Guardian shall pay Intermolecular the royalty set forth in the royalty section below for the applicable Field .

(b) In the event that Guardian elects to receive a non-exclusive license to any of the Project Sets under this Task Order #1, Guardian shall pay Intermolecular the royalty set forth in the royalty section below for the applicable Field .

(c) For Project Sets where Guardian has taken a non-exclusive license, and Intermolecular grants licenses to third parties to use such Project Sets, Intermolecular agrees to pay Guardian a revenue share amount of [*] percent ( [*] %) of the net revenue actually received by Intermolecular in connection with Intermolecular’s license of such Project Sets to any third parties. The revenue share will be net of all of Intermolecular’s expenses related to commercializing or licensing such Project Sets as well as any taxes other than taxes based on Intermolecular’s net income.

(d) In the event that Guardian elects to receive an exclusive license to one or more Project Sets, Guardian will meet the commercialization thresholds set forth below in order to maintain exclusivity:

(i) Within [*] ( [*] ) months after the completion of the applicable portion of the Task Order for a particular Project Set, Guardian will demonstrate good-faith efforts to commercialize each such Project Set, whether on a standalone basis or in conjunction with other Project Sets, including by way of example by conducting commercial production of products incorporating materials or processes developed or improved as a result of a Product Set.

(ii) Within [*] ( [*] ) and [*] ( [*] ) months after completion of the applicable portion of the Task Order for a particular Project Set, Guardian will meet the minimum quarterly royalty targets set forth in the table below:

Project Set	Royalties Target ($/Qtr)* after [*]		Royalties Target ($/Qtr)* after [*]
*[]** Project Set	$	*[]**	$	*[]**

*[]** Project Set		$	*[]**		$	*[]**
*[]** Project Set		$	*[]**		$	*[]**

* If a product incorporates elements from two or more Project Sets, then the combined quarterly royalty target to maintain exclusivity for all related Program Technology will not exceed $ [*] per quarter after [*] months and will not exceed $ [*] per quarter after [*] months.

If Guardian has not met the targets set forth above for a particular Project Set by the applicable date, Guardian’s exclusive license to such Project Set will automatically convert to a non-exclusive license as of such date. Guardian will have the option to pay any difference between the minimum quarterly royalty targets outlined above and the actual royalties due in order to maintain exclusivity.

Field . Guardian’s licenses to each Project Set under this Task Order #1 will be subject to the following Field restriction: commercial production of large area glass coatings. In addition, the parties have agreed to define a narrower sub-Field that will be subject to limits on the maximum applicable royalty percentage, as discussed below. The sub-Field is [*] glass and [*] glass for use in [*] (“ [*] and [*] ”).The foregoing defines the “Field” for this Task Order as required by Section 5.2.1 of the Research Agreement.

Royalties .

Project Set	Royalty
*[]** Project Set	*[]**	%
*[]** Project Set	*[]**	%
*[]** Project Set	*[]**	%

The royalty percentages will be cumulative if more than one Project Set is used in a particular product. However, for products within the [*] and [*] Field, the maximum royalty will be capped at [*] % even if three or more Project Sets are used in the product.

Royalties will go for [*] years after Guardian starts using Program Technology that is owned or co-owned by Intermolecular in commercial production, or as long as the term of at least one patent that covers the Program Technology and is owned by Intermolecular has not expired, whichever is longer, but not to exceed [*] years from the completion of the Task Order from which the Program Technology was developed.

*Royalties will be calculated based on Guardian’s Net Sales of products and/or services incorporating or using the applicable Project Set or Sets. “Net Sales” means the gross amount received by Guardian for the Sale of products and services based on or including one or more Project Sets, less amounts actually incurred by Guardian for transportation, packaging, insurance, sales, use and excise taxes, tariffs and duties, normal and customary trade and quantity discounts, and credits to customers for rejection or return of products. “Sale” means every disposition of an item or provision of a service, including selling, renting, leasing, lending and bartering of an item or service. A Sale is considered to occur when the item is delivered or service is provided or when an invoice is issued, whichever occurs first. If a product incorporates or a service uses Program Technology from a different Task Order, additional royalties may apply to sales of such product.

Intermolecular, Inc.			Guardian Industries Corp.

By:	/s/ J. Craig Hunter		By:	/s/ Jean-Marc Lemmer

Print Name:		J. Craig Hunter	Print Name:			Jean-Marc Lemmer

Title:	VP & GM, Clean Energy Tech		Title:		Sr. Director, Product R&D

Date:	August 16, 2010		Date:		August 19, 2010

Task Order #2

[*].

This Task Order # 2 (“Task Order #2”) is entered into as of November 30, 2010 (the “Task Order Effective Date” under the terms of the Research Agreement dated July 15, 2010 (the “Agreement”) between Guardian Industries Corp. (hereinafter referred to as “Guardian”) and Intermolecular Inc. (hereinafter referred to as “Intermolecular”). Terms that are capitalized but not specifically defined herein shall have the meanings set forth in the Agreement.

Scope of the Collaboration

The scope of this Task Order #2 covers [*] .

Under the terms of the Task Order, [*] will be [*] and an [*] of the [*] to [*] the [*] .

Specific Goals for the Collaboration

The project should meet the following performance parameter goals:

[*]

[*]

The goal of this project task is to [*] to [*] of the [*] to be [*] a [*] as [*] to the [*] from the [*] with [*] .

[*] . It is [*] that [*] of [*] to the [*] will [*] of the [*] in [*] of [*] and [*] . [*] have been used in [*] for [*] , and [*] . In [*] , the [*] is [*] , for [*] , the [*] and [*] to be [*] has [*] the [*] . The [*] such as [*] . At the time when this Task Order is written, it is [*] which [*] will [*] the [*] to [*] with [*] and [*] of an [*] as [*] , or [*] that can [*] such as [*] or [*] . The [*] in [*] .

[*]:

[*]

[*]:

[*]

It is [*] what [*] are [*] for [*]. This effort should [*] the [*] for [*], and [*] the [*]. In all [*] it is [*] to [*] the [*] at the [*] of [*], and [*] a [*].

[*].

[*] is [*] to [*] and [*], and so [*] will need to be [*] — like [*] to [*] and so on. [*] such [*] must be [*] as [*] to [*] in as [*], and the [*] be used to [*] or otherwise.

In combination with [*] to the [*] to be [*].[*] of [*] must be [*] and [*] and [*] to [*] over [*] in both as [*] and [*]. ([*] is [*] for [*]).

[*]

It should be [*] that it is [*] that [*] is used in [*] and other [*] provide a [*] for [*] as well as [*] such as [*]. It is [*] that the [*] above [*] with [*].

[*] ([*])

It is [*] that the [*] of [*] will [*] in this task order. [*] is [*] to be used to [*] the [*] of [*] and [*], in [*] to [*].[*] should be [*] on the [*]. The [*] can be [*] on [*].[*] are the [*] to [*] the [*] to [*] of the [*].

[*]

[*]

[*] and [*] on each of the [*] to [*] any [*] of the [*]. As [*], the [*] can be[*]. The [*] or [*] is to [*] and [*].[*], it is [*] to [*] the [*].

Other [*] are [*] in the [*].

[*]

The goal of this project task is to [*] the [*] of the [*] that [*] the [*] both [*] and [*]. The [*] for [*] can be [*] for [*] in the [*]. The [*] must [*] to the [*] or [*], and [*] to [*] the [*]. In addition, the [*] also [*] to the [*] that [*] will also [*]. For the purposes of this work [*] can be [*] with [*]:[*]. It is possible that the [*] will [*] a [*] or [*] of the [*]:[*]. At this time, the [*] that are to be [*] for this [*] of the [*]. The [*] and [*] of [*] to [*] and will be [*] on the [*], the [*].

[*].

With the [*] of [*], the [*] of the [*] is [*], and should be [*] as a [*] of this [*].

[*]

[*] should be [*] on [*] with [*]. Based on current [*], a [*] is [*] as [*] for [*]. It is also possible that [*] is also [*] for [*], but we [*].

Based on current results and [*], it is [*] with the [*] and [*] for the [*]:

[*]

[*]

[*] on [*] of the [*] by [*] to [*] any [*] of the [*]. In addition, the [*] to [*] to [*]. From [*] of [*], it can be seen that it is [*] to [*] in the [*].

With the [*] we then need to [*] this [*] an [*], and [*] with [*].

Here the [*] are from the [*] but not a [*].[*] and [*] may [*] during the [*]. A [*] of these [*] could be [*] on the [*] and [*].[*] and [*] is also a [*] of the [*] and [*]. For [*], due to the [*] of [*] in the [*], it is possible that [*] will not [*] for [*].

[*] [*]

[*]

[*] should be [*] on [*] with [*] . [*] to [*] of [*] to [*] , and [*] to [*] . [*] will [*] .

[*] all [*] .

[*]:

This [*] be [*] in [*] with [*] . [*] will [*] at [*] , [*] by [*] on [*] .

[*]

The initial schedule for Task Order #2 has been defined as represented below:

[*]

Project Management

The project managers from Intermolecular and Guardian will discuss the progress of work under this Task Order #2 on a weekly basis.

For the purpose of this Task Order #2, Intermolecular’s project managers will be [*] . Guardian’s project manager will be [*] .

Intellectual Property

Any project related IP developed in the course of work shall be managed according to the terms of the Research Agreement between Guardian and Intermolecular.

Subcontracting

No subcontracting is expected for this task order. Any need for subcontracting must be reviewed and approved by Guardian prior to conducting any subcontracts.

Prior Technology

Guardian has extensive and specific prior technology that should be understood at the start of this program. Prior technology includes the following:

[*]

[*] .

[*]

[*] .

Technology described in items 1-7 above shall only be deemed to be Prior Technology if it can be established by written documentation that it was conceived and reduced to practice prior to the Task Order Effective Date.

[*] .

(i) For the purposes of this Task Order #2, there is [*] . This [*] for [*] on [*] and for [*] .

The [*] and [*] are [*] to [*] the [*] . These are [*] to [*] as a [*] . [*] to be [*] under Task Order #2 will be [*] that [*] or [*] in the [*] of [*] . [*] or [*] . The parties have made a good faith effort to identify Prior Technology that could be used in connection with the activities under the Task Order to make it easier to identify Program Technology. However, neither party waives the right to demonstrate through documents pre-dating the Task Order Effective Date that certain information generated under the Task Order is Prior Technology.

Project Term

It is anticipated that no project outlined in this Task Order #2 will require more than [*] months from the Task Order Effective Date to be completed. Unless otherwise agreed upon by the parties in writing or terminated under the Agreement, the development obligations under this Task Order #2 for the Project Set will expire if Guardian does not specify further tasks for that particular Project Set under this Task Order #2 for a period of [*] days. Completion of the Project Set will be the date of expiration of the Project Set.

Payment Terms

The payment terms for this task order will be managed according to the terms of the Research Agreement between Guardian and Intermolecular.

Exclusivity .

(a) Unless Guardian notifies Intermolecular within [*] days following the Task Order Effective Date of its election to take a non-exclusive license to a particular Project Set, Guardian will be deemed to have elected to receive an exclusive license to such Project Set and Guardian shall pay Intermolecular the royalty set forth in the royalty section below for the applicable Field of Use.

(b) In the event that Guardian elects to receive a non-exclusive license to any of the Project Sets under this Task Order #2, Guardian shall pay Intermolecular the royalty set forth in the royalty section below for the applicable Field of Use.

(c) For a Project Set where Guardian has taken a non-exclusive license, and Intermolecular grants licenses to third parties to use such a Project Set, Intermolecular agrees to pay Guardian a revenue share amount of [*] percent ( [*] %) of the net revenue actually received by Intermolecular in connection with Intermolecular’s license of such a Project Set to any third parties. The revenue share will be net of all of Intermolecular’s expenses related to commercializing or licensing such a Project Set as well as any taxes other than taxes based on Intermolecular’s net income.

(d) In the event that Guardian elects to receive an exclusive license to the Project Set, Guardian will meet the commercialization thresholds set forth below in order to maintain exclusivity:

(i) Within [*] after the completion of the applicable portion of the Task Order for a particular Project Set, Guardian will demonstrate good-faith efforts to commercialize each such Project Set, whether on a standalone basis or in conjunction with other Project Sets, including by way of example by conducting field evaluations or product validations prior to full commercialization, commercial production of products incorporating materials or processes developed or improved as a result of a Product Set.

(ii) Within [*] and [*] months after completion of the applicable portion of the Task Order for a Project Set related to this Task Order, Guardian will meet the minimum quarterly royalty targets set forth in the table below:

Project Set	Royalties Target ($/Qtr) after [*]		Royalties Target ($/Qtr) after [*]
*[]** Project Set	$	*[]**	$	*[]**

Field of Use . Guardian’s licenses to each Project Set under this Task Order #2 will be subject to the following Field restriction: commercial production of large area glass coatings, including but not limited to [*] . The foregoing defines the “Field” for this Task Order as required by Section 5.2.1 of the Research Agreement.

Royalties .

Project Set		Royalty* (per Field of Use)
*[]**		*[]**	%

For the above noted Project Set it should be noted that there may be reason for exception in such event that Guardian independently and outside the Project Set develops a [*] and commercializes such [*] -based product utilizing an [*] from within the Project Set, then the royalty will be [*] %.

*Royalties will be calculated based on Guardian’s Net Sales of products and/or services incorporating the applicable Project Set or Sets. “Net Sales” means the gross amount received by Guardian for the Sale of products based on or including one or more Project Sets, less amounts actually incurred by Guardian for transportation, packaging, insurance, sales, use and excise taxes, tariffs and duties, normal and customary trade and quantity discounts, and credits to customers for rejection or return of products. “Sale” means every disposition of an item or provision of a service, including selling, renting,

leasing, lending and bartering of an item or service. A Sale is considered to occur when the item is delivered or service is provided or when an invoice is issued, whichever occurs first. If a product incorporates Program Technology from a different Task Order, additional royalties may apply to sales of such product.

Intermolecular, Inc.				Guardian Industries Corp.

By:	/s/ J. Craig Hunter			By:		/s/ Jean-Marc Lemmer

Print Name:			J. Craig Hunter	Print Name:		Jean-Marc Lemmer

Title:		VP & GM, Clean Energy Tech		Title:	Sr. Director, Product R&D

Date:		January 19, 2011		Date:	January 23, 2011

Amendment Number One to Research Agreements — Guardian and Intermolecular

GUARDIAN INDUSTRIES CORP., a Delaware corporation located at 2300 Harmon Road, Auburn Hills, Michigan 48326 (hereinafter referred to as “ Guardian ”) and INTERMOLECULAR, INC., a Delaware corporation located at 3011 North First Street, San Jose, California 95134 (hereinafter referred to as “ Intermolecular ”), entered into a RESEARCH AGREEMENT effective Feb. 8, 2010 (“ [*] Agreement ”), which also incorporates by reference a Task Order effective February 8, 2010, a Task Order effective Jul. 22, 2010, a Task Order effective Oct. 22, 2010, and a Task Order effective May 1, 2011 as amended on November 1, 2011.

Guardian and Intermolecular also entered into a RESEARCH AGREEMENT effective Jul. 15, 2010 (“ Master Agreement ”), which also incorporates by reference a Task Order effective Jul. 22, 2010 and a Task Order effective November 30, 2010.

The [*] Agreement and the Master Agreement are herein collectively referred to as Agreements .

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to modify the terms of the [*] Agreement and Master Agreement (hereinafter “ Amendment ”) as set forth below.

1. AMENDMENT EFFECTIVE DATE.

1.1 This Amendment shall have an effective date of January 1, 2012 (“ Amendment Effective Date ”)

2. TERM AND TERMINATION.

2.1 Unless terminated by mutual agreement or for breach, each of the Master Agreement and the [*] Agreement shall terminate two (2) years from the Amendment Effective Date (hereinafter defined as “Term”).

2.2 Either party may terminate the Master Agreement or [*] Agreement if the other party has materially breached or defaulted in the performance of any of its material obligation under the respective Master Agreement and the [*] Agreement, and such default has continued for sixty (60) days after written notice was provided to the breaching party by the non-breaching party. Termination will be effective at the end of the sixty (60) day period unless the breach has been cured before the expiration of the sixty (60) day period.

2.3 Sections 6-11, 14-16, 19, 20, and 29 shall survive the expiration or termination of the [*] Agreement for any reason.

3. RESOURCES .

3.1 During the Term, Intermolecular agrees to provide the equivalent of [*] FTEs to support the tasks related to the Agreements.

3.2 During the Term, Intermolecular will dedicate at least [*] towards the tasks related to the Agreements.

3.3 Subject to Sections 3.1 and 3.2 of this Amendment, Guardian may adjust the allocation of Resources between the Master Agreement or [*] Agreement as reflected in the Task Orders issued under either the Master Agreement or [*] Agreement.

4. PROGRAM FEES .

4.1 Section 12 (“RESEARCH COMPENSATION”) of the [*] Agreement is deleted in its entirety.

4.2 Section 7.1 (“Program Fees”) and 7.2 (“Expenses”) of the Master Agreement is deleted in its entirety.

4.3 During the Term, Guardian shall pay Intermolecular $[*] (“ Program Fees ”) per month in exchange for the resources provided by Intermolecular under the Amendment.

4.4 It is understood that although the parties have agreed upon Program Fees to cover research under the Agreements, the parties have not defined up-front all the Task Orders for the research. The parties will work together in good faith to reach agreement on the Task Orders so that the research efforts are continuous. However, if Intermolecular has completed work on pending Task Orders but the parties are unable to reach agreement on the following Task Order(s), Guardian may suspend the payment of Program Fees to a maximum period of thirty (30) days until the parties have reached agreement and Intermolecular has resumed work under one or more new Task Orders.

4.5 Guardian will provide or pay for (a) consumables, such as [*], (b) outsourced metrology and characterization not supported internally by Intermolecular, (c) subject to Guardian’s written approval not to be unreasonably withheld, reasonable travel and lodging expenses for Intermolecular personnel performing activities at Guardian’s facilities, and (d) subject to Guardian’s written approval not to be unreasonably withheld, any other out of pocket costs to support the research under the Master Agreement or [*] Agreement. Notwithstanding the foregoing, Intermolecular agrees to provide targets for research under the Master Agreement at no cost to Guardian at a cost up to [*] Dollars ($[*]) per year. Any additional targets will be provided at Guardian’s reasonable expense with Guardian’s prior written approval being required before such targets are ordered.

5. Licenses.

5.1 Section 10 (“Licenses”) of the [*] Agreement is replaced in its entirety by Sections 5.2, 5.3. 5.4, 5.5, 5.6 and 5.7 of this Amendment.

5.2 Project-Related Technology . Subject to Sections 2 and 4 of this Amendment and Section 11 of the [*] Agreement, Intermolecular hereby grants Guardian a worldwide, royalty-bearing, non-transferable (subject to Section 28 of the [*] Agreement) license under and to Intermolecular’s Project-Related Technology to (a) engage in work under the [*] Agreement with Intermolecular and (b) use, make, have made, import, offer to sell and sell Guardian Products within the field of use (the “Field”) defined in the applicable Task Order from which the Project-Related Technology was generated.

5.3 Independent Technology . Subject to Sections 2 and 4 of this Amendment and Section 11 of the [*] Agreement, each party hereby grants the other party a worldwide, non-exclusive, non-transferable, royalty-free license, without right of sublicense, to use such party’s Independent Technology (a) to the extent necessary for such party to carry out its obligations under the [*] Agreement and (b) to the extent necessary to exercise any licenses granted under the Project-Related Technology.

5.4 Guardian’s Affiliate and Third Party Licensees . Subject to Sections 2 and 4 of this Amendment and Section 11 of the [*] Agreement, Guardian shall have the right, but

not the obligation, to grant sublicenses of part or all the Project-Related Technology (a) to Guardian’s Affiliates (as this term is defined in the Master Agreement) to use, make, have made, import, offer to sell and sell Guardian products incorporating Project-Related Technology, and/or (b) third party licensees to use, make, have made, import, offer to sell and sell products in the applicable Field. If Guardian exercises its right to sublicense the Project-Related Technology to third party licensees as allowed under this section, then unless pre-approved by Intermolecular in writing, Guardian shall pay Intermolecular a pass-through royalty equal to the greater of [*] percent ([*]%) of the royalties received by Guardian from the applicable sublicensed Project-Related Technology or an amount equal to the applicable non-exclusive royalty rate for the Project-Related Technology based on applying the sales calculations as set forth in the [*] Agreement to the third party licensee. Upon Intermolecular’s request, Guardian will conduct audits of such third party licensee to determine the accuracy of the sales figures provided to Guardian upon which Guardian calculates its payments to Intermolecular hereunder. Any other sublicensing arrangement and fee structure requires Intermolecular’s prior written consent on a case-by-case basis.

5.5 Exclusivity; Election .

A. With respect to each Project-Related Technology, Guardian must make an election by written notice to Intermolecular to take an exclusive license or a non-exclusive license within a time period defined within the applicable Task Order.

B. If Guardian elects in writing to receive an exclusive license, subject to any minimum volumes as set under Section 5.6 of this Amendment and the royalty obligations of Section 11 of the [*] Agreement, the license granted to Guardian under Section 5.2. of this Amendment, and the sublicense rights granted in Section 5.4 of this Amendment, will be exclusive in the Field, except as to Intermolecular for purposes of Intermolecular undertaking the research under the [*] Agreement for Guardian.

C. If Guardian elects in writing to receive a non-exclusive license or after a defined period of exclusivity has expired, and provided Guardian is in compliance with the royalty obligations of Section 11 of the [*] Agreement, the license granted to Guardian under Section 5.2. of this Amendment, and the sublicense rights granted in Section 5.4 of this Amendment, will be non-exclusive in the Field. If applicable, the Task Order will define the revenue sharing Guardian will receive from any licenses granted by Intermolecular to third parties under the Project-Related Technology. Intermolecular may not solicit third party licenses before the expiration of any defined period of exclusivity.

5.6 Minimum Volumes . After all elements of the Task Order are completed and the parties have more information about the expected time for development and commercialization of the products subject to the exclusive license, the parties agree to negotiate in good faith to establish the minimum targeted volume and date on which the minimums will begin to apply.

5.7 The Field for the Task Order effective February 8, 2010, the Task Order effective Jul. 22, 2010, the Task Order effective Oct. 22, 2010, and the Task Order effective May 1, 2011 as amended on November 1, 2011 will be coated glass used for [*] applications. The license under these above referenced Task Orders will be exclusive in the Field, non-exclusive in all other fields and exclusivity is subject to agreed-upon minimum targeted volumes and an agreed-upon date on which the minimums will begin to

apply.

6. Publications .

6.1 The following will be added to Section 12.14 of the Master Agreement and Section 29 of the [*] Agreement: Guardian recognizes that researchers at Intermolecular engaged in the Agreements may wish be permitted to present at symposia, national, or regional professional meetings, and to publish in journals, theses or dissertations, or otherwise, methods and results of the development efforts contemplated in the Agreements, provided, however, that Guardian shall have been furnished copies of any proposed publication, abstract or presentation for review at least one month in advance of the submission of such proposed publication, abstract or presentation to a journal, editor, or other third party. Guardian shall have one month after receipt of said copies, to object to such proposed presentation or proposed publication because there is patentable subject matter that needs protection or because Confidential Information is contained therein. In the event that Guardian makes such objection based on patentable subject matter, Intermolecular shall refrain from making such publication or presentation for a maximum of four months from date of receipt of such objection in order to file patent application(s) with the United States Patent and Trademark Office or foreign patent office(s) directed to the patentable subject matter contained in the proposed publication, abstract or presentation. Intermolecular shall comply with Guardian’s request to delete Confidential Information from any such proposed publication, abstract or presentation.

All capitalized terms not defined herein shall have the meanings given them in the Agreements, as applicable. This Amendment shall be deemed to be incorporated into each of the Agreements and made a part thereof. All references to the [*] Agreement or the Master Agreement in any other document shall be deemed to refer to the [*] Agreement or the Master Agreement, as applicable, as modified by this Amendment. Except as modified by this Amendment, all of the terms and conditions of the Agreements shall remain in full force and effect. In the event that the terms of this Amendment conflict with the terms of the [*] Agreement or the Master Agreement, the terms of this Amendment shall control.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Amendment Effective Date.

Guardian Industries Corp.		Intermolecular, Inc.

By:	/s/ Scott Thomsen	By:	/s/ J. Craig Hunger

Name:	Scott Thomsen	Name:	J. Craig Hunter

Title:	President	Title:	Sr. VP & GM, Clean Energy Group

Date:	January 31, 2012	Date:	January 27, 2012

Exhibit 31.1

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, David E. Lazovsky, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Intermolecular, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2012	/s/ David E. Lazovsky
	David E. Lazovsky
	President and Chief Executive Officer

Exhibit 31.2

Certification of Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Peter L. Eidelman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Intermolecular, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2012	/s/ Peter L. Eidelman
	Peter L. Eidelman
	Chief Financial Officer

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Intermolecular, Inc. (the “Company”) on Form 10-Q for the three month period ended March 31, 2012, as filed with the Securities and Exchange Commission (the “Report”), David E. Lazovsky, President and Chief Executive Officer of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

· The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

· The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2012


By:	/s/ David E. Lazovsky
	Name:	David E. Lazovsky
	Title:	President and Chief Executive Officer

A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

Exhibit 32.2

Certification of Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Intermolecular, Inc. (the “Company”) on Form 10-Q for the three month period ended March 31, 2012, as filed with the Securities and Exchange Commission (the “Report”), Peter L. Eidelman, Chief Financial Officer of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

· The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

· The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2012


By:	/s/ Peter L. Eidelman
	Name:	Peter L. Eidelman
	Title:	Chief Financial Officer